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Neuroinflammation in 
Alzheimer’s disease (AD) may 
aggravate or clear amyloid 
plaques. In this thesis by 
employing transgenic mouse 
models of AD, we examined 
the impact of pharmacological 
and genetic immunomodulators 
on progression of amyloid 
pathology. Treatment with 
polyclonal human intravenous 
immunoglobulins as well 
as Nfkb1 gene deletion both 
resulted in meagre effects on 
plaque pathology but distinctly 
suppressed CD45 positive 
activated microglia around 
amyloid plaques.
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ABSTRACT 
 
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that primarily disturbs 
cognitive and memory functions of elderly people. Amyloid beta (Aβ) protein deposits and 
neurofibrillary tangles in brain parenchyma with additional brain atrophy as a consequence 
of massive loss of neurons are key pathological features of this disease.  Chronic 
neuroinflammation also plays a very important role in progression of AD. Microgliosis, 
astrogliosis, overexpression of cytokines and chemokines are notable features of ongoing 
neuroinflammatory processes. Innate and cellular arms of immune system play a very 
decisive role in shaping the progression of AD neuropathology. Such innate or cellular 
immune responses can either be detrimental or beneficial. Nuclear factor kappa B (NFκB) 
family transcription factors regulate both immune as well as neuroinflammatory functions 
in many pathophysiological conditions. Taming detrimental neuroinflammation while 
harnessing benefits of own immune activation is a promising avenue for current 
therapeutic strategies. Immunomodulation by genetic and pharmacological agents is a 
good experimental tool to understand the role of neuroinflammation in AD pathogenesis. 
Our present thesis is a combination of two experimental studies that were designed to 
study the role of neuroinflammation in AD pathogenesis. In both studies we employed 
APPswe/PS1dE9 transgenic mice as an animal model of AD. In our first study, we used a 
clinically well-known anti-inflammatory and immunomodulator known as human 
polyclonal intravenous immunoglobulin (hIVIG).  We treated young and aged 
APP/PS1mice with hIVIG for durations ranging from 3 weeks to 8 months. We assessed 
treatment effects on behaviour, amyloid pathology, and neuroinflammatory parameters. In 
our second study, we crossed APP/PS1 mice with mice deficient in Nfkb1 gene, a key 
member of  NFκB family transcription factors, thereby creating a novel APP/PS1 mouse line 
under Nfkb1 knockout background. We assessed the impact of Nfkb1 gene knockout on 
behaviour, amyloid pathology and chronic neuroinflammatory processes of mice at three 
different ages. Acute inflammatory responses of LPS injection in brains of these novel mice 
were also investigated.  
Data from our first study indicate that irrespective of treatment duration, dose or age of 
mice at treatment onset hIVIG had little effect on preformed Aβ deposits. Furthermore, 
chronic hIVIG treatment in APP/PS1 mice resulted in elevation of soluble levels of Aβ in the 
hippocampus. Mechanisms related to disintegration of Aβ plaques, phagocytosis by 
microglia and peripheral Aβ sink consistently failed to reduce Aβ load significantly in brain 
and serum of hIVIG treated mice. However, chronic hIVIG treatment brought about 
significant changes to microglia. Treatment with hIVIG for 8 months resulted in 30% 
decrease in CD45 expressing activated microglia. Furthermore, confocal analysis revealed 
significant morphological changes in ionized calcium binding adaptor molecule 1 (Iba-1) 
positive microglia both near and away from Aβ plaques, indicating a change in activation 
of specific microglia sub-populations. Chronic hIVIG treatment also suppressed tumor 
necrosis factor (Tnf) gene expression in both wild-type and APP/PS1 mice. Furthermore, a 
direct correlation between expression of pro-inflammatory cytokine genes and CD45 
microglia observed in saline treated mice flipped to an inverse correlation in hIVIG treated 
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mice, suggesting a change away from pro-inflammatory phenotype of microglia. Chronic 
hIVIG treatment also resulted in >50 % increase in new born doublecortin positive neurons 
in dentate gyrus, irrespective of mouse genotype, suggesting a strong neurogenic effect due 
to hIVIG treatment. Data from the first study clearly indicate that immunomodulation by 
hIVIG can change microglial phenotype irrespective of amyloid pathology and that anti-
inflammatory and neurogenic effects of hIVIG might mediate beneficial effects in AD 
patients.  
In our second study, deletion of Nfkb1 gene did not cause any overt abnormal behavioural 
changes in mice, suggesting minimal prospects of adverse effects related to blocking NFκB 
in the AD brain. Data from our second study consistently showed limited impact of Nfkb1 
gene deletion on progression of amyloid pathology across all the ages tested. Furthermore, 
also an acute stimulation of microglia by lipopolysaccharide did not result in any changes 
to amyloid pathology. In aged Nfkb1 knockout mice under APP/PS1 background, we 
noticed >50% decrease in CD45 microglia, suggesting suppression of activated microglia. 
However, we saw a significant increase in pro-inflammatory cytokine gene expression like 
Tnf and interleukin 1 beta in Nfkb1 knockout mice under APP/PS1 background. Data from 
this study suggest a change in microglial and inflammatory phenotypes. 
Results from both of these studies clearly indicate that immunomodulation in AD may have 
limited effects on amyloid pathology but can have profound effects on activated microglia 
and their pro-inflammatory phenotypes. 
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TIIVISTELMÄ 
 
Alzheimerin tauti (AT) on krooninen aivojen rappeumasairaus, joka ensisijaisesti 
ilmenee muistin ja päättelykyvyn heikentymisenä ikääntyneillä ihmisillä. Taudin 
patologialle tunnusomaisia piirteitä ovat aivokudoksen amyloidi-β (Aβ) proteiinin 
kertymät ja hermosäievyyhdet sekä aivojen kutistuminen huomattavan hermosolukadon 
seurauksena. Hermoston kroonisella tulehdusreaktiolla on myös merkittävä osuus AT:n 
etenemisessä. Käynnissä olevan hermoston tulehdusreaktion tunnusomaisia piirteitä ovat 
mikrogliasolujen ja astrosyyttien aktivoituminen sekä sytokiinien ja kemokiinien yli-
ilmentyminen. Sekä luotainen että soluvälitteinen immuniteetti vaikuttavat ratkaisevasti 
AT:n tautiprosessin etenemiseen aivoissa, niin että vaikutus voi olla joko haitallinen tai 
suotuisa. Tumatekijä kappa-B (NFκB) perheen transkriptiotekijät säätelevät sekä 
immuniteettia että hermokudoksen tulehdusvastetta monissa tautitiloissa. Haitallisen 
hermoston tulehdusreaktion kesyttäminen ja toisaalta oman immuniteetin aktivoiminen 
ovat lupaavia lähestymistapoja AT:n hoitoon. Immuunivasteen muuntelu joko geneettisesti 
tai farmakologisesti on hyvä kokeellinen työkalu selvitettäessä hermoston tulehdusreaktion 
osuutta AT:n tautimekanismissa.  
Tämä väitöskirjatyö yhdistää kaksi kokeellista tutkimusta, joiden tarkoituksena oli 
selvittää hermoston tulehdusreaktion osuutta AT:n synnyssä. Molemmissa tutkimuksissa 
käytimme AT:n mallina APPswe/PS1dE9 siirtogeenisiä hiiriä. Ensimmässsä tutkimuksessa 
hyödynsimme kliinisessä käyttössä hyvin tunnettua tulehdusta hillitsevää ja 
tulehdusvastetta muuntelevaa hoitoa, polyklonaalista ihmisen laskimoverestä kerättyä 
immunoglobuliinia (hIVIG).  Annoimme nuorille ja vanhoille APP/PS1 hiirille eripituisia 
hIVIG hoitoja, joiden kesto vaihteli 3 viikosta 8 kuukauteen. Arvioimme hoidon vaikutusta 
eläinten käyttäytymiseen, amyloidipatologiaan ja hermoston tulehdusreaktioon. Toisessa 
tutkimuksessa risteytimme APP/PS1 hiiriä hiiriin, joilta puuttui keskeinen NFκB 
transkriptiotekijän perheen Nfkb1 geeni, ja loimme näin uudenlaisen Nfkb1-tekijän suhteen 
poistogeenisen APP/PS1 hiirilinjan. Selvitimme Nfkb1 geenin poiston vaikutuksia hiirten 
käyttäytymiseen, amyloidipatologiaan ja hermoston tulehdusreaktioon kolmessa eri 
ikäpisteessä. Lisäksi selvittelimme LPS-injektion aiheuttamaa akuuttia tulehdusvastetta 
näiden hiirten aivoissa.  
Ensimmäisen tutkimuksemme tulokset viittaavat siihen, että riippumatta hoidon 
kestosta, hoitoannoksesta tai hiirten iästä hoidon aloitushetkellä hIVIG vaikuttaa hyvin 
vähän jo aivoissa oleviin Aβ kasautumiin. Lisäksi krooninen hIVIG hoito APP/PS1 nosti 
liukoisen Aβ:n tasoja hiirten hippokampuksessa. Tunnetut immuunihoitojen Aβ:n tasoja 
laskevat mekanismit, Aβ plakkien hajotus, mikorigliavälitteinen fagosytoosi tai 
perifeerinen Aβ nielu, johdonmukaisesti epäonnistuivat aivojen tai seerumin Aβ määrän 
vähentämisessä hIVIG:llä hoidetuilla hiirillä. Kuitenkin krooninen hIVIG hoito aiheutti 
merkitseviä muutoksia mikrogliasoluissa. Kahdeksan kuukauden hIVIG hoito vähensi 30% 
CD45 pintamolekyylin ilmentymisetä aktivoituneissa mikrogliasoluissa. Lisäksi 
konfokaalimikroskopiassa tuli esiin merkitseviä rakennemuutoksia ionisoivaa kalsiumia 
sitovaa sovitinmokelyyli 1:tä (Iba-1) ilmentävissä mikrogliasoluissa sekä amyloidiplakkien 
läheisyydessä että niistä etäällä, mikä viittaa määrällisiin muutoksiin spefisissä mikroglian 
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alapopulaatioissa. Krooninen hIVIG hoito myös vaimensi tuumorinekroositeijän (Tnf) 
geeniekspressiota sekä villityyppisillä että APP/PS1 siirtogeenisillä hiirillä. Lisäksi 
positiivinen tulehdusta edistävien sytokiinien geeniekspression ja CD45-positiivisten 
mikrogliasolujen määrän korrelaatio kääntyi päinvastaiseksi hIVIG:llä hoidetuilla hiirillä, 
mikä viittaa mikrogliasolujen ilmiasun muuttumiseen vähemmän tulehdusta suosivaksi. 
Krooninen hIVIG hoito lisäsi myös >50 % doublecortin-merkkimolekyyliä ilmentävien 
uudishermosolujen määrää hippokampuksen pykäläpoimussa (gyrus dentatus) 
molemmilla genotyypeillä, mikä puhuisi sen puolesta, että hIVIG on voimakkaasti 
hermosolujen uudismuodostusta edistävä hoito. Ensimmäisen tutkimuksen tulokset siis 
selvästi osoittivat, että hIVIGin välittämä immuunivasteen muuntelu voi muuttaa 
mikrogliasolujen ilmiasua amyloidipatologiasta riippumatta ja että hIVIG hoitojen suotuisa 
vaikutus AT potilailla voi osittain selittyä hermosolujen uudismuodostuksen 
lisääntymisellä.  
Toisessa tutkimuksessamme Nfkb1 geenin poisto ei aiheuttanut hiirillä ilmeistä 
poikkeavaa käyttäytymistä, mikä viittaa NFκB signaloinnin salpauksella olevan hyvin 
vähän sivuvaikutuksia. Toisaalta tutkimustuloksemme johdonmukaisesti viittasivat siihen, 
että Nfkb1 geenin poistolla on vain vähäisiä vaikutuksia myös amyloidipathologiaan 
kaikissa tutkituissa ikäpisteissä. Akuutti mikrogliasolujen stimulaatio 
lipopolysakkaridillakaan ei aiheuttanut sanottavia muutoksia aivojen 
amyloidipatologiassa. Vanhoilla Nfkb1 poistogeenisillä, APP/PS1-taustaisilla hiirillä CD45:n 
ilmeneminen mikrogliasoluissa laski yli  50% Nfkb1 geenin suhteen villityyppisiin hiiriin 
verrattuna. Kuitenkin havaitsimme merkitsevän nousun tulehdusta suosivien sytokiinien, 
kuten  Tnf:n and interleukiini 1 beetan, ilmaantumisessa APP/PS1-taustaisilla Nfkb1 
poistogeenisilla hiirillä. Tuloksemme viittaavaat siis Nfkb1 geenipoiston aiheuttavan 
muutoksia mikrogliasoluissa ja tulehdusvasteen luonteessa. 
Kummankin tutkimuksen tulokset viittaavaat selvästi siihen, että aivojen immuunivasteen 
muuntelu ei merkitsevästi vaikuta aivojen amyloidipatologiaan, mutta voi sen sijaan 
muuttaa ratkaisevasti mikrogliasolujen ominaisuuksia. 
 
Luokitus: WT 155, QW 920, QZ 150, WL 102, WL 348 
Yleinen Suomalainen asiasanasto: Alzheimerin tauti/patologia; tulehdus; hermosto; aivot; tautimallit; eläin; 
hiiri, siirtogeeninen; immuunisäätely; immunoglobuliinit, suonensisäinen; käyttäytyminen; amyloidi-beeta 
peptide; plakki, amyloidi; poistogeenitekniikat; transkriptiotekijät; NF-kappa B; lipopolysakkaridit; 
microgliasolut; tuumorinekroositekijät; interleukiini-1beeta; hermosolujen uudismuodostus 
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1 Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects the 
cognitive functions of elderly and thereby, severely erodes quality of life for patients. By 2010 
more than 35.6 million people worldwide were affected by dementia. Nearly 70% of dementia 
patients suffer from AD (Launer et al., 1999). Currently, little is known about causation of 
AD, and available drugs can provide only symptomatic relief but cannot stop or delay the 
disease progression. All along the disease progression, AD brain reacts by fomenting natural 
self-defensive neuroinflammatory processes that are meticulously enacted by a plethora of 
inflammatory proteins and immune cells. In the absence of exact knowledge about disease 
causation, delaying disease progression by understanding the complex spatial and temporal 
relationships between various components of neuroinflammatory pathways might reveal 
novel drug targets. Here, we have used two different strategies to tame neuroinflammation in 
a mouse model of AD. In the first study, we used a clinically established anti-inflammatory 
drug, and in the second study, we used a novel transgenic AD mouse line, which is deficient 
in one of the key component of an important signalling pathway responsible for 
inflammatory gene expression. In both these studies, our objective was to modulate 
inflammatory processes in the APP/PS1 transgenic AD mouse brain. We used human 
polyclonal intravenous immunoglobulins (hIVIG) in our first study to assess its acute and 
chronic effects on neuropathology and cognitive functions of APP/PS1 mouse. A decade long 
immunotherapy research in AD provided overwhelming evidence for beneficial effects of 
amyloid beta (Aβ) antibodies. Since hIVIG also contains antibodies against Aβ, we set out to 
test the hypothesis that treatment with hIVIG would alleviate cognitive deficits and amyloid 
pathology in the APP/PS1 mouse. In our second study, we targeted NFκB pathway which is a 
key transcriptional regulator of inflammation. NFκB subunit NFKB1 is one of the active 
components of protein dimers regulating the canonical pathways of NFκB activation. We 
crossed APP/PS1 and Nfkb1 gene knockout mice and created a novel mouse line of Nfkb1 
knockout under APP/PS1 background. This way we hoped to study the impact of Nfkb1 
transcription factor on the behaviour, amyloid and inflammatory pathologies of APP/PS1 
mouse.  Modulation of inflammatory processes by brain immune cells, microglia, is the key in 
both studies. Either pharmacological or genetic immunomodulation strategies may reveal 
novel drug targets, which may be employed to confer long-lasting benefits to chronically 
inflamed degenerating AD brains. 
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2 Literature review 
2.1 ALZHEIMER’S DISEASE 
2.1.1 Alzheimer’s disease: Flashback 
Alzheimer’s disease is a chronic neurodegenerative disorder that primarily disrupts mental 
and intellectual capacities of elderly. The first documented case report of this debilitating 
disease was presented in 1906 at the 37th German Psychiatric Assembly by Alois Alzheimer. 
He described in detail clinical and neuropathological observations of his patient Auguste D, a 
51-year-old suffering from severe amnesia. Alzheimer took special note of this particular case 
as her symptoms and neuropathological findings did not fit into any known class of diseases 
during that time. English translation of that German report was recently published 
(Alzheimer, 2006). Briefly, Auguste D’s first symptoms were noticed as jealousy towards her 
husband.  Her memory impairment rapidly progressed and this hampered her from 
executing routine household chores. She had difficulties to navigate around her apartment 
and moved objects purposelessly and often hid them. She seemed to be extremely delirious 
and often was disoriented for place and time. She would suddenly scream out loudly with a 
belief that someone wanted to kill her. She would at times hurl phrases of intense indignation 
towards the doctor examining her and seemed to have auditory hallucinations. She would 
scream with a horrible cry for many hours and her behaviour at asylum was described as 
total helplessness (Maurer , 2006). On memory tests, she correctly recognized and named the 
objects but failed to recall the last object shown a little while ago. While reading she skipped 
lines, read phonetically or used senseless intonations. As for writing she repeated single 
syllables, skipped others and very soon got distracted (amnestic writing disorder). While 
talking, she often used embarrassingly unusual phrases and chose to use expressions like 
“milk pourer” instead of cup. Sometimes she did not seem to hear or listen anything at all. 
She could not recall utility of certain objects that were previously quite familiar to her.  Her 
gait was undisturbed with normal patellar and pupillary reflexes. All these focal signs waxed 
and waned as dementia progressed. At the time of death in 1906, 4.5 years after admission to 
asylum, she was totally apathetic, lying on her bed with retracted legs and incontinent. Cause 
of death was septicaemia due to decubitus (Maurer , 2006).   
Autopsy showed that her brain was uniformly atrophied without any visible 
abnormalities. Among other post-mortem findings were moderate external and internal 
hydrocephalus, atherosclerosis of blood vessels, pneumonia of both inferior lobes and 
nephritis. Bielschowsky’s silver stain revealed several histopathological abnormalities. A 
number of tangled bundles of fibrils were found inside neurons. These intracellular 
neurofibrils remained even after the cell destruction. Roughly, a quarter to a third of neurons 
in cerebral cortex showed neurofibrillary changes. Alzheimer also noticed complete 
disappearance of neurons from upper cell layers. Throughout the cortex especially on the 
upper cell layers he noticed the presence of many miliary foci (amyloid plaques) which were 
visible even without staining. He also noticed glial reaction but did not see any signs of vessel 
infiltration. However, there were signs of endothelial proliferation and formation of new 
blood vessels. For Alzheimer, this was a unique and ‘‘peculiar disease’’ with unknown cause. 
In the following years, four more such cases were described in great detail by Perusini, 
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Bonfiglio and Sarteschi. All these cases differed from typical senile dementia with respect to 
early age of onset (around 50’s) and were accordingly considered ‘‘senium praecox’’. These 
‘‘peculiar’’ cases were  later classified under “Alzheimer’s disease” by Emil Kraepelin in 1910 
in his classic text book of psychiatry and hence the eponym (Ralf Dahm, 2006). 
Atherosclerotic changes of blood vessels were later omitted by Perusini in his 1909 article 
describing Auguste D.  Furthermore, Graeber and coworkers, after reanalysing original slides 
from Auguste D in 1998,  confirmed the histopathological findings of Alois Alzheimer 
(Graeber and Mehraein, 1999; Graeber et al., 1998; Graeber et al., 1997; Graeber, 1999)  and 
also ruled out atherosclerosis and metachromatic leukodystrophy as clinical diagnosis for 
Auguste as hypothesized by some scientists (Amaducci et al., 1991). Alzheimer’s autopsy 
findings from his patient Auguste D became what are known today as hallmarks of 
Alzheimer’s disease: cognitive impairment, neuronal loss, amyloid plaques and 
neurofibrillary tangles.  
Interestingly, Alzheimer was not the first person to discover and describe tangles, plaques, 
neuronal loss or clinical dementia. In fact, around the same time as Alzheimer, Oskar Fischer 
in 1907 carried out systematic clinicopathological studies in a number of demented and 
normal individuals. He used Bielschowsky silver stain and described neuritic plaques (See 
Figure 2.1) for the first time (Goedert, 2009). He also sorted out eight different types of senile 
plaques and correlated them to their clinical symptoms which were similar to that of Auguste 
D. In only 2 out of 35 cases of normal individuals he noticed senile plaques which led him to 
conclude senile plaques as morphological substrates for the clinical symptoms (Goedert, 
2009). Nevertheless, Alzheimer’s outstanding contribution was in that he exemplified how 
careful clinical observations may be linked to elegant neuropathology, in simple words, 
clinical psychiatry was fused with microscopy and neurochemistry. Alzheimer described 
brain pathology at the backdrop of detailed clinical picture, but he did not speculate about 
how to cure it or what causes the disease. Several key milestones that shaped AD field during 
early times are briefly presented for inquisitive readers who like to know how the story of 
Alzheimer’s unfolded chronologically (Table 2.1a). 
Table 2.1a: Highlights of AD research. Important milestones (in grey) offered new directions. 
Year Significance for AD field  
1838 
 
Remak; described intracellular neurofibrils.
1883 
 
Paul Böttiger; first synthesized azo dye called Congo red. 
1892 
 
Blocq and Marinesco; described senile plaques in epileptics. 
1898 
  
Redlich; identified “miliary sclerosis” in senile atrophy. 
1898 
 
Binswanger; coined the term presenile dementia. 
1902  
 
 
Bielschowsky; discovered silver staining technique to visualize intracellular 
neurofibrils. 
1906  
 
 
Alzheimer; presented his first case report at 37th Assembly of Southwest German 
Psychiatrists in Tubingen. Abstract was published same year. 
1907 Fischer O; miliary sclerosis as marker for senile dementia.
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1907 
 
 
 
Alzheimer; full lecture of this case report was published in “General Journal of 
Psychiatry and Psycho-forensic Medicine” under the title “Proceedings of Psychiatric 
Associations.” 
1908 
 
 
Bonfiglio; published a case of a 60-year-old, in Italian with similar symptoms and 
histopathological findings.(Influenced by Alzheimer)   
1909 
 
 
Perusini; described Alzheimer’s first case in “On histological and clinical findings of 
some psychiatric diseases of older people”.  
1910 
 
 
Emil Kraepelin first used the eponym Alzheimer’s disease in his text book of 
psychiatry. 
1911 
 
Alzheimer; AD case without neurofibrillary tangles. 
1911 
 
T Simchowicz; coined the word “Senile plaque”. 
1922 
 
Bennhold; Congo red is a specific stain for amyloid. 
1926 
 
E Grunthal; relationship between neurofibrillary degeneration and senile plaques. 
1927  
 
 
Divry; Congo red staining of plaque cores to be amyloid. Tau also stains with congo 
red.  Plaque cores were called ‘‘amorphous material’’ until Divry. 
1936  
 
 
Rothschild and Kasanin; senile dementia is different from pre senile dementia (AD). 
Rothschild noticed plaques from cognitively normal patients. 
1942 
 
Coons; principles of first immunohistochemistry
1948  
 
Alvarez; multiple occlusions of small cortical vessels caused senile dementia. 
1948 
 
 
Newton; Senile dementia, plaques and tangles are related to AD (presenile 
dementia). 
1955 
 
Brody; normal loss of cortical neurons due to ageing.
1959  
 
 
Margolis; demonstrated significant staining differences between tangles and amyloid 
with Congo red. 
1961 
 
Sjogren and Sourander; relationship between AD and normal ageing.  
1963 
 
Terry; Neurofibrillary tangles made of twisted tubules by electron microscopy. 
1963 
 
Kidd; Tangles are paired helical filaments. 
1964 
 
Terry; electron microscopy studies of AD lesions. 
1966 
 
Roth; correlation between dementia and senile plaques of elderly. 
1967 
 
 
Suzuki and Terry; amyloid plaques with dystrophic neuritis and involvement of 
axioplasmic transport.  
1967 Gonatas; abnormal synaptic complex near amyloid plaques. 
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1968 
 
 
Blessed; correlation between plaques and cognition implied major role of amyloid in 
AD. 
1968 
 
 
Blessed, Tomlinson and Roth; Senile dementia and presenile dementia (AD) are 
pathologically and clinically same. 
1971 
 
Gallyas; Silver staining for Alzheimer’s NFTs.
1974 
 
 
Drachman and Leavitt; Scopolamine produced memory loss and confusion in normal 
patients similar to that of AD patients. 
1976 
 
Davies and Moloney; deficiency of choline acetyl transferase in AD cortex. 
1976  
 
 
Bowen; neurotransmitters and indices of hypoxia in senile dementia. 
Neuropharmacologists entered AD research. 
1976 
 
Scheibel; loss of dendritic spines in AD cases.
1976 
 
 
 
Katzman; Senile dementia and AD are one single disease. Importance to frequency 
and mortality due to AD.  Aftermath of this paper many clinical neurologists, 
epidemiologists, radiologists, and psychiatrists got interested in AD.  
1977 
 
Perry; necropsy evidence for cholinergic deficits in senile dementia. 
1981 
 
Terry; neuron loss quantification in AD and correlation to cognition. 
1984 
 
Glenner and Wong; Aβ sequence was discovered. 
1985 
 
Masters and Beyreuther; APP protein sequence discovered.
1985 
 
 
Jean-Pierre Brion found that anti-tau antibodies labelled NFTs and also this was first 
ever successful immunohistochemistry on neurodegenerative diseases. 
1987 
 
 
Terry; selective loss of cortical neurons due to normal ageing while maintaining the 
total. 
1987 
 
Terry; several cases of typical AD without neurofibrillary tangles. 
1987 
 
McGeer; expression of inflammatory markers and involvement of immune cells in AD. 
1990 
 
Levy; Dutch mutation E693Q on APP identified. 
1991 
 
Terry; synapse loss quantification in AD and correlation to cognitive impairment.
1991 
 
Braak and Braak; staging of Alzheimer’s disease.
1991 
 
Goate; London mutation V717I on APP identified.
1991 
 
Murrell; Indiana mutation V717F on APP identified.
1992 
 
Mullan; Swedish mutation K670N/M671L on APP identified. 
1992 Hardy and Selkoe; amyloid cascade hypothesis pinpoints Aβ as ‘‘THE TARGET’’. 
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1993 
 
APOE4 as risk factor for sporadic or late onset AD.
1993 
 
Masliah; neocortical synaptic loss due to normal ageing.
1995 
 
Games; first transgenic APP mouse showing Aβ pathology.
1997 
 
Graeber; rediscovery of Alzheimer’s second patient (1911 case).
1999 
 
Schenk; immunotherapy for Alzheimer’s disease. 
2002 
 
Phase 2b trial of active Aβ vaccine AN1792 halted due to aseptic meningitis.  
2004 
 
Klunk; in vivo amyloid PET Scan imaging using  Pittsburgh compound B 
2007 
 
 
Tramiprostate (Alzhmed) fails in phase 3 clinical trial (unexpected improvement in 
more than 30% placebo treated patients due to concomitant medication). 
2008 
 
Ginkgo biloba prevention trial is negative. 
2008 
 
 
Tarenflubril or R-Flurbiprofen (Flurizan) fails in phase 3 clinical trial. (Poor brain 
permeability together with lack of potency) 
2008 
 
 
Bapineuzumab fails in phase 2 trial with hints of efficacy in post hoc sub-group 
analysis. 
2010 
 
 
Dimebon (latrepiridine) fails in phase 3 trial –CONNECTION Study (No one knew how 
it works, but still it reached phase 3 only to fail.) 
2010 
 
Semegacestat fails in phase 3 trail (Dose was compromised to prevent toxicity).
2010 
 
Polyunsaturated fatty acid DHA (Docosahexaenoic acid) failed in 18 month trial.
2011 
 
Phase 2b trial with RAGE inhibitor PF-04494700 stopped as it failed interim analysis.
2011 
 
Phase 2 trial of Ponezumab stopped. It is a C-terminal Aβ antibody. 
2012 
 
Jonsson; protective APP mutation discovered. 
2012 
 
 
 
Coenzyme Q, Vitamin C, E and α- lipoic acid failed to improve CSF biomarkers and 
cognition of AD patients. All drugs except Conzyme Q  did reduce brain oxidative 
stress as a consequence of treatment.  
2012 
 
Dimebon yet another phase 3 trial - CONCERT trial fails.
2012 
 
 
 
Human intravenous immunboglobulin stops AD progression in 4 mild to moderate  AD 
patients in phase 2 trial for more than 3 years.(may be suppressed inflammation and 
fostered  neurogenesis) 
2012 Bapineuzumab and Solaneuzumab fail in phase 3 clinical trials. Pathology in mild to 
moderate AD too severe to rescue (Too little, too late?). 
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 Many perceived AD as a rare “presenile dementia” due to Emil Kraepelin’s classification. 
However, in 1968 a very important study by Blessed, Tomlinson and Roth found clinical and 
pathological features of senile dementia to be indistinguishable from AD (presenile dementia) 
(Blessed et al., 1968). Later in 1976, an editorial by Katzman observed that neither clinical, nor 
neuropathological or ultrastructural features could differentiate these two forms of dementia 
except for age (Katzman, 1976). He strongly exhorted to combine these two forms of dementia 
into one single disease, AD. Further, he cautioned clinicians about the impending malignancy 
of AD in western societies where average life expectancies were on rise (Katzman, 1976). In 
the aftermath of this editorial, several clinicians, neuropathologists, epidemiologists, 
radiologists, psychiatrists, biochemists, geneticists joined the race to understand AD etiology.  
Today, we still do not know exactly what causes AD and whether these hallmarks even 
qualify as drug targets in AD. 
Even though the ultimate cause of AD still remains a mystery, a lot has been understood 
about its progression. This disease has clinically insidious onset and features progressive loss 
of memory, language, executive and analytical skills, delirium, hallucinations and depression. 
Definitive diagnosis of AD is done at post mortem with the presence of neurofibrillary tangles, 
amyloid plaques and neuronal loss in the cortex and hippocampus.  
2.1.2 Alzheimer’s disease: Today 
Roughly 106 years later, genetics and biochemistry has contributed immensely towards 
our understanding how the disease begins and evolves. Amyloid-β (Aβ) protein was 
discovered to be the key component of Alzheimer’s “miliary foci”. Intracellular tau protein 
was later discovered to be principal component of neurofibrillary tangles (NFT).  Detailed 
clinical correlates of these key lesions have been investigated. Spreading of pathology across 
various brain regions has been studied in relation to the clinical stage of the disease. Novel 
imaging techniques, transgenic mouse models, cerebrospinal fluid (CSF) biomarkers all have 
contributed immensely towards understanding time course and pathogenetic mechanisms for 
plaques and tangles. Aβ was found to be neurotoxic in various in vitro models and was 
shown to be affecting neuronal function.  Abnormal changes to tau protein are now 
considered as downstream to Aβ pathology (Jin et al., 2011b).  
Neuropathological hallmarks of AD can be classified as lesions due to protein 
accumulation (Aβ plaques and NFT), lesions due to losses (neurons and synapses) or lesions 
due to body’s response (neuroinflammation, glial reactivity) (Duyckaerts et al., 2009). Only 
the accumulated lesions are currently of diagnostic value. Extracellular Aβ deposits and 
intracellular aggregation of tau protein are hydrophobic in nature with abnormal misfolded 
fibrillar structures. Heterogeneity in AD neuropathology was evident right from Alzheimer’s 
time, when his much popularised second case Johann F., lacked neurofibrillary tangles 
(Klunemann et al., 2002). Thanks to current neuropathological diagnostic criteria 
strengthened by advances in neuroimaging and CSF biomarkers, the accuracy of clinical 
diagnosis of AD is more than 90% (Clark et al., 2008).   
2.1.3 Amyloid pathology 
The Aβ peptide deposits can be detected either by Aβ immunohistochemistry or by Congo 
red histological stain. The term “senile plaque” for Aβ deposits is not common any more. It 
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was widely used during early twentieth century to describe extracellular lesions that were 
characteristically associated with senile dementia (Goedert, 2009). Currently, all extracellular 
accumulations are called deposits, preceded by a term indicative of technique used to detect 
them e.g. Aβ deposits are those detected by anti-Aβ antibodies whereas amyloid deposits are 
those revealed by Congo red or thioflavin S staining. In addition, a term indicative of their 
shape was also used as prefixes, such as diffuse, focal or stellate Aβ deposit. Diffuse Aβ 
deposit show very weak immunopositivity (50 μm2 to > 100μm2), with loosely defined 
boundaries and often rely on the quality of immunohistochemistry. Sometimes these diffuse 
deposits were called “lake-like” (Wisniewski et al., 1998) or “fleecy” (Thal et al., 1999) . 
Diffuse Aβ deposits were also found in the brains of people with intact cognitive functions 
indicating that these lesions may not be overtly toxic (Delaere et al., 1990; Dickson et al., 
1992). Ability of Pittsburgh compound B (PIB) to bind diffuse Aβ deposits also explains why 
many cognitively normal subjects showed higher PIB binding (Lockhart et al., 2007).  
However, it is also believed that most if not all these visibly normal individuals with diffuse 
Aβ deposits will eventually develop full–blown AD.  Anti-Aβ antibodies directed at the N-
terminus sometimes fail to detect diffuse Aβ deposits because APOE binds to the N-terminus 
of the Aβ peptide during early stages of Aβ deposition (Uchihara et al., 1996; Thal et al., 
2005). 
Focal deposits, on the other hand, are dense spherical accumulations of Aβ peptide. Focal 
Aβ deposits may or may not be positive for Congo red or thioflavin S stain indicating that not 
all Aβ deposits are amyloid deposits. Also, not all focal deposits show neuritic corona. In 
transgenic mouse models of AD, activated microglia are associated with both focal Aβ and 
amyloid deposits.  Amyloid deposits may show a dense core surrounded by a clear halo that 
separates light and diffuse Aβ immunopositive outer area from the core. The plaque core 
mainly contains Aβ42 peptide. A single Aβ plaque core has been estimated to contain 50-100 
fmol of total Aβ peptide (Rufenacht et al., 2005).  The halo surrounding the core is occupied 
by 5-6 microglial cells. The corona of focal Aβ deposit contains neuritic and astrocytic 
components. The Aβ focal deposit together with neuritic corona constitutes “mature”, 
“classical”, “neuritic plaque” (Duyckaerts et al., 2009).  The neuritic processes of corona were 
described in great detail by Oskar Fishcer way back in 1907 (Goedert, 2009). See figure 2.1a 
for examples of neuritic plaques. These neurites as revealed by silver methods were very 
abnormally large and “dystrophic”. Early neuropathologists used Bielschowsky’s technique 
to visualize neurites, which was soon replaced by Bodian’s and Gallyas methods (for better 
selectivity). Axonal or dendritic nature of these processes was better shown by Golgi’s 
method but this falls short in staining plaques.  
Under electron microscope, these degenerating neurites from plaque corona were 
distended, contained large amounts of lipofuscin, degenerating mitochondria, synaptic 
vesicles (Luse and Smith, 1964; TERRY et al., 1964) and paired helical filaments (PHF) made 
of tau protein. Sensitive tau antibody like AT-8 can stain the processes present in plaque 
corona. Swollen astrocytic processes are also present in the plaque corona, but unlike 
microglia they do not touch the plaque core but rather occupy the plaque periphery. 
Advanced AD brains show increased densities of “remnant plaques”   that are characterized 
by mesh-like astroglial fibrils within the entire part of plaque. These possibly indicate a 
regressive stage of lesions (Oide et al., 2006). Characteristic “cotton wool plaques” were 
discovered from familial AD patients with deletion of exon 9 of presenilin 1 (PSEN1) gene 
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(Crook et al., 1998). These distinctly large, numerous eosinophilic round plaques resembling 
cotton wool balls were immunoreative for Aβ but lacked congophilic dense core. Plaque 
related neuritic pathology and cellular infiltrates were absent. Mostly these are composed of 
N-truncated forms of Aβ42 (Mann et al., 2001). Another characteristic plaque called as 
“Inflammatory plaque” has also been described recently in AD cases with PSEN1  mutations. 
Inflammatory plaque cores were positive for thioflavin-S, cresyl violet and silver stains but 
were negative for both Aβ and tau or for any other protein that were consistently associated 
with classic cored plaques (e.g. APOE, IgG, α-synuclein). Some Aβ was evident in the 
periphery of the core and the core itself was surrounded by numerous HLA-DR positive 
microglial cells, hence the name Inflammatory Plaque (Shepherd et al., 2005). Most of these 
plaques were described from AD brains with varying degrees of pathology and is currently 
not possible to understand chronological progression of these deposits. However, it is 
believed that initially plaques are of diffuse type, then become Congo-red positive in the core, 
and finally are surrounded by neuritic corona to form a mature neuritic amyloid cored senile 
plaque (Metsaars et al., 2003).   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1a. Oscar Fischer’s illustrations of neuritic plaques from brains of patients with senile 
dementia. Adapted from Brain (2009) 132: 1102 
 
2.1.4 Amyloid angiopathy 
Accumulation of congophilic material, i.e., Aβ protein inside the meningeal and cortical 
arteries, arterioles, and veins causes cerebral amyloid angiopathy (CAA). Most elderly, 
whether demented or not, commonly show CAA pathology associated with ageing. Roughly 
80% of AD patients show some degree of mild CAA. Familial forms of CAA were associated 
with Dutch, Flemish and Iowa mutations on the amyloid precursor protein (APP) gene. 
Further, APP gene duplication has also been linked to severe CAA. Aβ is first deposited 
around the basement membrane of blood vessels followed by tunica media. In severe cases 
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vessels look like a double barrel, and media shows fibrinoid necrosis. Such vascular 
pathologies result in hemorrhages and cortical infarcts. Moreover, not all cases of AD show 
CAA; however, some degree of CAA is usually seen in age-matched non-AD brains. Mainly 
Aβ40 is deposited in arteries and capillaries (Thal et al., 2008). Occipital cortex is affected with 
CAA more often than any other brain regions, and correlates significantly with AD pathology 
irrespective of Apolipoprotein E (APOE) genotype (Attems et al., 2005). Based on capillary 
involvement sporadic CAA can be either be CAA-Type 1 or CAA-Type2 (Thal et al., 2002).  
The first type is characterized by immunohistochemically detectable Aβ in cortical capillaries 
along with leptomeningeal and cortical arteries, arterioles, veins and venules.  However, in 
the second type cortical capillaries are devoid of immunohistochemically detectable Aβ. 
CAA-Type1 is also linked with presence of APOE4 genotype and is sometimes also called as 
dyshoric angiopathy (horos meaning barrier), as amyloid seems to be getting out of blood 
vessels indicating disruption of blood-brain barrier. CAA-Type2 is more common and is not 
associated either with APOE genotype or AD severity. Capillary CAA can also be detected by 
antibodies against Aβ42 (involves perivascular space and glial limitans), and this correlates 
with AD pathology. On the other hand, Aβ40 immunopositive capillary CAA largely limits 
itself to the vessel wall, and this type of pathology does not correlate to AD pathology (Thal 
et al., 2002). 
2.1.5 Intraneuronal Amyloid beta pathology 
Accumulation of Aβ has also been reported within neurons of humans and many other 
species. Cell culture experiments indicate subcellular localization of Aβ in endoplasmic 
reticulum, Golgi complex and endosomal-lysosomal systems (LaFerla et al., 2007). Such sub-
cellular Aβ has been proposed to be detrimental for neuronal survival.  Pyramidal neurons in 
the human brain accumulating Aβ intracellularly undergo lysis to form amyloid plaques 
(D'Andrea et al., 2001). Furthermore, in the APP(SL)/PS1KI AD mouse at 10 months age, more 
than 50% loss of CA1/2 neurons correlates with intraneuronal Aβ rather than extracellular Aβ 
(Casas et al., 2004). Moreover, the earliest cognitive impairments in the 3xTg-AD AD mouse 
model correlate with intraneuronal Aβ accumulation in the hippocampus and amygdala 
(Billings et al., 2005). Further, in 3xTg-AD AD mouse, passive immunization with Aβ 
antibodies cleared not only extracellular Aβ but also diminished intraneuronal and tau 
pathologies, thus further implicating Aβ within neurons to be a key target for alleviating AD 
pathology (Oddo et al., 2004). However, the role of intraneuronal Aβ in the AD pathogenesis 
has been subjected to intense scrutiny and skepticism seemingly due to technical reasons. 
Firstly, the antibodies destined to react with Aβ also cross-react with both APP holoprotein 
and proteolytic derivatives of APP, thereby the immunoreactive signal might not be specific 
to Aβ itself. Secondly, pretreatment protocol employed for Aβ immunostaining influenced 
the quality of intraneuronal signal. Heating protocols enhanced the visualization of 
intraneuronal Aβ signal whereas formic acid pretreatment did not, which further strengthens 
the idea that mostly intraneuronal staining might be just a staining artifact. One study (Aho et 
al., 2010)  clearly showed that commonly used 6E10, 4G8 and 82E1 clones of Aβ antibodies 
fail to distinguish Aβ from APP in human brain tissues irrespective of AD pathology or age. 
Furthermore, intracellular Aβ staining with C-terminal Aβ neoepitope antibodies is strongly 
depended on the antibody chosen and pretreatment strategy employed. A very recent study 
(Winton et al., 2011) using end specific Aβ antibodies (which exclusively recognized Aβ 
peptides ending in either Aβ40 or Aβ42 but not Aβ sequences within APP) provided elaborate 
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and conclusive evidence that indeed the intraneuronal Aβ staining was coming from APP or 
its derivatives. This evidence was further corroborated in mice obtained by crossing 3xTg-AD 
mice with beta-site APP cleaving enzyme 1 (Bace1) knockout mice (Winton et al., 2011).   
Thai and coworkers have proposed staging of parenchymal Aβ plaque pathology in order 
to delineate the AD progression (Thal et al., 2002).  In phase 1, amyloid deposition is 
restricted to only neocortex (frontal, temporal, parietal or occipital). In phase 2, pathology 
additionally spreads to allocortical brain regions (entorhinal cortex and hippocampus); while 
diencephalon, striatum and basal forebrain get involved during phase 3 in addition to 
neocortex and allocortex. Finally, brainstem and cerebellum get involved during phase 4 and 
5, respectively. As for cerebral amyloid angiopathy (Duyckaerts et al., 2009), three stages have 
been formally recognized.  Blood vessels of isocortex are involved in stage 1, followed by 
vessels of allocortex, midbrain and cerebellum at stage 2. In stage 3, vessels of basal ganglia, 
thalamus, pons, medulla oblongata get involved. One should note that in cerebellum, 
amyloid deposition in vessels occurs earlier (stage 2) than corresponding (phase 5) 
parenchymal deposits (Duyckaerts et al., 2009). 
2.1.6 Neurofibrillary tangles and tau pathology 
The other hallmark lesion of AD is neurofibrillary tangle (NFT). See figure 2.1b for some 
examples of NFTs from brains of senile dementia patients. Neurofibrils are normal 
cytoskeletal components of neurons that can be visualized by silver staining. Alzheimer in his 
first case report of Auguste D reported neurofibrils to be abnormally thickened, bundled and 
persistent even after the death of the cell. Dyes that do not stain normal healthy neurofibrils 
stained NFTs, thus hinting towards its pathological nature. Around same time in 1907, S. C. 
Fuller also described neurofibrils in pathological conditions including senile dementia. 
Alzheimer also described similarities of neurofibrillary pathology in cases referred to him by 
Dr. Pick that were different from Auguste’s NFTs in terms of their distinct round shape and 
total lack of plaque pathology (this disease is nowadays called Pick’s disease, although 
Alzheimer first described the changes). Subsequently, amyloid nature of NFTs was 
established by thioflavin S staining (Divry, 1934) hinting that these were composed of highly 
organized structures. Later in 1960s, electron microscopy revealed paired helical filament 
(PHF) structures to be components of abnormal cytoskeletal filaments (KIDD, 1963; TERRY, 
1963). PHF filaments are fibrils of 10 nm diameter, and they pair in a helical conformation at a 
regular periodicity of 65 nm. Filaments are made of tau in cross β-sheet configuration. Several 
polyclonal and monoclonal antibodies were raised either to purified PHF or to normal 
cytoskeletal associated proteins. Immunocytochemistry and biochemical studies revealed that 
these PHF composed neither of neurofilament proteins nor tubulins but contained 
microtubule associated tau protein (Brion et al., 1985).  This microtubule associated tau 
protein was later found to be abnormally phosphorylated (Grundke-Iqbal et al., 1986). 
Abnormal phosphorylation fuelled research for identifying relevant kinases and 
phosphatases, which ultimately resulted in identification of glycogen synthase kinase-3 beta 
(GSK3-β) enzyme which currently is one pharmacological drug target for AD.  
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Figure 2.1b. Oscar Fischer’s illustrations of neurofibrillary tangles from brains of patients with 
senile dementia. Adapted from Brain (2009) 132: 1102 
 
Such tau deposits were also detected in many other conditions like progressive 
supranucleur palsy, corticobasal degeneration and Pick’s disease that lack Aβ plaque 
pathology. Tau mediated neurodegeneration may result from toxic gain of function acquired 
by aggregated conformations of tau and loss of normal functions of tau in diseased 
conditions. Tau has many important cellular functions in healthy neurons which precludes it 
from being a viable drug target during diseased conditions. Tau is microtubule-associated-
protein, abundant in axons and primarily helps to stabilize microtubules. There are six 
isoforms of tau based on alternate splicing of mRNA. Structurally, towards the carboxy-
terminal portion of protein, microtubule binding domain is present which is composed of 
repeats of highly conserved tubulin binding motif, followed by basic proline rich region and a 
projection domain comprising acidic amino terminal region. The six isoforms differ from each 
other in the number of tubulin binding repeats (either three or four, hence called 3R or 4R 
isoforms respectively) and in the presence or absence of 29 amino acid long inserts on the N-
terminal region. During development, expression of various tau isoforms is variable; 
however, in the adult expression in many brain regions of 3R and 4R isoforms follows 1:1 
ratio, and any deviation from this ratio is characteristic of neurodegenerative FTD taupathies 
(Hong et al., 1998).  In a widely accepted model, tubulin binding repeats of tau bind to 
specific pockets in β-tubulin protein on the inner surface of microtubules whereas proline rich 
positive region binds tightly to negatively charged  microtubule surface and negatively 
charged projection domain branches away from microtubule surface possibly due to 
electrostatic repulsion. Further, tubulin binding pockets on adjacent protofilaments may be 
occupied by different repeats of same microtubule binding domain, thereby causing cross-
linking of three or four dimers (Amos, 2004). Apart from microtubule stabilization function of 
tau, other functions like interaction of projection domain with plasma membrane, binding of 
proline rich domain with the SH3 domains of src-family tyrosine kinases such as FYN, RNA, 
and presenilin 1 involves tau as promiscuous partner to heterologous interactions (Ballatore 
et al., 2007).  
Accumulation of tau deposits in human brain takes place exclusively in neurons. Tau 
accumulations can be seen in both axons and dendrites. Tangles and pretangles are associated 
with accumulation of tau in soma.  Abnormal accumulation of phosphorylated tau that fills 
14 
 
 
 
the entire soma but without aggregation constitutes “pretangle” (Bancher et al., 1989).  Tau 
positivity in neuropil threads are mostly dendritic processess while in neuritic plaque corona 
are mainly composed of tau positive axonal processes (Duyckaerts et al., 2009). Their 
presence in astrocytes (Thorn-shaped astrocytes) is mostly associated with age rather than 
AD pathology. Double labeling with monoclonal antibodies like AT-8 and GFAP reveal 
abnormal tau accumulation in distal and proximal processes of astrocytes (Schultz et al., 
2004). Extracellular NFTs retain cell shape but lack plasma membrane, and is the common 
end point for neurofibrillary pathologies. Intracellular NFTs show identifiable nucleus and 
plasma membrane. In addition, some advanced cases of AD show ghost tangles characterized 
by absence of intracellular neurofibrillary pathology and absence of C-terminus of 
abnormally phosphorylated tau (Endoh et al., 1993). NFTs can be located mainly to medium-
sized pyramidal neurons of the hippocampus, entorhinal cortex and of layers III and V of the 
isocortex. Neurons of the transentorhinal area (layer III +V) and of layer II of the entorhinal 
cortex are the first to show NFT pathology (Braak and Braak, 1990). Olfactory regions are also 
reported to be involved during early stages of AD (Kovacs et al., 2001). Alz50 and AT8 are 
two popular monoclonal antibodies that are in use to visualize NFTs. Alz50 is a 
conformational antibody that recognizes and requires two discontinuous epitopes, one on N-
terminus and other at microtubule binding domain for efficient binding (Carmel et al., 1996). 
AT8 antibody recognizes an epitope double phosphorylated at serine 202 and threonine 205 
or serine 199 and 202 or serine 205 and 208 (Porzig et al., 2007). NFTs can also be detected by 
antibodies against ubiqutin (p62), prothrombin, thrombin, heparan sulfate proteoglycan, 
Fe65, flotillin, CDK5 and GSK-3β (Duyckaerts et al., 2009). Neurofibrillary pathology is not 
cleared from the brain and it can remain in the extracellular space without causing an 
inflammatory reaction. This feature allows researchers to relate density of NFTs to the 
severity of disease stage and to track progression of lesions at each stage. Progression of NFTs 
seemed to be related to anatomical tracts. Such extension of tau pathology through 
anatomical connections demonstrates hierarchical distribution of tau pathology that can be 
linked to clinical symptoms. This is the basis for Braak neurofibrillary stages. Braak and Braak 
characterized the progression of AD in the cerebral cortex based distribution of NFTs and 
neuropil threads into six distinct stages. Stages I and II involve trans-entorhinal and 
entorhinal regions followed by involvement of hippocampus in stages III and IV. Isocortex 
gets finally involved in stages V and VI (Braak and Braak, 1991). Braak staging of 
neurofibrillary pathology is currently being used routinely in neuropathology. Subcortical 
nuclei are not considered in Braak staging; however, the involvement of for instance nucleus 
basalis of Meynert and locus coeruleus is seen quite early in the disease progression (Duyckaerts 
et al., 2009).  
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1c. Illustration of amyloid core of neuritic plaque surrounded by glia. Also, a neuron 
bearing tangle pathology is also seen near the plaque microenvironment. Adapted from Nature 
Neuroscience (2002)5:633 
 
The relationship between Aβ and tau pathologies (Figure 2.1c) is very controversial. 
Familial APP and PS1 mutations cause abundant Aβ as well as tau pathologies, whereas tau 
mutations result only in NFT pathology without Aβ deposition. Hence it appears that APP 
processing or abnormal Aβ accumulation triggers a disease mechanism that ultimately results 
in neuronal death and NFTs. Furthermore, in vitro demonstration that Aβ oligomers can 
phosphorylate tau and evidence from 3xTg-AD mice (Oddo et al., 2004) suggest that tau 
hyperphosphorylation is a secondary event to or consequence of Aβ pathology.  However, if 
this is true, one should find NFTs only near Aβ deposits, which is not the case. Spatially, 
NFTs location is not determined by Aβ deposits. Moreover, tau pathology has been reported 
to start many decades before Aβ pathology initiates (Duyckaerts and Hauw, 1997). 
2.1.7 Neuronal loss and synaptic pathology 
Another hallmark of AD brain is massive neuronal loss in focal brain regions. Estimation 
of neuronal loss needs to apply a correction for potential bias in counting neurons. Large 
neurons have a higher probability than small ones to be incorporated in a microscopic section 
thereby leading to overrepresention of large neurons. Moreover, atrophy of large neurons 
may lead to a wrong conclusion that neurons have been lost when in fact they have only 
become smaller (Duyckaerts et al., 1989). Counting nucleoli (much smaller in size) might 
decrease the bias. Unbiased dissector technique (Sterio, 1984) or Dirichlet tessellation 
methods (Duyckaerts et al., 1994) defined neuron loss in AD to be focal rather than global in 
nature (Regeur et al., 1994). Up to 90% neuronal loss has been documented in layer II of 
entorhinal cortex, CA1 region (three-fold reduction), superior temporal gyrus and 
supramarginal gyrus (Duyckaerts et al., 2009). A correction factor needs to be incorporated 
while reporting neuronal densities because of a potential bias.  In the isocortex, large and 
medium sized neurons are most vulnerable while large Betz cells are relatively spared. 
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Olfactory bulb, amygdala, nucleus basalis of Meynert, locus coeruleus, substantia nigra and 
serotoninergic raphe nuclei are the major brain structures with well-established neuronal loss 
in AD.  Loss of neurons in AD may not be primarily due to neurofibrillary degeneration. 
Typically, it would take 15-25 years for tau pathology to evolve from tau 
hyperphosphorylation to formation of NFTs but neuronal loss by apoptosis takes just a day 
(Buee et al., 2010). Apoptosis due to Aβ toxicity has been suggested to be the one of the 
reason for neuronal loss. 
Synaptic pathology in AD patients has been appreciated by electron microscopical studies 
on biopsy and autopsy tissues (Scheff and Price, 1993; DeKosky and Scheff, 1990). Synaptic 
pathology in AD is characterized by alteration of synapses, presence of synapses near and 
within Aβ deposits, and loss of pre- and post-synaptic markers (Duyckaerts et al., 2009).  
These changes correlated with cognitive decline in mild AD patients (Scheff et al., 2007). 
Changes to number and morphological alterations in pre-synaptic, post-synaptic endings, 
axons, dendrites, in and around Aβ deposits are evident also with light microscopy (Gonatas 
et al., 1967). Presynaptic vesicular markers like synaptophysin are decreased in AD, while 
presynaptic membrane markers like SNAP25 remain stable (Shimohama et al., 1997) (Masliah 
et al., 2001). Loss of synaptophysin appears to be the best correlate for intellectual deficit 
(Terry et al., 1991). Degenerative synapses found in Aβ deposits and clusters of synapses 
along the neuropil may be non-functional. Loss of dendritic spines has also been reported in 
AD mice (Grutzendler et al., 2007).  
Macroscopically, AD brains exhibit massive atrophy. Inferior temporal and superior and 
mid-frontal gyri are affected severely.  Microscopic lesions contribute in part to macroscopic 
changes. Areas commonly involved in tau pathology (Whitwell et al., 2008) and those 
exhibiting neuronal loss (entorhinal, hippocamous and amygdale) also show atrophy 
(Halliday et al., 2003)(Duyckaerts et al., 2009)(Duyckaerts et al., 2009)(Duyckaerts et al., 
2009)(Duyckaerts et al., 2009)(Duyckaerts et al., 2009)(Duyckaerts et al., 2009)(Duyckaerts et 
al., 2009)(Duyckaerts et al., 2009). Atrophy does not correlate with amyloid deposits but 
shows strong correlation to neuronal loss (Kril et al., 2004). MRI measurements show both 
decrease in thickness and length of cortical ribbon. One visible consequence of cortical 
thinning is prominent dilatation of lateral ventricles. MRI scans can detect this pattern of 
cortical thinning quite early in the clinical course of AD (Dickerson et al., 2011). Atrophy of 
grey matter is accompanied by atrophy of white matter (Lerch et al., 2008). 
2.1.8 Pathomechanisms for Alzheimer’s disease 
Genetic, biochemical, and ultra-structural studies have contributed to our understanding 
of complexities involved in AD. Alzheimer’s disease has become a major social and economic 
burden on developed as well as developing countries around the world (Qiu et al., 2009). It is 
estimated that worldwide by 2030 there will be 65.7 million people suffering from dementia, 
most of which will be suffering from AD (70%) and this figure is projected to double every 20 
years, to 115.4 million by 2050. In Europe, there will be 16.2 million people suffering from 
dementia by 2050 (Wancata et al., 2003). Worldwide estimated costs of dementia were 
approximately US$ 604 billion in 2010, which is bound to increase quickly. With 7.7 million 
new cases of dementia each year worldwide (implies one case every 4 seconds); it is going to 
throw a serious challenge to our efforts and resources (WHO report, 2012).  Incidence of AD 
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in people > 65 years age increases exponentially with age and mostly this rise is noted in 
seventh and eighth decades of life. 
Age is the biggest risk factor of AD. Roughly, less than 5% of the AD cases are early-onset 
(familial) and more than 95% of the cases are sporadic or late-onset. Mutations in amyloid 
precursor protein (APP) and presenilin genes (PSEN1 and PSEN2) cause early-onset 
autosomal dominant form of AD (onset age < 60 years).  APP and PSEN1 gene mutations 
predispose to familial onset AD, whereas APOE4 genotype is the strongest risk factor for 
sporadic AD. APOE has been to shown to be involved in Aβ clearance, and alleles APOE2, 
APOE3 and APOE4 are increasingly less effective in clearing Aβ from brains of PDAPP mice 
(Holtzman et al., 2000). Even though many risk and protective factors have been shown to be 
linked to AD it should be noted that these factors merely tell us about the probability of 
acquiring the disease. These factors signal their involvement in disease mechanisms and may 
provide us a probabilistic clue about the outcome of the disease. However, disease risk 
indicated by these factors falls short of sensitivity and/or specificity to be used as diagnostic 
marker (Reitz et al., 2011). 
Human APP, PSEN1 and PSEN2 genes are all involved in the production and processing of 
Aβ protein, the principal component of senile amyloid plaques found in the brains of AD 
patients. Mutations on these three genes increase Aβ production and ratios of Aβ42/Aβ40, thus 
implicating the role of Aβ in the AD pathogenesis (Bertram and Tanzi, 2008). Duplication of 
the APP gene has also been reported to cause early-onset AD (Rovelet-Lecrux et al., 2006). 
Furthermore, Down syndrome patients with an extra copy of chromosome 21, on which APP 
gene resides, develop symptoms similar to early-onset AD (Millan Sanchez et al., 2012). 
Clinically, early- and late-onset AD are indistinguishable and remain undetectable at the 
desease onset, while by the time cognitive deficits appear, the patient’s brain is already 
engrossed with full-blown irreversible pathology. Owing to massive loss of neurons and 
synaptic connections during late stages of disease, it is now believed that there might be a 
therapeutic window during the early phases of disease progression when neurons, synapses 
as well as cognitive functions are still intact.   
Mechanisms related to processing, formation, aggregation and deposition of Aβ peptide 
offer many opportunities for drug discovery programs to intervene in disease pathogenesis. 
Aβ peptide is formed by the sequential proteolytic cleavages of the 695 amino acid APP 
protein. The APP gene is located on chromosome 21, and alternative splicing of the transcript 
from this gene results in various isoforms like APP695 (common in neurons), APP751 and 
APP770.  APP protein is a type 1 integral membrane protein (Kang et al., 1987), with a large 
extracellular region (Kunitz protease inhibitor, E1 and E2 domains), hydrophobic 
transmembrane domain and amyloid precursor protein intracellular domain (AICD) 
containing C-terminal. APP knockout mice are viable and fertile; however, they show age-
related cognitive decline, reactive gliosis and deficits in neuronal and muscular functions 
(Zheng et al., 1995; Dawson et al., 1999). 
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Figure 2.1d. APP processing  by α-, β- and γ secretases and their major proteolytic products. 
Adapted from Neuron (2010) 66:631 
 
APP protein is processed in two distinct pathways (Zhang et al., 2012). First, in non-
amyloidogenic pathway APP is sequentially cut by two processes, α- secretase and γ- 
secretase. Cleavage by α-secretase results in release of large extracellular soluble sAPP-α and 
membrane bound C-terminal fragment containing 83 amino acids (C83). C83 is then cleaved 
by γ-secretase to release p3 peptide and AICD. sAPP-α has neurotrophic and neuroprotective 
effects. In the second, amyloidogenic pathway, APP is first cleaved by β-secretase, thus 
releasing sAPP-β and membrane associated C93 fragment. Further, C93 is cleaved by γ-
secretase to release AICD and Aβ peptide (Zhang et al., 2012). The released extracellular Aβ 
peptide aggregates to form amyloidogenic Aβ assemblies and eventually gets deposited in 
amyloid plaques.  See figure 2.1d for illustration of APP processing. 
Gene mutations related to APP, PSEN1 and PSEN2 genes have been implicated in familial 
AD. Table 2.1b summarizes some popular APP mutations. These mutations cause aberrant 
APP processing resulting in overproduction of the more amyloidogenic Aβ42. Interestingly, 
Osaka mutation of APP gene results in enhanced formation of Aβ variant lacking glutamate-
22 (E22Δ) causing excessive formation of Aβ oligomers but not Aβ fibrils. Dementia caused 
by this mutation reinforces the idea that synaptic and cognitive impairments in AD are 
caused by Aβ oligomers (Tomiyama et al., 2008). Nearly all mutations of the APP gene lead to 
early onset AD except for one recently reported protective APP mutation which not only 
reduces risk for sporadic AD but also reduces cognitive decline in the elderly (Jonsson et al., 
2012).  
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Table 2.1b: Common APP mutations associated with familial Alzheimer’s disease 
NAME MUTATION REFERENCE 
Swedish K670N/M671L (Mullan et al., 1992) 
Dutch  E693Q (Levy et al., 1990) 
London  V717I (Goate et al., 1991) 
Indiana  V717F (Murrell et al., 1991) 
Florida  I716V (Eckman et al., 1997) 
Iowa  D694N    (Grabowski et al., 2001) 
Arctic  E693G (Nilsberth et al., 2001) 
Osaka E693∆ (Tomiyama et al., 2008) 
Iceland A673T (Jonsson et al., 2012) 
 
2.1.9 Amyloid cascade hypothesis 
Unfortunately, causation of AD has not been established fully. According to the amyloid 
cascade hypothesis, Aβ protein gets deposited in the brains of AD patients due to some 
unknown reason which triggers a cascade of events downstream resulting in formation of 
neurofibrillary tangles and neuronal death (Hardy and Higgins, 1992; Hardy and Selkoe, 
2002). Aβ isolated from AD patients was sufficient to affect neuronal function and caused 
neurotoxicity (Mucke and Selkoe, 2012). Autosomal mutations in APP, PSEN1 and PSEN2 
genes resulting in overproduction of Aβ cause familial forms of AD. The same mutations 
when expressed in mice results in AD-like pathological features. Also, the presence of APOE4 
allele, which is strongest risk factor for sporadic AD, is associated with reduced clearance of 
Aβ from brains of PDAPP mice (Holtzman et al., 2000). Increased gene dosage of APP in 
Down’s syndrome patients also causes AD like pathology (Hardy and Selkoe, 2002). This 
biochemical, genetic and histopathological evidence shows that Aβ deposition in brain is the 
primary event that initiates a sequence of downstream events that ultimately lead to AD 
dementia (Hardy and Allsop, 1991). Therefore, irrespective of the trigger continuous presence 
of Aβ levels inside brain is toxic for the normal functioning of neurons. More recently, Aβ 
oligomers are considered to be the most toxic species responsible for loss of synapses.  In 
addition, microglia and astrocyte release many pro-inflammatory chemokines and cytokines 
that are neurotoxic. Also, it has been shown that Aβ dimers isolated from cortex of AD 
patients at subnanomolar concentrations induced tau hyperphosphorylation and neuritic 
degeneration; this was reversed by Aβ targeting antibodies (Jin et al., 2011b). These findings 
suggest that accumulation of toxic Aβ species lies upstream to tau pathology and neuronal 
dysfunction in AD. Altered neuronal homeostasis and oxidative injury further deteriorates 
causing widespread neuronal dysfunction ultimately leading neurodegeneration and 
dementia. See figure 2.1e for graphic illustration. 
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Figure 2.1e. Amyloid cascade hypothesis. Adapted from Science (2002) 297:353 
 
An important role for Aβ peptide in the AD pathomechanism is undoubtedly accepted but 
it is still not clear if Aβ is initiating the disease, driving the disease, or a mere end product of 
disease. Mere presence of Aβ in brain does not precipitate AD symptoms, thus it is unlikely 
that it causes sporadic AD. A host of direct and indirect Aβ mediated neurotoxicity studies in 
vitro and in vivo, indicate that Aβ might be an active driver of disease. Therefore,Aβ targetting 
antibodies (Bapineuzumab, Solaneuzumab, Ponezumab) considered as disease modifying 
agents were presumed to influence AD progression. These Aβ antibodies should have at least 
slowed deterioration of cognitive and daily functions in patients, but unfortunately this did 
not happen (Strobel, 2012b)(Fagan, 2012) and all these antibodies failed in clinical trials. 
21 
 
 
 
Beginning the treatments at early stages of AD might be a good avenue. For mild-moderate 
stage AD patients, neuronal loss and concominant pathogies are too severe for drugs to 
confer clinically visible benefits. Nevertheless, all the drugs so far targeting Aβ production or 
clearance have failed. So, there might be factors other than Aβ which actively drive the 
disease. This gap between the basic concepts and facts from clinical trials are the key reasons 
that Aβ hypothesis has been challenged by some researchers.  Also, some clinically diagnosed 
AD patients do not show amyloid deposits in brain whereas some other cognitively normal 
people show abundant amyl(Jin et al., 2011a)(Jin et al., 2011a)oid in the PET scans (Edison et 
al., 2007) (Jin et al., 2011a).  
Initial deposition of neurotoxic Aβ is necessary for subsequent tangle pathology, 
neurodegeneration and cognitive decline (Jin et al., 2011b). This implies a direct correlation 
between neuritic plaques and memory decline but such clinicopathological correlations are 
however very weak (Giannakopoulos et al., 2009). Furthermore, in a small number of AD 
patients harbouring PSEN1 mutations amyloid pathology is diffuse and resembles cotton 
wool plaques. Neuritic plaques and inflammatory pathologies of AD are absent, suggesting 
that Aβ plaques may not be necessary for AD (Hardy et al., 1998). More perplexingly, even 
very high expression of Aβ in mouse brains results in very scanty loss of neurons (Zahs and 
Ashe, 2010). Interestingly, familial AD mutations of APP and PSEN1 genes might also result 
in defective endolysosomal trafficking and proteolysis independent of Aβ. Furthermore, 
synaptic dysfunction and neuronal degeneration can be also caused by defective PS1 
(Pimplikar et al., 2010). Moreover, if Aβ pathology lies upstream to tau pathology as noted in 
amyloid cascade hypothesis, one would expect to find NFTs around Aβ deposits, but in 
reality spatial location of NFTs and Aβ lesions do not correspond and appear independent of 
each other. Finally, as tau pathology starts decades before of Aβ deposition, it does not seem 
to be a consequence of initial Aβ deposition (Karran et al., 2011). Mutations in tau gene can 
also result in neuronal pathology similar to that of AD patients (Hardy et al., 1998). However, 
due to absence of genetic, biochemical and clinical data challenging the mechanistic role of 
Aβ in AD pathogenesis many researchers are hesitant to pursue alternatives for amyloid 
cascade hypothesis (Karran et al., 2011; Selkoe, 2011). However, absence of proof about 
causation of AD by Aβ is by no means itself evidence that Aβ is a wrong AD target. In the 
same tone, scanty evidence for Aβ as clinically validated target is by no means itself evidence 
that it is the end of road for AD therapeutics. AD is a complex and challenging disease. 
2.1.10 Transgenic mouse models of Alzheimer’s disease 
Several early attempts to mimic and reproduce AD pathology in laboratory animals failed. 
Initially, direct Aβ injections into rat brains were used.  Injections of Aβ in combination with 
chaperones like perlecan resulted in extracellular congophilic, thioflavin S positive amyloid 
deposits (Snow et al., 1994). Even though such extracellular amyloid fibrils caused astrocyte 
activation and massive phagocyte infiltration, they did not cause neurotoxicity and 
neurodegeneration similar to that seen in AD patients (Holcomb et al., 2000).  Discovery of 
APP gene mutations in familial cases of AD greatly fuelled the race to create the first 
transgenic mouse model. Various mutations discovered in human APP gene were 
overexpressed in the mouse genome with the aid of a variety of promoters for expression in 
cortical and hippocampal neurons. Table 2.1c provides a brief summary of popular transgenic 
models of AD. These mice developed both diffuse and classic fibrillar Aβ plaques in the 
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cortex and hippocampus in an age-dependent manner, similar to human AD. Moreover, these 
mice also showed progressive cognitive deficits in a number of behavioural tests for memory 
and cognition (Lee et al., 2004; Arendash et al., 2001; Kelly et al., 2003). However, there was 
no linear relationship between levels of Aβ and memory impairments (Westerman et al., 
2002b). Overproduction of Aβ by these mice was found to be responsible for cognitive 
impairments, because the Bace1 -/- APP mouse was protected from memory impairment (Luo 
et al., 2001). When presenilin gene mutations were introduced in addition to APP mutations, 
the plaque pathology became much more aggravated (Borchelt et al., 1997).  The Aβ present 
in diffuse deposits was predominantly Aβ42, whereas Aβ40 was mainly deposited in cerebral 
blood vessels (Savage et al., 1995). 
The mouse model used in our studies, APP/PS1dE9, harbours both APP and PSEN1 gene 
mutations, which aggravates the severity of plaque and inflammatory pathology.  At 15 
months of age, APP/PS1dE9 mice display diffuse and fibrillar Aβ plaques, activated microglia 
and astrocytes, elevated brain levels of pro-inflammatory cytokine, greatly diminished 
neurogenesis and impaired cognitive functions (Garcia-Alloza et al., 2006).  
Table 2.1c: Some commonly used AD transgenic mouse models. 
Mouse Genetic make-up Pathology Reference 
PDAPP  
695, 751and 771 hAPP isoforms 
with Indiana mutation; PDGF 
promoter.  
Aβ deposits from 6 months; 
hyperphosphorylated tau and 
synapse loss.  
(Games et al., 
1995) 
Tg2576  
695 hAPP isoform with Swedish 
double mutation (K670N/M671L); 
hamster prion protein promoter.  
Aβ deposits from 9-11 
months; Intraneuronal Aβ 
  
(Hsiao et al., 
1996) 
APP23  
(Novartis 
mouse)  
751 hAPP isoform with Swedish 
double mutation (K670N/M671L); 
mouse Thy-1.2 promoter.  
Aβ deposits from 6 months; 
profound CAA;  Little 
neuronal loss  
(Sturchler-Pierrat 
et al., 1997) 
TgCRND8  
hAPP with both Indiana and 
Swedish double mutation; prion 
protein promoter 
Aβ deposits  and learning 
impairment from 3 months  
(Chishti et al., 
2001) 
J20  
hAPP with both Swedish and 
Indiana mutations; PDGF 
promoter 
Aβ plaques from 8-10 
months; Loss of presynaptic 
synaptopyhsin 
immunoreactivity; Aβ plaque 
independent toxicity.  
(Mucke et al., 
2000) 
LineC3-3  
Chimeric mouse/human APP with 
swedish double mutation  & 
containing humanized 
Aβ  domain; mouse prion 
No plaques until 18 months  
(Borchelt et al., 
1997) 
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Partial recapitulation of human AD pathology in a transgenic mouse was considered, as 
vindication for the amyloid cascade hypothesis. Mechanisms downstream of Aβ deposition 
are nicely modelled by these transgenic mice. An ideal mouse model for any disease should 
have construct validity, face validity and predictive validity. Construct validity ensures that 
the causation of pathology in the mouse model is similar to humans. Face validity ensures 
that different pathological manifestations, symptoms and phenotypes that appear in the 
model are similar to that in humans. Lastly, predictive validity ensures translation of drug 
efficacy in mice to humans. So far these transgenic APP mice have incomplete construct 
validity for both familial and sporadic AD. As for face validity, it is also partial as only 
amyloid, synaptic, inflammatory and cognitive pathologies are seen while key NFT 
pathology and neuronal loss are absent. Lastly, so far they have extremely low predictive 
validity (ability to translate efficacy in mouse models to humans). Furthermore, in the 
absence of cause-effect relationship for Aβ in AD, one needs to be aware of the caveats 
associated with these models. . Further, in many transgenic mouse models of AD (e.g. APP23 
(Van Dam, 2003) and Tg2576,(Westerman et al., 2002a)) , cognitive decline occurs well before 
the initiation of Aβ deposition. Even with massive Aβ deposition in these mice very little 
neurodegeneration is seen. In the absence of any noticeable neurodegeneration in these mice, 
they may at best model asymptomatic AD patients (Zahs and Ashe, 2010).  
2.1.11 Drugs for Alzheimer’s disease 
Currently available drugs can provide only symptomatic relief to AD patients and they 
cannot stop, delay or reverse the disease pathogenesis. Donepezil, rivastigmine and 
galantamine are acetylcholinesterase enzyme inhibitors (AChEIs), whereas memantine is 
uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist (Reisberg et al., 2003; 
Birks, 2006).  AChEIs are indicated for mild to moderate AD, whereas memantine is approved 
for moderate to severe AD either as monotherapy or in combination with AChEIs. yet 
another AChEI huperzine is currently approved in China for mild to moderate AD (Wang et 
al., 2009). Drug discovery for AD has been a daunting exercise for researchers at academia 
and industry. As prevention rather treatment paradigm is becoming increasingly favored, 
promoter.  
APPswe/PS1A
246E 
Coexpress huPS1-A246E and  
Chimeric mouse/human APP with 
swedish double mutation  & 
containing humanized 
Aβ  domain; mouse prion 
promoter. 
Aβ plaques by 12 months (Borchelt et al., 
1997) 
3xTg-AD hAPP with Swedish mutation, Tau 
with P301L mutation and PS1 
with M146V 
Progressively develop 
intracellular Aβ, plaques, 
Neurofibrillary tangles, 
synaptic dysfunction 
(Oddo et al., 
2003) 
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early diagnostic markers of AD progression are needed to identify patients with mild 
cognitive impairement (MCI). Moreover, 30-40% of MCI patients do not develop AD and are 
negative on amyloid positron emission tomography (PET) scanning. Predictors of progression 
like APOE genotype, clinical and cognitive scores, CSF markers, amyloid imaging may 
greatly help decreasing the heterogeneity of AD patient population (Sperling et al., 2011b). 
Presence of amyloid signal in PET scan together with low CSF Aβ42 and high CSF tau in 
prospective AD subjects will minimize diagnostic innacuracies. Eventhough, patient 
stratification based on markers like APOE4 genotype is good, however might necessitate 
separate trials for carriers and noncarriers as 30-50% of AD patients are APOE4 negative 
(Aisen, 2011). Amyloid cascade hypothesis promulgates two signature lesions of AD as 
mostly sought drug targets for AD. Many of the investigational drugs act by targeting either 
Aβ production or enhancing Aβ clearance. Inhibitors for BACE and γ-secretase enzymes, Aβ 
aggregation blockers work by reducing Aβ production or aggregation, while active and 
passive vaccination strategies aim to enhance clearance of Aβ from brain. Other strategies like 
targeting tau phosphorylation, mitochondrial function, neurotransmission, balance of growth 
factors and anti-inflammatory drugs are in various stages of clinical development 
(Mangialasche et al., 2010).  
Figure 2.1f provides a brief summary of the current drug trials in humans. However, the 
first wave of drugs failed to bring any meaningful clinical improvements to subjects in 
clinical trials and thus were abandoned. Tramiprostate (Alzhmed), tarenflubril (Flurizan), 
semagacestat, latrepiridine (Dimebon), antioxidants and latest bapineuzumab have failed in 
phase 3 clinical trials. Many excuses like drug not entering the brain in sufficient 
concentrations, patients on placebo not deteriorating as much as they should, patients with 
severe pathologies, drugs not engaging target Aβ efficiently, wrong and compromised dosage 
regimens, unacceptable adverse effects were put forward to account for these failures. Also, it 
is not clear how much reduction of brain amyloid is necessary to attain meaningful clinical 
outcomes. Lately, researchers have also been stressing for initiating the treatments early on 
before the onset of symptoms because there will be not much remaining to rescue by these 
drugs when given at advanced stages of AD. However one should cautiously note that rate of 
Aβ deposition is much more steeper during early stages than later stages, where it relatively 
plateaus off (Karran et al., 2011). Thus targeting Aβ can be even more challenging during 
early stages of AD. Apparently, in AD drug development program, right target, right drug 
and right disease stage seem to be extremely critical for favourable outcomes (Sperling et al., 
2011b).  
 
 
 
 
 
 
 
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1f. Current status of AD drugs in various clinical phases of drug development. Adapted 
from Lancet Neurology (2011) 10:501 
 
Aβ as drug target is very elusive in that different researchers see it in many different forms 
and quantify it differently. Aβ protein with 40 or 42 amino acids on C-terminal are 
distributed differentially in the brain. Aβ40 is predominantly present in vasculature, whereas 
Aβ42 present in neuritic plaques is more hydrophobic and prone to aggregation. It is not clear 
which one is a better target. Also, neuropathologists detect and quantify fibrillar Aβ deposits 
of brain parenchyma and vasculature with Congo red or thioflavin S staining, whereas 
diffuse Aβ is detected only by Aβ immunohistochemistry. Biochemists detect and measure 
Aβ from the perspective of solubility in different reagents like water-soluble fractions, 
detergent-soluble fractions, and water-insoluble fractions (solubilized in formic acid or 
guanidine solution). Physical chemists view Aβ from the standpoint of aggregation status like 
oligomers (monomers, dimers, trimers etc), protofibrils (Aβ aggregated in β pleated 
structure) and 6-9 nm fibrils that form Aβ deposits. It is still not clear which pool of Aβ is 
responsible for the loss of cognition in AD patients. Recently, it was found that Aβ oligomers 
interfere with normal functioning of neurons and are also synaptotoxic in nature (Wilcox et 
al., 2011). Aβ oligomers are difficult to isolate as they quickly convert into other forms 
(Benilova et al., 2012). Different researcher use diverse protocols and designate different 
nomenclatures to identify them (Aβ*56 as a good example,(Lesne et al., 2006)). Basically, 
Failed drugs 
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apart from vague target (Aβ), limited CNS penetration of drugs and AD patient heterogeneity 
might be responsible for recent setbacks in phase 3 clinical trials. 
Many high profile failures in late phases of clinical trials definitely did dampen the 
progress but did not decrease the spirit of AD drug discovery. Numerous phase 3 clinical 
trials that are in progress will validate these targets in near future. Recently, at Alzheimer 
Association International Conference (AICC)Vancouver 2012 (http://www.alz.org/aaic/), 
phase 2 data from Gammagard trial reported stabilisation of 4 AD patients for more than 
three years which is encouraging (Relkin, 2012). Also, many novel drugs like EVP-6124, a 
small-molecule partial agonist selective for the alpha-7 nicotinic acetylcholine receptor, 
improved cognition and function in Phase 2 clinical study (Strobel, 2012a). Certainly, we are 
dealing with a complex disease which may need more than one silver bullet to cure and 
prevent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
 
2.2 NEUROINFLAMMATION  
Inflammation is body’s response to noxious stimuli. Celsus described four cardinal signs of 
inflammation:  redness (rubor), heat (calor), swelling (tumor), pain (dolor). Virchow added the 
fifth sign as loss of function (functio laesa).  Tissue vasculature plays a pivotal role in this 
classic model of inflammation. In fact, local vasodilatation ensures excess blood supply, 
thereby resulting in redness and heat at the site of inflammation. Increased vascular 
permeability resulting in leakage of plasma proteins and fluid causes swelling. Bradykinins, 
prostaglandins and other lipid mediators, provide molecular signals necessary for cellular 
infiltration and heightened pain sensitivity. Therefore, tissue vasculature has an important 
role in maintenance of inflammatory responses. Further, classic triple response described by 
Lewis in 1924 featuring flush, flare and wheal are also typical vascular consequences of a 
cutaneous irritation (by stroking metal). Different cellular, molecular and genetic inducers 
regulate various phases of inflammation.  Regulation of inflammation is important for 
maintaining homeostasis.  Immune cells in circulating blood play a very crucial role in 
initiation, maintenance and resolution of inflammation (Serhan et al., 2010). Resolution of 
inflammation is equally important to limit collateral damage caused by inflammation. During 
resolution phase of inflammation, infiltration of macrophages and monocytes ceases and their 
apoptosis ensue; mediators like lipoxins, resolvins, protectins, prostaglandin D and 
transforming growth factor beta-1 (TGF-β-1) play an important role in resolution of 
inflammation (Serhan and Savill, 2005; Serhan et al., 2007).   
 Inflammation in general can be characterized by nature of stimuli and duration of stimuli. 
Acute inflammatory responses arise from short-lived stimuli like tissue injury caused by a 
knife cut. Chronic stimuli in comparison are due to stimuli for prolonged durations like those 
seen during allergies or systemic infections. Chronic inflammatory processes are known to be 
driving forces behind molecular pathogenesis of many diseases. Inflammatory diseases can 
be classified as allergic, neurodegenerative or autoimmune diseases. In case of allergic 
diseases, an exaggerated inflammatory response to foreign antigen drives the disease as 
happens for example in bronchial asthma. In case of neurodegenerative diseases, an abnormal 
toxic protein assembly or conformation when deposited initiates a cascade of inflammatory 
events as happens in AD. Lastly, in case of autoimmune diseases, uncontrolled inflammatory 
responses against self-antigens are at the root of disease pathogenesis in condisions such as 
multiple sclerosis and rheumatoid arthritis.  
Inflammatory responses occurring within central nervous system (CNS) microenvironment 
are termed as “neuroinflammation”.  Neuroinflammation is simply brain’s response to 
stimuli like infection, mechanical or chemical injury, ischemic shock or abnormal protein 
deposits etc. These responses are deemed beneficial if neuroinflammatory processes cease 
after stimuli is removed. However, in many neuropathological conditions, these processes fail 
to cease either due to persistent stimuli or failure of normal resolution mechanisms (Serhan et 
al., 2008). Chronic neuroinflammation is detrimental and causes collateral damage to CNS, 
further deteriorating homeostasis (Glass et al., 2010). Various CNS diseases caused by 
bacteria, viruses, prion bodies, and abnormal protein conformations always display a chronic 
component of neuroinflammation. Mechanical brain injuries due to accidents etc. involve 
initial acute inflammatory response followed by a much prolonged chronic inflammation. 
The cellular mediators differ during acute and chronic inflammatory conditions. These 
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cellular mediators are amenable to immunomodulation which may further impact 
prospective or ongoing inflammatory responses. Immunomodulation of microglia is a 
promising tool for researchers who wish to control neuroinflammatory responses occurring 
inside CNS. 
2.2.1 Inflammation vs. neuroinflammation 
Inflammatory responses within brain contrast significantly with those occurring outside 
CNS. Owing to the presence of blood-brain-barrier (BBB) and skeletal structures surrounding 
the brain, it is not feasible to manifest classic signs of inflammation, described by Celsus. 
Table 2.2a summarizes the main differences of inflammation outside brain and inside brain.  
Table 2.2 a:  Inflammation differs inside and outside brain.   
INFLAMMATION 
Outside Brain Inside Brain 
Rednesss, heat, swelling, pain and loss 
of function are present. 
 
Swelling and pain are mostly absent. 
 
Both innate and adaptive immune systems 
are involved. 
 
Restricted and controlled involvement 
of innate and adaptive immune cells. 
Depending on stimulus mostly neutrophils,   
macrophages, B cells andT cells and other 
immune cells are present. 
Microglia are the key immune cells. 
Antigen presentation by dendritic cells. Dendritic cells are absent. 
Lympahtic system is involved. Lymphoid organs are absent. 
Abundant expression of MHC proteins. Very low constitutive expression of MHC.  
 
Immune cell recruitment and functions 
are normal. 
 
Very restricted entry and significantly 
dampened  B cell and T cell functions. 
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Glial cells, microglia and astrocytes, are distributed ubiquitously in the brain parenchyma, 
such that noxious stimuli (external or internal) are quickly intercepted by their long actively 
sensing processes. Armed with basic host-defence mechanisms and extensive molecular 
coordination, these cells aim to provide efficient immune surveillance in spite of restricted 
immune cell access into CNS. In the absence of cellular and molecular components of blood, 
inflammation is supported by these resident microglial cells and astrocytes, in addition to 
their other housekeeping functions. There are also similarities in inflammatory processes 
inside and outside brain, of which worth mentioning are the roles of cytokines and 
chemokines. Further, NFkB transcription factors regulate pro-inflammatory gene expression 
inside as well as outside brain. One should note that these differences in part stem from much 
believed “immune privilege” status of brain. 
For long, brain has been thought to be an immune privileged organ. Tissue grafts, tumors, 
viruses, bacteria when introduced into brain parenchyma evade immune detection 
consolidating this traditional view.  Most of the time term “immune privilege” is linked 
inaccurately with BBB.  Immune privilege is a relative term applicable only to brain 
parenchyma (Galea et al., 2007). Brain meninges, choroid plexus, circumventricular organs 
and ventricles lack “immune privilege” status.  Afferent arm of immune system comprising 
of professional antigen presenting cells (dendritic cells) is typically lacking in CNS (Galea et 
al., 2007) and this deficiency contributes towards cellular basis of immune privilege. In the 
absence of cellular transport for antigens, soluble antigens reach nearest cervical lymph nodes 
by taking fluid route via perivascular spaces of capillaries and arteries to elicit an immune 
response which is further skewed towards humoral rather than cell mediated responses 
(Harling-Berg et al., 1999). This suggests that the afferent arm of immune system is deficient 
in brain. In the efferent arm, the major obstacle for incoming immune cells in CNS is their 
apoptotic cell death, executed by Fas ligand engagement. All CNS cells express Fas ligands 
(Bechmann et al., 1999). Furthermore, high local concentrations of anti-inflammatory 
cytokines like interleukin-10 (IL-10), TGF-β-1 and presence of gangliosides suppress efficient 
T-cell activity within the brain parenchyma (Strle et al., 2001; Malipiero et al., 2006; Irani et al., 
1996). Even if peripheral immune cells survive this initial roadblock, very low constitutive 
expression of major histocompatibility complex (MHC) within CNS (Perry, 1998) dampens 
antigen recognition. Modulation by astrocytes and microglia also greatly influence normal 
functioning of immune cells within CNS (Trajkovic et al., 2004; Magnus et al., 2005). 
Furthermore, the immune privilege status of CNS is severely compromised during 
neuroinflammation, probably due to breach of BBB and local immunostimulation by 
chemokines and cytokines. Therefore, inadequacies of adaptive and innate immune system, 
age and anatomical location of brain region all together determine the immune status of CNS 
(Galea et al., 2007). These shortcomings of immune system seem to be necessary as CNS has 
restricted capacity to regenerate post-mitotic, non-regenerating neurons if lost during a full-
fledged inflammatory reaction (Horner and Gage, 2000). 
Innate immune system of brain can be activated by a plethora of physiological and 
pathological stimuli. Circulating Lipopolysaccride (LPS), bacterial and viral components 
during systemic infections (meningitis), tumors, infiltration of infectious agents into CNS 
(encephalitis), energy and metabolic dysregulation, neural dysfunction, traumatic injuries of 
physical and chemical nature, accumulation of misfolded proteins etc. constitute stimuli 
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lasting either acutely or chronically in CNS with a global or local consequences (Glass et al., 
2010).  
2.2.2 Mediators of inflammation 
Since the beginning of 20th century, microglia were known by many names such as “Nissl’s 
Stäbchenzellen,” “Gitterzellen,” or “third element of Cajal”. Microglia are the major resident 
immune cells of CNS and were known long for their migratory and phagocytic functions 
(Penfield, 1925). They represent approximately 5-10% of all brain cells. Microglia execute 
many important physiological house-keeping functions. In normal conditions, microglia 
exhibit quiescent phenotype, show anti-inflammatory and neuroprotective functions, and are 
constantly surveying their microenvironment for any internal or external cues that might 
endanger brain homeostasis (Streit, 2002).  By using in vivo two-photon imaging, microglial 
cells in cortex of live mouse were found to be very active in their presumably resting or non-
activated state (Nimmerjahn et al., 2005). Bacteria, viruses, injuries, cellular fragments of dead 
cells, apoptotic cells, mis-folded protein deposits etc. activate microglia. Activation of 
microglia can be characterized by changes in its cellular morphology and induction of many 
genes related to innate immune system. Activation by LPS is the gold standard for studying 
microglia activation under experimental conditions (Hanisch and Kettenmann, 2007). Other 
than tissue surveillance, microglia also carries out synaptic pruning (Ekdahl, 2012). Microglia 
are also important mediators of tissue regeneration and neurogenesis. In CNS lesions of 
leeches, accumulation of microglia was necessary for axonal sprouting suggestive of their 
beneficial role in CNS injuries (Ngu et al., 2007).  
Evidently, microglia needs to acquire appropriate activation phenotype in order to display 
diverse effector functions related to tissue surveillance and repair. CNS macrophages 
(analogous to activated microglia) displaying  M1/M2 phenotype, at the opposing ends of 
activation scale,  is too simplistic model (Gordon, 2003). This classification is akin to Th1 and 
Th2 responses of T cells. Both LPS and IFN-γ induce  M1 phenotype in microglia/macrophage 
via activation of TLRs and thereby produce  proinflammatory cytokines, chemokines, induce 
oxidative stress, promotes Th1 reponses, and cytotoxicity. In contrast, M2 macrophage is 
activated by IL-4 or IL-13 promotes down regulation of proinflammatory mediators and 
further promotes tissue remodelling (Gordon, 2003). Expression of mannose and galactose 
receptors, production of ornithine and polyamines through the arginase pathway, high 
expression of chitinase 3-like 3 (YM1)  and release of cytokines like IL-4,IL-13, IL-10 etc. 
charecterize M2 phenotype. In addition, downstream signalling pathway like STAT1 and 
STAT3/STAT6 promotes M1 and M2 polarizations respectively (Sica and Mantovani, 2012). 
Further, M2 phenotype is sub divided into M2a (IL-4,Arginase-1, YM-1,IL-13)  for stopping 
proinflammatory pathways, M2b (Il-10 and CCL-1) for remove reactive oxygen and nitrogen 
species produced during inflammation and M2c for tissue repair and remodelling (Varnum 
and Ikezu, 2012). Many subsets of microglia/macrophages with varying degrees of classic 
(M1) and alternate (M2) effector functions in diverse acute  and chronic stimuli, arising from a 
wide array of physiological and pathological  conditions, only further complicates this  model 
of microglia/macrophage activation. 
Microglia in CNS are important players of innate immune inflammatory responses in 
various neurological conditions like Parkinson’s disease (Rogers et al., 2007), HIV dementia 
(Garden, 2002), multiple sclerosis (Muzio et al., 2007), amyotropic lateral sclerosis (Dewil et 
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al., 2007), and AD (Mandrekar-Colucci and Landreth, 2010). Microglia respond to a wide 
variety of noxious stimuli by producing soluble pro-inflammatory mediators that specifically 
target removal of bacteria, viruses, debris from injured tissue or locally deposited abnormal 
proteins(Kettenmann et al., 2011). 
Many of the inflammatory mediators like complement proteins (Osaka et al., 1999) and 
cytokines (Feuerstein et al., 1994) are known to cause neuronal damage apart from affecting 
neuronal functions. CNS specific expression of TNF in neurons caused seizures, ataxia and 
early death resulting from widespread infiltration of Tcells into CNS, astrocytosis, 
microgliosis and focal demyelination (Probert et al., 1995). In a different model, expression of 
TNF in astrocytes caused chronic inflammatory encephalopathy further consolidating the 
detrimental role of inflammation on maintaining neuronal structure and function (Stalder et 
al., 1998). Proinflammatory mediators are also known to inhibit trophic factors like brain-
derived neurotrophic factor (BDNF) thus indirectly contributing towards neurodegeneration 
(Nagatsu and Sawada, 2005). Moreover, acute neuroinflammatory processes can lead to 
excitotoxicity followed by microglial activation and neuronal degeneration, which can be 
suppressed by NMDA receptor antagonists (Morimoto et al., 2002). As nitric oxide (NO) 
production by astrocytes is involved in NMDA receptor mediated neuronal death, 
neuroinflammation can be further mechanistically linked to excitotoxicity (Hewett et al., 
1994). Anti-NMDA receptor encephalitis also links NMDA receptors to neuroinflammation. 
This acute neuroinflammatory condition involves production of autoantibodies against 
NMDA receptor thus precipitating seizures, confusion and amnesia in patients (Irani et al., 
2010). Further, antibodies caused NMDA receptor internalization and their levels correlated 
with clinical severity of disease. Even in the absence of any explicit structural damage to 
neurons, chronic treatment with proinflammatory cytokine TNF inhibited long-term 
potentiation (LTP) in a dose-dependent way (Tancredi et al., 1992). Similarly, cytokine 
interleukin-6 (IL-6) decreased LTP in hippocampal CA1 region along with concomitant 
inhibition of mitogen activated protein kinase(MAPK)/extracellular signal-regulated kinase 
(ERK) phosphorylation that was further reversed by tyrosine kinase inhibitors (Tancredi et 
al., 2000). In addition, an inverse relationship between interleukin -1 beta (IL-1β) in dentate 
gyrus (DG) and LTP in synapses of perforant pathway was reported in aged, stressed as well 
as in rats pretreated with IL-1β suggesting that inflammatory cytokines induce formation of 
reactive oxygen species that trigger lipid peroxidation, and that these changes further lead to 
depletion of membrane arachidonic acid that correlates with LTP (Murray and Lynch, 1998). 
Inducible nitric oxide (iNOS) produced by microglia activated by Aβ was also shown to be 
responsible for inhibition of LTP (Wang et al., 2004). All these data indicate that 
neuroinflammatory processes are detrimental for synaptic plasticity and normal neuronal 
function. 
Chemokines and the cells bearing chemokine receptors play a very important role in 
supporting neuroinflammatory processes of CNS (Veenstra and Ransohoff, 2012). In fact, 
their role has been studied in various neuropathological conditions like traumatic brain injury 
(Semple et al., 2010), multiple sclerosis (Holman et al., 2011) and AD (Lee et al., 2010; Cho et 
al., 2011). Chemokines facilitate chemotaxis, tissue extravasation and modulation of 
lymphocyte function. Neuroinflammatory responses ensuing bacterial and viral infections 
result in massive infiltration of immune cells like neutrophils, monocytes and lymphocytes 
into the affected tissue. This immune cell infiltration is mediated by chemokines like 
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interleukin-8 (IL-8),interferon-gamma-inducible protein 10 (IP-10) and macrophage 
chemoattractant protein 1 (MCP-1) (Luster, 1998). Furthermore, proinflammatory cytokines 
like interferon gamma (IFN-γ) are also capable of inducing chemokine production that 
further perpetuates inflammation (Owens et al., 2005). 
Cytokines are capable of crossing blood-brain barrier (BBB) thereby forming a direct link 
between periphery and CNS. Moreover, cytokines in CSF might be absorbed back into 
circulation. Also, there is increasing evidence of cytokine involvement in various 
pathomechanisms of neuroinflammation. IL-1β induces expression of IL-6 production and 
inducible nitric oxide synthase (iNOS) activity in astrocytes. Further, it also activates 
microglia, increases production of macrophage colony-stimulating factor (M-CSF), which in 
turn induces production of S100β from astrocytes, thus launching a self-perpetuating cycle 
(Griffin et al., 1998). IL-6 promotes astrocytosis, microgliosis and stimulates release of acute 
phase proteins. Moreover, IL-6 knockout mice exhibit faster acquisition and facilitation of 
radial maze learning suggestive of its physiological role in memory processes (Braida et al., 
2004). TNF is neurotoxic (Combs et al., 2001) but can also have protective roles by preventing 
neuronal apoptosis. Overexpression of TNF in astrocytes of aged transgenic mice resulted in 
increased deposition of amyloid in cerebral blood vessels and meninges indicating 
amyloidogenic potential of cytokines (Wyss-Coray et al., 1997). 
Microglia, astrocytes, and macrophages in culture release an inducible form of nitric oxide 
(iNOS) upon stimulation with LPS (Corradin et al., 1993; Galea et al., 1992). Expression of 
iNOS and NO has been described in many neurological disorders like  experimental 
autoimmune encephalitis (EAE) (Willenborg et al., 1999), cerebral ischemia (del Zoppo et al., 
2000), AIDS dementia (Hori et al., 1999) and ALS (Almer et al., 1999). 
Cyclo-oxygenases are known to important mediators of inflammation in health, and their 
role in many inflammatory disorders is well appreciated (Dubois et al., 1998). Primary 
astrocytes and microglia cultures exposed to LPS or cytokines are capable of synthesizing 
cyclooxygenase-2 (COX-2) (O'Banion et al., 1996; Bauer et al., 1997). In rat microglial cultures 
prostaglandin E2 (PGE2) is a major enzymatic product of COX-2 and capable of further 
inducing COX-2 in microglial cells in a paracrine or autocrine manner (Minghetti et al., 1997). 
The microglial receptor for PGE2, EP2 subtype (EP2), inhibits phagocytosis and enhances 
neurotoxic activities (Shie et al., 2005a; Shie et al., 2005b). Accordingly, deletion of EP2 
receptor in APP/PS1dE9 mice resulted in reduction in lipid peroxidation in ageing mice, 
reduced oxidative stress, suppressed Aβ levels and reduced Aβ deposition (Liang et al., 
2005). So, it appears that neuroinflammation caused oxidative stress leads to enhanced 
amyloid pathology via EP2 signalling. 
Both microglia and astrocytes express Toll-like receptors (TLRs) (Lehnardt, 2010; Gorina et 
al., 2009). Bacteria, viruses and other microbial stimuli are mediated by pathogen associated 
molecular patterns (PAMPs). PAMPs activate TLRs, which in turn via induction of NFκB, 
increase gene transcription of IL-1β, resulting in production of inflammatory pro-peptides. 
Such pro-IL-1β peptides are cleaved by caspase-1 to release active IL-1β (Martinon and 
Tschopp, 2004) (Hanamsagar et al., 2012).  Function of yet other innate immune receptors, 
nucleotide-binding domain leucine rich repeat containing receptors (NLRs), is necessary for 
activation of caspase-1. Upon activation by diverse stimuli such as adenosine triphosphae 
(ATP), uric acid, bacterial ribonucleic acid (RNA), and bacterial muramyl dipeptide, the 
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function of NLRs is dependent on assembly of large complexes of inflammasomes. 
Inflammasomes recruit and activate caspase-1, thus complimenting pro-inflammatory 
response of initial TLR activation by PAMPs. Such dual innate signalling ensures effective 
protection from microbial infections in CNS (Chakraborty et al., 2010).  In case of stroke or 
trauma (sterile tissue injury), damage associated molecular patterns activate TLRs while 
NLRs are activated by endogenous substances like aggregated peptides (Halle et al., 2008) or 
uric acid crystals. ATP from damages CNS tissue also can also be sensed by NLRs via 
purinergic receptor activation.   
2.2.3 NF-κB as mediator of neuroinflammation  
NFκB proteins, which were initially discovered as nuclear factor enhancing expression of 
κ-immunoglobulin light chains of B-lymphocytes, are highly conserved during evolution and 
are expressed by all cell types. NFκB transcription factors comprise of 5 subunits, namely 
RelA (p65), RelB, c-Rel, NFκB1 (p50; p105) and NFκB2 (p52; p100). These subunits can exist in 
cytoplasm as heterodimers or homodimers. All NFκB proteins show Rel homology domains 
that are necessary for dimerization, nuclear localization and DNA binding. Normally, NFκB 
proteins are bound to inhibitory IκB proteins in cytoplasm. Again there are three different 
inhibitory IκB proteins IκBα, IκBβ and IκBε are identified and they show characteristic 
ankyrin repeat  domains. Interestingly, B-cell lymphoma 3 protein homolog (BCL-3), p105 
and p100 also can act as inhibitory proteins as they also possess ankyrin repeat domains (Li 
and Verma, 2002). Many diverse inflammatory stimuli such as LPS, TNF, and ligands for 
TLRs activate their cognate receptors thus initiating a signalling cascade that ends by 
phosphorylating the inhibitor of NFκB kinase complex (IKK complex). This complex is 
composed of IKK1, IKK2 and NFκB essential modulator (NEMO). Activation of NFκB 
pathway is controlled by activation of IKK (see figure 2.2a). Activation of IKK complex leads 
to phosphorylation of IκB and further to its polyubiquitylation and proteasomal degradation. 
Thereby NFκB dimers are realeased in the cytoplasm and enter the nucleus, where they 
initiate expression of many genes involved in immune and inflammatory responses 
(Pasparakis, 2009).  
Induction of NFκB mediated gene transcription in response to environmental, mechanical, 
chemical and microbial stimuli is an adaptive response that aims to bring back homeostasis. 
However, maladaptive responses are not uncommon during pathophysiological conditions.  
Aberrant activation of NFκB transcription factors have been implicated in a plethora of 
neuroinflammatory conditions and vice versa. In addition, mutations in key NFκB genes have 
been implicated in many diseases(Mattson and Camandola, 2001). 
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Figure 2.2a. Canonical NF-κB pathway. Adapted from Nature reviews Immunonology(2009) 9:778 
 
2.2.4 Constitutive NFκB activity is important for learning and memory 
Constitutive NFκB activity has been reported in several rodent brain regions including the 
amygdala, hypothalamus, olfactory lobes, cortex and hippocampus (Schmidt-Ullrich et al., 
1996; Bhakar et al., 2002). One needs to exercise reasonable caution with 
immunohistochemical reports of staining p65 or p50 in neuronal tissue, as data related to 
antibody specificity in western blots and immunostaining from tissues from knockout mice 
appeared contradictory (Herkenham et al., 2011). Antibodies raised against the C-terminus 
containing transactivation domains were reported to be much more successful in specificity 
tests than those raised against the N-terminus proto-oncogene c-Rel (REL) homology domain 
or nuclear localisation sequence (NLS) region. Probably amino acid sequences are conserved 
in many proteins, which can account for this non-specificity. Genuinely, very low amounts of 
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p65 and p50 inside cells can sometimes be the cause for negative staining, but in such 
situations raising the antibody concentration to an extent of seeing cellular labelling amounts 
to nonspecific staining. One should be especially careful when interpreting neuronal staining 
patterns in the hippocampus because of the high neuronal density in this brain area. Namely, 
high density renders cells to appear as specifically stained, especially at lower magnifications 
(Herkenham et al., 2011). Immunostainings have shown basal NFκB activity in many 
glutamatergic neuron populations in the cortex and hippocampus (Kaltschmidt et al., 1993; 
Kaltschmidt et al., 1994; Kaltschmidt et al., 1995).  The fact that this basal activity can be 
blocked by glutamate antagonists and calcium channel blockers indicates that it might be 
involved in physiological synaptic functions. Similarly, presence of inducible NFκB in 
biochemically purified synapses indicates that NFκB activity is necessary for maintaining 
synaptic function at the molecular level (Kaltschmidt et al., 1993; Meffert et al., 2003). In 
contrast, ablation of NFκB reduced synaptic densities in stratum lucidum of the hippocampus 
(Kaltschmidt and Kaltschmidt, 2009). Moreover, it has been found that knockout of the p65 
subunit (also, Tnfrsf1a -/-) or forebrain specific NFκB inhibition in neurons in mice results in 
not only in poor performance on spatial navigation tests but also  reduced LTP and LTD 
(Meffert et al., 2003; Fridmacher et al., 2003). Recently, NFκB has been shown to regulate the 
protein kinase A / cyclic AMP-responsive element-binding protein (CREB) pathway 
(Kaltschmidt et al., 2006). In addition, evidence from chemically induced brain injury in wild-
type and Nfkb1 null mice demonstrate that NFκB regulated genes are involved in 
neuroplasticity in the hippocampus (Kassed et al., 2002). All this evidence indicates a 
prominent role for neuronal NFκB activity in learning and memory functions. 
 
 
2.2.5 NFκB in neuroprotection and neurodegeneration 
 
Typically, NFκB activation is implied in neuronal death induced by glutamate toxicity 
(Grilli et al., 1996), haloperidol induced oxidative stress (Post et al., 1998) and focal ischemia 
(Schneider et al., 1999). However, some in vitro studies have shown that pre-treatment of 
neuronal cells with TNF and lymphotoxin-alpha (LT-α) protects neurons against Aβ induced 
neurotoxicity via activation of NFκB (Barger et al., 1995). Cultured neurons pretreated with 
0.1μM Aβ40 or 2ng/ml of TNF protected cerebellar granule cells from cell death induced by 
10μM of Aβ40 via NFκB activation (Kaltschmidt et al., 1999). Similarly, activation of NFκB was 
found protective against ferrous sulphate mediated oxidative stress (Kaltschmidt et al., 2002), 
glutamate and Aβ neurotoxicity (Goodman and Mattson, 1996). Protective anti-apoptotic 
effects on cultured neurons by NFκB activation was shown to be primarily mediated by 
induction of Mn-superoxide dismutase, inhibition of peroxynitrate formation and 
suppression of lipid peroxidation (Mattson et al., 1997). Furthermore, induction of NFκB 
activation increased levels of anti-apoptotic proteins and was strongly neuroprotective 
against recombinant adenovirus induced neuronal death in one study (Bhakar et al., 2002). 
Similarly, in three different mouse models in vivo preconditioning with 3 min sublethal 
ischemia or 5 mg/kg kainic acid or 500nM of linolenic acid led to rapid activation of NF-κB, 
which could be  blocked by NFκB inhibitor diethyldithiocarbamate or kappaB decoy DNA 
(Blondeau et al., 2001). All these data support physiological neuroprotective and anti-
apoptotic effects of NFκB activation in CNS. Along similar lines, transgenic overexpression of 
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IkBα super-repressor in forebrain neurons inhibited NFκB activation (Fridmacher et al., 2003) 
and augmented neurodegeneration induced by kainic acid or oxidative stress (Fe+2).   
 
Opposing roles of NFκB activation in various in vitro models of neuronal apoptosis and 
survival were ascribed to the balance of the p65 and c-Rel subunits (Pizzi et al., 2002). 
Metabotropic glutamate receptor type 5 activation drives c-Rel dependent antiapoptotic 
pathway responsible for neuroprotection against Aβ peptide (Pizzi et al., 2005). Under 
ischemic stress, unbalanced activation of p65/Nfkb1 dimers over p65/c-Rel leads to cell death 
by inducing transcription of proapoptotic Bim and Noxa genes while p65/c-Rel dimers induce 
antiapoptotic Bcl-xL genes (Sarnico et al., 2009).  Neuroprotective role for another NFκB sub 
unit was demonstrated in Nfkb1 null mice.  Mice deficient in Nfkb1 gene were treated with 
trimethyltin, 3-nitropropionic acid (mitochondrial toxin) or kainic acid (excitotoxin), they 
displayed aggravated neuronal damage compared to wild-type animals (Kassed et al., 2004; 
Yu et al., 2000; Yu et al., 1999). In transient middle cerebral artery occlusion (tMCAO) model, 
massive neurodegeneration in the hippocampus and striatum was evident with Flouro-Jade 
staining (marker of apoptotic cells). When compared to non-transgenic littermates, Nfkb1-/- 
mice showed an 8-fold increase in hippocampal Fluoro-Jade staining, indicating a pivotal role 
for NFκB activation in neuronal survival (Duckworth et al., 2006). This is in direct contrast to 
studies which showed reduction of infarct volume in Nfkb1-/- mice (Schneider et al., 1999). 
Similarly, in permanent MCAO model, Nfkb1-/- mice developed a smaller infarct than wild-
type controls (Nurmi et al., 2004).   
 
In Nfkb1-/- mice, all CNS cells including neurons and microglia are deficient in the Nfkb1 
gene. Thus it becomes difficult to untangle NFκB activation or suppression in a cell specific 
manner, which is pivotal to explain contrasting roles of NFκB in neuroprotection and 
neurodegenration. When mice with microglia specific IKK-2 ablation were subjected to 
transient middle cerebral artery occlusion (tMCAO), they displayed a 10% reduction in 
infarct size compared to their wild-type littermates (Cho et al., 2008), indicating that NFκB 
activation in neurons is important for survival but NFκB activation in microglia is deleterious 
for neuronal survival. Similar observations were also made in astroglia as well. Cultured 
cortical astrocytes when treated with Aβ42 showed NFκB activation in dose-dependent 
manner. However, this NFκB activation in astrocytes resulted in increased iNOS expression 
and NO production (Akama et al., 1998), indicating a deleterious role of NFκB activation in 
astrocytes. Spinal cord injury in transgenic mice with NFκB inhibition specifically in 
astrocytes (expressing dominant negative form of IκBα under GFAP promoter) showed 
improved functional recovery, decreased lesion volume, reduced pro-inflammatory 
expression of cytokines and chemokines, and salvaged white matter (Brambilla et al., 2005). 
Present data indicates that NFκB signalling in astrocytes might regulate chemokine (C-C 
motif) ligand 2 (CCL2) induced infiltration of immune cells to the lesioned brain. Similarly, in 
the EAE model, inhibition of NFκB signalling (NEMO and IKK-2 ablation) prevented 
expression of pro-inflammatory cytokines, chemokines and adhesion molecules, resulting in a 
milder pathology (van Loo et al., 2006). 
 
Understanding the mechanisms involved in the proliferation of neural stem cells in adult 
CNS may reveal novel drug targets for the treatment of many neurodegenerative diseases. A 
recent in vitro report showed that neural stem cells isolated from subventricular zone when 
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treated with 10ng/ml of TNF, induced IKK-2 mediated NFκB activation and up regulation of 
cylin D1 expression, resulting in increased cellular proliferation (Widera et al., 2006). 
Furthermore, NFκB subunit p65 and p50 were found to be necessary for normal growth and 
expansion of neuropshere cultures (Young et al., 2006).  Similarly, a recent in vivo study found 
a 50% reduction in number of newly born neurons in the hippocampus of adult Nfkb1-/- mice 
compared to wild-type controls (Denis-Donini et al., 2008), which further strengthens the role 
of NFκB signalling in adult neurogenesis. All these data consolidate the notion that targeting 
NFκB signalling in glial cells is a good idea for curtailing pro-inflammatory consequences of 
CNS diseases, whereas in neurons and neural stem cells, augmenting canonical NFκB 
signalling might be beneficial for survival and protection from apoptosis as well as for 
boosting adult neurogenesis. 
 
Several genetically engineered mouse models have been developed to elucidate the roles of 
NFκB family members.  However, one has to be mindful of potential caveats while 
interpreting the phenotypes of these mice. Several of these mice exhibit embryonic lethality; 
therefore much of the observations are limited to only early stages of development. One has 
to also appreciate the fact that there exists considerable redundancy among the 
transcriptional factors in cell type and developmental stage-specific manner. In addition, the 
propensity of crosstalk at the level of IKKs and transcription factors further confounds 
interpretation of results from these transgenic mice. As seen in Nfkb1-/- mice, loss of NFκB 
activity might as well disrupt other important intracellular signalling pathways (tumor 
progression locus 2 (Tpl2)/ERK signalling). Furthermore, IKKs are also known to 
phosphorylate proteins other than those involved in the NFκB pathway. In spite of the above 
limitations, genetically engineered mice have enormously expanded our understanding about 
both canonical and alternative pathways of NFκB activation.  
Canonical NFκB pathway offers many good targets for controlling inflammatory diseases. 
However, chronic inhibition of this vital pathway might result in precipitation of unwanted 
side effects as this pathway is pivotal in regulating many physiological functions. NFκB c-Rel 
was shown to be one such good candidate for neuronal survival in various in vitro toxicity 
models (Pizzi et al., 2005). Furthermore, mGlu5 receptor mediated expression of MnSOD and 
Bcl-XL are both transcriptional targets of c-Rel. In contrast, p105 has a much more restricted 
role in regulating immune responses and hence is a better target than IKK of the canonical 
pathway.  
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2.3 NEUROINFLAMMATION IN ALZHEIMER’S DISEASE 
 
Neuroinflammation has been implicated in many neurodegenerative diseases like 
Parkinsons’s disease, stroke and AD (Akiyama, 1994). In addition, plethora of inflammatory 
processes and abnormal innate immune responses are observed in brains of people with AD 
(Akiyama, 1994; Wyss-Coray and Mucke, 2002). Several cytokines, chemokines, complement 
proteins and other proteins typically associated with immune and inflammatory processes 
were abnormally expressed in AD (Akiyama et al., 2000). Such neuroinflammatory processes 
in AD may begin quite early in the course of the disease, which is indicative of causation. 
However, it is unclear whether neuroinflammation may be a driving force for the disease, or 
might even induce beneficial responses that may slow or modify the disease progression. 
2.3.1 Evidence from humans  
Epidemiological and genetic evidence supports the idea of an early involvement of 
inflammatory processes in AD. The Honolulu-Asia aging study reported an increase in C-
reactive protein 25 years before the diagnosis of dementia in Japanese-American men 
(Schmidt et al., 2002), potentially suggesting an early involvement of inflammatory processes 
during AD pathogenesis.  Also, patients taking anti-inflammatory drugs like NSAIDs showed 
decreased risk for developing dementia indicating that inflammation might play a critical role 
in the AD pathogenesis (McGeer et al., 1990; in t'Veld et al., 2001; Launer, 2003). Recently, 
genome-wide association studies as well hint to a role for inflammatory genes like clusterin 
(CLU) and complement receptor 1 (CR1) in AD (Hollingworth et al., 2011). Gene expression 
analysis from post-mortem AD tissue also indicated an upregulation of many proteins and 
transcription factors typically associated with neuroinflammation (Colangelo et al., 2002).  
Genes related to NF-κB, IL-1α, CCL-2 and TNF induced protein 2 were consistently shown to 
be increased in AD patients, whereas upregulation of complement 4A and 4B, CD68 and glial 
fibrillary acidic protein (GFAP) genes in transgenic AD mice was similar to that in humans 
(Wyss-Coray, 2006). However, several gene microarray studies in humans with AD did not 
overlap consistently, highlighting issues with reproducibility and reliability caused by 
differences in experimental setups, inter-individual differences and differences in statistical 
procedures used. Moreover, immune responses of inbred mice might be different from 
genetically heterogeneous human population, and in addition, chronic transgenic 
overexpression of APP in these mice might cause an aggravated activation of innate immune 
responses, which may not be representative of human AD patients (Wyss-Coray, 2006). Thus 
validation in various mouse models and ultimately in humans is necessary to make gene 
expression data to be more reliable.  Genetic differences with APOE also seemed to modulate 
immune responses (Lynch et al., 2003a; Lynch et al., 2003b).   
Early studies established increased expression of immune system-associated antigens in 
white and grey matter samples from both controls and AD patients. Furthermore, by using 
immunohistochemistry microglia, astroglia, macrophages, pericytes were identified as chief 
cellular mediators (Luber-Narod and Rogers, 1988). Microglia or macrophages expressing 
histocompatibility glycoprotein HLA-DR were conspicuously found to be present 
surrounding lesions of AD (McGeer et al., 1987)(McGeer et al., 1988). Moreover, brains of 
normal elderly showed meagre HLA-DR immunoreactivity, whereas virtually all neuritic 
plaques of AD brains co-localized with HLA-DR signal (Rogers et al., 1988). Triple 
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immunohistochemistry on post-mortem entorhinal and hippocampal AD brain tissue 
revealed spatial relationships between Aβ plaques, microglia and astrocytes (Dandrea et al., 
2001). These studies show diversity of cellular mediators surrounding Aβ deposits.  More 
recently, in vivo imaging of activated microglia using PET with benzodiazepine ligand (R)-
PK11195 showed higher regional binding (entorhinal, temporoparietal and cingulated cortex) 
in AD patients than in normal controls (Cagnin et al., 2001). Plasma levels of cytokines like IL-
12, IL-16, IL-18 and TGF-β-1 were found to be higher in AD patients than controls, and they 
correlated with disease progression (Motta et al., 2007). Secretion of cytokines like IL-2 and 
IFN-γ were implicated in moderately severe AD patients, whereas reduction in TNF and IL-3 
was implicated in mild stages of AD, suggesting a defect even in peripheral immune 
responses (Huberman et al., 1994). However, measurements of peripheral cytokines and 
chemokines in AD and controls were inconsistent but surely reflected defective immune 
responses (Lee et al., 2009). Peripheral monocytes and macrophages from AD patients 
displayed defects in immune functions (Beloosesky et al., 2002; Khansari et al., 1985) while 
frontal cortex of AD brains showed a higher expression of the CD45 marker than that of 
controls. In addition, CD45 immunopositivity was localized to microglial plasma membrane 
further consolidating their role in AD progression (Masliah et al., 1991). These observations 
established the role of immune cells enduring neuroinflammatory processes in AD. 
Furthermore, early ultrastructural studies indicated that microglia might not be able to 
phagocytose Aβ but instead be involved in the formation of fibrillar Aβ plaques (Frackowiak 
et al., 1992; Wisniewski and Wegiel, 1994; Wegiel et al., 2000).  
2.3.2 Evidence from cell cultures and mouse models 
 
Neuroinflammation may also be a driving force in the progression of AD neuropathology. 
Immunostimulation with proinflammatory cytokines increased mRNA levels of BACE (Sastre 
et al., 2003). Similarly, treatment of human astrocytes with TGF-β-1 elevated APP mRNA 
levels (Amara et al., 1999). Also, exposure of NT2 neurons to oxidative stress increased BACE 
expression and its activity (Tamagno et al., 2002). Furthermore, IL-1β exposure increased APP 
synthesis by 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells 
(Rogers et al., 1999). All these data indicate that neuroinflammation regulates Aβ production 
at multiple levels. In vitro studies show that neurotoxic mediators released by activated 
microglia are responsible for neuronal injury (Meda et al., 1995).  Stimulation with Aβ 
increased CD40 expression on microglia, which when further treated with CD40 ligand 
induced TNF expression and caused neuronal loss, suggesting that CD40-CD40 ligand 
interaction is important for Aβ neurotoxicity (Tan et al., 1999). Activated microglia of 
inflamed CNS differ from resting quiescent microglia of normal CNS with respect to 
overexpression of CD45 marker (Sedgwick et al., 1991). Microglial CD45 activation inhibits 
proinflammatory signalling pathways, such as CD40 ligand induced activation of the src-
family kinases, lck and lyn (Tan et al., 2000b), and also Aβ induced microglial activation of 
p44/42 mitogen-activated protein kinases (Tan et al., 2000a). 
 
Systemic inflammation is known to increase brain amyloidosis in mice (Guo et al., 2002). In 
many human amyloid depositing mouse models, neuroinflammatory LPS stimuli increased 
Aβ and tau pathologies (Qiao et al., 2001; Sheng et al., 2003; Kitazawa et al., 2005), supporting 
the idea that inflammation is a driving force for AD progression. It is important to note that in 
these early studies LPS was not given directly into the brain by intracerebral or 
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intrahippocampal injections, but was administred either intracerebroventricular or 
intraperitoneal, suggesting that both innate and adaptive immune systems responses might 
have played role in aggravating Aβ pathology. Modulation of innate as well as adaptive 
immune responses in transgenic APP mice was achieved by various genetic and 
pharmacological tools that could profoundly influence specific molecular components of 
neuroinflammatory mechanisms. For example, stereotactic brain injections of recombinant 
adeno-associated viral vector expressing proinflammatory TNF in 3xTg-AD mice resulted in 
infiltration of inflammatory immune cells and caused neuronal death (Janelsins et al., 2008). 
This along with previous systemic LPS injection experiments suggests that 
neuroinflammation not only aggravates early Aβ and tau pathologies but is also detrimental 
for neuronal survival.  In line with this observation, inhibition of soluble TNF signalling by 
dominant negative TNF prevented accumulation of early Aβ plaques in LPS treated 3x-TgAD 
mice (McAlpine et al., 2009). Surprisingly however, more complete blocking of TNF 
signalling by genetic ablation of TNF receptor 1 and 2 in 3xTg-AD mice resulted in 
aggravated amyloid and tau pathologies suggestive of a critical role of TNF-signalling in 
microglia mediated uptake and clearance of extracellular Aβ (Montgomery et al., 2011).  
 
On similar lines, reducing CD45 expression either pharmacologically or genetically 
worsened amyloid pathology. Gene deletion of microglia activation marker CD45 in APP/PS1 
mice increased cerebral amyloidosis,  elevated Aβ oligomer levels and caused neuronal loss 
due to neurotoxic TNF and IL-1β releasing phenotype of microglia (Zhu et al., 2011). In 
concert, mouse Aβ vaccine trials showed increased CD45 expression by microglia associated 
with greater reductions of fibrillar Aβ (Wilcock et al., 2001). Therefore, modulation of CD45 
seems to be a promising target if one wishes to influence amyloid pathology. Many other 
mediators of inflammation like complement proteins, TGF-β, CCR2, CX3CR1, CD40, and 
microglia themselves were manipulated to influence inflammation in the context of amyloid 
pathology. Activation of complement proteins plays a pivotal role in AD neuroinflammation. 
In Tg2576 mice,  deficiency of C1q protein did not change amyloid pathology but 
significantly subdued inflammatory reactions of both astrocytes and microglia surrounding 
Aβ plaques and decreased loss of synaptophysin and microtubule-associated protein 2 (MAP-
2) markers (Fonseca et al., 2004). However, very old APP mice with complement C3 
deficiency showed increased Aβ deposition in the brain and suppressed iNOS and TNF with 
elevated interleukin-4 (IL-4) and IL-10, indicative of a M2 microglia activation (Maier et al., 
2008). Furthermore, inhibition of C3 activation by expressing soluble complement receptor-
related protein y, a complement inhibitor, in brains of APP mice also resulted in 2-3 fold 
higher Aβ burden and prominent neurodegeneration (Wyss-Coray et al., 2002). Similarly, 
increased expression of C3 in APP mice overexpressing TGF-β was associated with greater 
reduction in Aβ loads (Wyss-Coray et al., 2001). Therefore, activation of C3 was found to be 
beneficial for ameliorating Aβ pathologies.  Likewise, expression of TGF-β-1 in astrocytes of 
APP mice resulted in reduction of Aβ in brain parenchyma (Wyss-Coray et al., 2001). In line 
with this observation, neuronal inhibition of TGF-β in APP mice resulted in Aβ accumulation 
and neurodegeneration (Tesseur et al., 2006). In contrast, genetic ablation of TGF-β signalling 
in Tg2576 mice also mitigated parenchymal, cerebrovascular amyloid and Aβ by 90%, which 
might be due to an increased infiltration of peripheral macrophages into CNS (Town et al., 
2008). Thus, it appears that CNS overexpression of TGF-β or peripheral inhibition of TGF-β 
on macrophages is beneficial for ameliorating Aβ pathologies.  
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Chemokine receptor CCR2 in microglia mediates accumulation of microglia around sites of 
neuroinflammation and deficiency of CCR2 in Tg2576 mice impaired microglia accumulation, 
elevated Aβ levels by suppression of Aβ degrading enzyme neprilysin and accumulated Aβ 
deposits much earlier (El Khoury et al., 2007). Therefore, CCR2 dependent microglia 
accumulation seems to be protective in early stages of AD. Deficiency of microglial 
chemokine CX3CR1 or fractalkine receptor prevented layer 3 neuron cell loss in 3xTg-AD 
mice suggesting a critical role for Fractalkine-CX3CR1 in neuron microglia communication 
(Fuhrmann et al., 2010).  Microglia directly interact with Aβ via TLR-2, TLR-4 and CD14, 
triggering microglia mediated inflammatory activation as well as microglia mediated Aβ 
clearance (Fassbender et al., 2004)(Reed-Geaghan et al., 2009). Innate immune response 
elicited by TLRs is mediated by myeloid differentiation factor 88 (MyD88) resulting in 
activation of AP-1 and NFκB transcription factors (Akira et al., 2001). However, MyD88 
deficient microglia in APP mice, produced by MyD88 deficient reconstruction of bone 
marrow, improved cognitive functions, attenuated pro-inflammatory TNF-α, IL-1β and CCL-
2 gene expression, and reduced Aβ burden by enhanced phagocytosis (Hao et al., 2011). In 
spite of overwhelming evidence supporting the role of microglia in clearance of Aβ plaques, a 
recent study involving complete microglia ablation in APP mice, however, suggested their 
limited role in formation and maintenance of Aβ plaques (Grathwohl et al., 2009). 
 
Transgenic APP mice mimic many features of AD neuroinflammation. In APP/PS1dE9 
mice used in our studies, neuroinflammation is typically characterized by accumulation of 
microglia around Aβ deposits as early as 4 months of age. This is also the same time when 
these mice deposit their first plaques. In addition to microgliosis, many markers of activated 
microglia like CD45 expression increases (See figure 5.1.4e-C).  Microgliosis is clearly evident 
around Congo red positive fibrillar Aβ deposits. Both resident microglia and peripheral 
macrophages can be detected by CD45 immunostaining. Using anti-CD45 monoclonal 
antibody as marker, it is also possible to see peripheral macrophage infiltration into the brain 
parenchyma. In APP/PS1dE9 mice this infiltration begins around 12 months of age.  
Interestingly, cognitive deficits in Morris water maze show up in these mice around this age. 
Such infiltrating cells are characterized by their round cell shape, relatively smooth surface 
bearing few to no processes and an intense CD45 immunostain signal (See figure 5.1.4e-
D,E,F).  Such wandering cells can often be seen in the grey and white matter, hippocampus, 
thalamus, striatum, meninges, choroid plexus, and around circumventricular tissues of brain. 
Even though they appear to be infiltrating from periphery, it is difficult to ascertain their 
exact origin as there is no protein marker available that is faithfully restricted to either 
peripheral or CNS compartments.  Another microglia marker, Iba-1, is also elevated 
considerably but more conspicuously in microglia that are present in the immediate vicinity 
of Aβ plaques. With Iba-1 immunohistochemistry, one can easily differentiate between 
activated and quiescent resting microglia (See figure 5.1.4e-A,B).  Other markers like CD11b, 
and CD68 are also elevated in activated microglia. CD68 is a lysosomal marker of 
macrophages indicative of putative phagocytosis (See figure 5.1.4d-C). Inflammation in other 
transgenic AD mouse models appears more or less similar.  Neuroinflammation in Tg2576 
mice is further characterized by the presence of TNF and IL-1β immunopositive microglia 
around fibrillar Aβ, while IL-6 immunopositivity was confined to astrocytes surrounding 
thioflavin positive Aβ deposits (Benzing et al., 1999a). 
42 
 
 
 
 
2.3.3 Mediators of inflammation in AD  
Microglia from aged human brains are rich in cytokines, chemokines and complement 
mediators of inflammation (Lue et al., 2001).  Apart from these, cyclooxygenases, iNOS, 
MMP-9, VEGF, APOE are significant mediators of inflammation in the AD brain. There is in 
vitro evidence that Aβ can directly activate cytotoxic classic complement pathways (Rogers et 
al., 1992). Similarly, Aβ also stimulated production of chemokines like C-C motif chemokine 3 
(MIP-α) and C-C motif chemokine 4 (MIP-β) mRNA in macrophages and MCP-1 in astrocytes 
(Smits et al., 2002). In addition, infiltration of immune cells require upregulation of 
chemokines, and several of these chemokines and their receptors have been reported to be 
upregulated in AD brains with intact blood-brain barrier (Xia and Hyman, 1999) (Heneka et 
al., 2010).  
Cytokines as mediators of inflammatory processes in AD are released by microglia and 
astrocytes surrounding Aβ deposits. IL-1β, TNF, and TGF-β-1 are among the many cytokines 
involved in AD.  Treatment with IL-1 has been shown to increase APP gene expression in 
human umbilical vein endothelial cells (Goldgaber et al., 1989). Another cytokine, TGF-β, was 
also shown to be modulating APP gene expression in microglial BV-2 cell line (Monning et 
al., 1994). A transformed human monocyte cell line, THP-1, when stimulated by Aβ also 
induced production of TNF (Klegeris et al., 1997), suggesting that cytokines can induce APP 
expression and Aβ in turn can as well induce cytokine production. Many of the pro-
inflammatory cytokines in AD are produced by microglia. Aβ and IFN-γ synergistically 
activate microglia by triggering production of reactive nitrogen intermediates and TNF 
causing neuronal cell injury in vitro (Meda et al., 1995). Apart from fibrillar Aβ, even Aβ 
oligomers can stimulate adult microglia to release TNF (Floden and Combs, 2006). Freshly 
dissolved Aβ40 stimulated microglia to release IL-1β while freshly dissolved  Aβ42 stimulated 
microglia to release IL-1α and IFN-γ (Lindberg et al., 2005). Microglia can be stimulated by 
Aβ in the same manner as IFN-γ and LPS, thereby unleashing a cytotoxic proinflammatory 
responses, which stand in contrast to those microglial responses stimulated by IL-4 cytokine 
(Butovsky et al., 2005). This clearly suggests that cytokines can tune and tame microglial 
responses towards a direction defined by pathology and physiology of brain 
microenvironment. Moreover, inflammatory cytokines released by activated microglia may 
cause activation of astrocytes, which in turn may further induce APP expression  and thus 
amplify the pro-inflammatory cytokine production to a never ending cycle (Ho et al., 2005). 
Besides, presence of many inflammatory cytokines such as IL-1β, TGF-β. IL-10, TNF, IL-6 was 
detected in the brain of Tg2576 AD mice, where much of the cytokine signal was restricted to 
Aβ plaque microenvironments (Benzing et al., 1999b; Apelt and Schliebs, 2001) (Sly et al., 
2001). Furthermore, progressive age-dependent upregulation of IL-12 and IFN-γ mRNA was 
detected  by in situ hybridisation technique in cerebral cortices of Tg2576 mice (Abbas et al., 
2002).  
Even though cyclooxygenases are involved in neuroinflammation, their role in AD is 
controversial. Some studies have indicated increased expression of COX-2 in the AD brain 
(Ho et al., 2001), while some other studies reported decreased COX-2 in late stages of AD 
(O'Banion et al., 1997). PGE2 is an end product of COX-2, and EP2 is principle receptor for 
PGE2.  PGE2 signalling via EP2 receptor was found to be promoting age-dependent oxidative 
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damage and increased amyloid burden in APP/PS1 mice via BACE1 activity(Liang et al., 
2005). 
Apolipoprotein E (ApoE) is associated with neurodegenerative diseases, including AD and 
Parkinson’s disease. In addition to its role lipid transport and pathogenesis of atherosclerosis, 
it is also known for its immunomodulatory properties. Strong induction of circulating TNF, 
IL-1β and IL-6 levels by LPS injection was inhibited by ApoE co-administration, suggestive of 
its cytokine modulatory effects (Van Oosten et al., 2001). Apoe deficient mice respond to 
bacterial infections by producing higher circulating TNF level than controls (de Bont et al., 
2000). Apoe deficient mice also express higher levels of circulating cholesterol that might 
further aggravate inflammatory responses (Martens et al., 2008). Upon LPS stimulation, Apoe 
deficient mixed glia cultures produced higher amounts of TNF and IL-6 than wild–type 
controls. Similarly, intravenous injection of LPS to Apoe deficient mice upregulated brain 
levels of Tnf and Il6 (Lynch et al., 2001). Moreover, ApoE can modulate CNS immune and 
inflammatory responses in an isoform specific manner. Mouse Apoe when replaced with 
human APOE4 displayed greater serum and brain levels of TNF and IL-6 than mice with 
human APOE3 upon intravenous LPS injection (Lynch et al., 2003b). Similarity of CNS and 
systemic inflammatory effects in both Apoe-/- and APOE4 mice suggest that at least some 
APOE4 effects might be reflective loss of function of ApoE protein.  
 
Recently, it was shown that microglia had higher expression of vascular endothelial 
growth factor (VEGF) and its receptor Flt-1 in AD brains than in nondemented controls (Ryu 
et al., 2009). Subsequently, VEGF receptor subtype Flt-1 has been shown to play an important 
role as microglial chemotactic receptor necessary for mobilizing microglia around Aβ 
plaques.  Furthermore, this Flt-1 dependent mobilization of microglia resulted in 
neurodegeneration (Ryu et al., 2009). 
In AD brains, iNOS expression in microglia was clearly detected by 
immunohistochemistry (Heneka et al., 2001). More specifically, increased iNOS expression 
was seen associated with Hirano bodies (eosinophilic rod like inclusions), Aβ plaques and 
NFTs of AD brains than in control brains (Lee et al., 1999)(Wallace et al., 1997). Injection of 
fibrillar Aβ into rat striatum resulted in increased activation of microglia and astrocytes that 
also expressed iNOS, suggesting that Aβ can activate glial cells which in turn can release 
inflammatory mediators (Weldon et al., 1998). Apart from microglia and astrocytes in AD 
brain, NFTs and neuropil threads also express iNOS (Vodovotz et al., 1996). In addition, AD 
brains showed higher levels of nitrotyrosine in neurons than controls indicative of 
peroxynitrate involvement in oxidative damage associated with AD (Smith et al., 1997). 
2.3.4 Neuroinflammation in Alzheimer’s disease - Good or bad? 
Neuroinflammation in AD is characterized by the presence of reactive astroglia and 
microglia around Aβ plaques. In addition, presence of complement proteins, pro-
inflammatory cytokines, chemokines, infiltration of peripheral monocytes and brain edema 
are also signs of detrimental neuroinflammation in AD (McGeer and McGeer, 2001).  
Activated microglia and astroglia release many neurotoxic factors, such as reactive oxygen 
species, excitatory neurotransmitters, proteases, nitric oxide,  which ultimately results in loss 
of neurons, synapses and cognition (Akiyama et al., 2000). Such microglial activation in the 
presence of pro-inflammatory cytokines has been shown to hinder degradation or 
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phagocytosis of Aβ plaques (Koenigsknecht-Talboo and Landreth, 2005)(Akiyama et al., 2000; 
Hickman et al., 2008). Moreover, proinflammatory cytokines TNF and IL-1β may impair 
synaptic plasticity and cause memory impairment (Wang et al., 2005). The above mechanisms 
constitute representative examples for detrimental neuroinflammation in AD. 
Astute application of the immunological principles to target Aβ peptide in experimental 
AD mice uncovered unexpected beneficial potential of inflammatory processes and ushered a 
new avenues for disease modifying strategies. Brain processes involving activation of 
microglia, such as traumatic brain injury were reported to reduce Aβ burden in APP mice 
(Morgan et al., 2005). This particular activation of innate immune response was deemed to be 
beneficial. Subsequent investigations revealed mechanisms like Fcγ mediated phagocytosis of 
Aβ by activated microglia (Bard et al., 2000), suppression of reactive astrocytosis by active 
vaccination against Aβ (Schenk et al., 1999), reduction of Aβ load by stimulation of microglia 
by LPS (DiCarlo et al., 2001), and infiltration of peripheral macrophages into CNS (Malm et 
al., 2005b), these constitute good examples of beneficial neuroinflammation in AD.  
Currently, there is no evidence that suggests an early role of inflammation in AD. All the 
evidence from genetic mouse models suggests that neuroinflammation is a driving force in 
AD rather than a cause. Inflammatory mediators in AD interact at multiple cellular, 
molecular and transcriptional levels to facilitate mechanisms underlying neurodegeneration 
and neuroprotection in AD. Therefore, for modifying AD disease progression one strategy is 
to balance detrimental and beneficial effects of neuroinflammation, which requires dynamic 
engagement of innate immune system, and to a minor extent, even elements of adaptive 
immune system. This incessant relationship between immune cells and neuroinflammation 
opens up a large untapped opportunity to specifically modify progression of AD. 
Mechanisms like suppression of activated microglia and astroglia, switching cytokine profiles 
between Th1 and Th2, protection of neurons and synapses, and fostering neurogenesis are 
tangible objectives to regulate immune responses. Experimental and therapeutic approaches 
in this direction offer many immunomodulatory avenues for the treatment of AD.  
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2. 4 IMMUNOMODULATORS FOR ALZHEIMER’S DISEASE 
Undisputable involvement of cellular and molecular mediators of innate immune system 
in pathogenesis of various neurodegenerative diseases is well appreciated (Bordon, 2010; 
Goni et al., 2010). Microglia, astroglia and neurons are the major cellular mediators while, 
Toll-like receptors, cytokines, chemokines etc. are some important molecular mediators. 
Under aseptic conditions, these cellular and molecular mediators regulate diverse 
neuroinflammatory and immune responses to a variety of endogenous and exogenous 
stimuli. Any experimental intervention through pharmacological or genetic approaches bears 
consequences on both innate and adaptive arms of immune system thereby influencing 
neuroinflammatory milieu. Such modulators of immune responses may be 
immunostimulants, immunosuppressant drugs, vaccines, adjuvants or monoclonal and 
polyclonal antibodies. Neurotransmitter glutamate recently joined the ranks of 
immunomodulators. Metabotropic glutamate receptor 4 (mGluR4) in dendritic cells 
modulates regulatory T cells and supresses neuroinflammation in a mouse model of multiple 
sclerosis (Hansen and Caspi, 2010). In another example, transgenic mice expressing  human 
APOE4, upon LPS stimulation had elevated brain expression of TNF-α and IL-6 than APOE3 
counterparts suggesting isoform–specific immunomodulatory properties of Apo-E (Lynch et 
al., 2003a). Furthermore, treatment with small ApoE-mimetic peptide in these mice 
suppressed systemic and brain neuroinflammation. Thus, immunomodulation by ApoE can 
be beneficial in a variety of neuroinflammatory conditions associated with stroke, multiple 
sclerosis, septic shock, traumatic brain injury and Alzheimer’s disease (Lynch et al., 2003a). In 
the context of AD, immunomodulators can simply provide temporary relief from the 
toxicities associated with Aβ peptide or at least decrease, if not cease, the impact of ongoing 
neuroinflammation by suppressing the neurotoxic activation of glial cells and by influencing 
network of cytokines or chemokines etc. In addition, immunomodulators may also switch 
beneficial cellular phenotypes such as phagocytic and neurogenic microglia. In AD 
therapeutic pipeline, NSAIDs, Peroxisome proliferator-activated receptor gamma (PPAR-γ) 
agonists, statins, thalidomide and other TNF inhibitors, omega-3 fatty acids, curcumin, 
sodium valproate, alpha-7 nicotinic receptor agonist,  Aβ vaccines, monoclonal Aβ 
antibodies, human intravenous immunoglobulins, umbilical cord stem cells, NFκB inhibitors 
like pyrrolidine dithiocarbamate (PDTC) are some examples of potential immunomodulators.   
2.4.1 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Some epidemiological studies indicate that rheumatoid arthritis patients on NSAID 
treatment are less likely to develop AD (McGeer et al., 1990; Launer, 2003). The Canadian 
Study of Health and Aging also showed reduced risk of AD with history of arthritis,  usage of 
NSAIDs, or use of corticosteroids (Anonymous 1994). Furthermore, the Rotterdam study 
revealed that consistent long-term use of NSAIDs reduced the risk of AD by 80% (in t'Veld et 
al., 2001).  Moreover, protective effect of NSAIDs was strongly dependent on the treatment 
duration and APOE genotype. In some studies, NSAID mediated protection to AD was 
limited to only those with APOE epsilon 4 allele (Szekely et al., 2008);(Pasqualetti et al., 2009). 
Several mechanisms were hypothesized for the protective effect of NSAIDs, such as anti-
inflammatory, neuroprotective, anti-amyloidogenic, and anti-Aβ aggregational effects.  
NSAIDs are clinically widely used for pain, fever and inflammation. They act by inhibiting 
cyclooxygenase enzymes leading to suppression of prostaglandin synthesis (Smith et al., 
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2000). Certain NSAIDs like ibuprofen and naproxen are nonselective for COX isoforms (COX-
1 vs. COX-2). NSAIDs like celecoxib, rofecoxib, diclofenac, nimesulide etc are COX-2 
selective. As inflammation is a silent component of AD pathology, these classic anti-
inflammatory drugs were deemed to confer relief to AD patients. Epidemiological and 
experimental data from in vitro cultured cells and transgenic APP mice further revealed 
many underlying mechanisms. As Aβ peptide is the prime drug target in AD, early 
experiments investigated anti-amyloidogenic effects of NSAIDs. Aspirin not only prevented 
Aβ aggregation in vitro but also reversed β-sheet conformation of preformed Aβ fibrils at 
clinically relevant doses (Thomas et al., 2001). This property was also seen in a number of 
NSAIDs like indomethacin, naproxen, ketoprofen, ibuprofen, celecoxib and rofecoxcib 
(Gasparini et al., 2004). Similar anti-aggregation effects were also demonstrated by naproxen 
and ibuprofen using PET molecular imaging probes for in vitro and in vivo Aβ binding 
(Agdeppa et al., 2003). In addition, NSAIDs may also induce expression of amyloid binding 
proteins like transthyretin, whose function is to sequester and prevent Aβ aggregation 
(Gasparini et al., 2004). Besides, NSAIDs like indomethacin, ibuprofen, and nimesulide 
increased expression of APP protein and were further shown to stimulate non-amyloidogenic 
α-secretase processing of APP through activation of MAP kinases (Avramovich et al., 2002). 
Effects of NSAIDs on secretion of Aβ largely depended on the type of cell culture system 
employed (Gasparini et al., 2004). R-flurbiprofen directly targeted γ-secretase and hence 
lowered Aβ42 levels. COX inhibition is the principal mode of action for NSAIDs (Smith et al., 
2000). However, Aβ lowering effect of NSAIDs was also reported to be independent of COX 
inhibition (Weggen et al., 2001). In this study by Weggen et al. sulindac sulphide, ibuprofen 
and indomethacin lowered Aβ42 levels in cultured cells by more than 80% irrespective of the 
cell-type used. In the same study, however, aspirin, naproxen (non-secetive COX inhibitor), 
meloxicam (preferential COX-2 inhibitor), SC-560 (selective COX-1 inhibitor) and celecoxib 
(selective COX-2 inhibitor) failed to show any Aβ lowering effects.  
Transgenic Tg2576 mice fed on chow mixed with ibuprofen for 6 months caused 
reductions in IL-1β, GFAP, microglia, dystrophic neurites, and suppressed amyloid 
pathology by ~50% (Lim et al., 2000). Similarly, in a comparative study 8 of 20 commonly 
used NSAIDs lowered Aβ42 in APP transgenic mice after acute dosing suggestive of their 
potential in AD therapeutics (Eriksen et al., 2003). In Tg2576 mice, short treatments with 
ibuprofen but not with naproxen caused reductions of Aβ levels (Weggen et al., 2001). 
Microglial reactivity, as measured by CD45 and CD11b expression, was decreased alongside 
lowering of Aβ42 in response to buprofen treatment (Yan et al., 2003). Nitric oxide releasing 
derivatives of flurbiprofen, HCT 1026 and NCX 2216 also showed Aβ lowering effects 
(Gasparini et al., 2004; Jantzen et al., 2002). Early and chronic ibuprofen treatment regimens 
resulted in reductions of Aβ consistently in several APP mouse models. In another study, 
indomethacin treatment for 7 months in Tg2576 mice decreased brain levels of Aβ but also 
interestingly suppressed NFκB activity significantly (Sung et al., 2004). Cognitive impairment 
and memory functions of Tg2576 mice were restored by naproxen, ibuprofen and the 
selective COX-2 inhibitor MF-tricyclic (Kotilinek et al., 2008). This beneficial effect was not 
due to lowered Aβ42 or suppression of inflammatory cytokines like TNF and IL-1β, but 
depended inversely on PGE2levels suggestive of COX-2 inhibition by NSAID treatment 
(Kotilinek et al., 2008).  
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In spite of epidemiological and experimental evidence, clinical trials with NSAIDs have 
been disappointing possibly due to many reasons like inadequate dose or treatment duration 
or wrong therapeutic window (Heneka et al., 2011). A short, 12-month randomized controlled 
clinical trial for ibuprofen in mild to moderate AD patients, however, showed no significant 
deterioration of cognitive status in a subset of APOE epsilon 4 carriers, in spite of no overall 
treatment differences (Pasqualetti et al., 2009). Alzheimer’s disease anti-inflammatory 
prevention trial (ADAPT) comprised of naproxen, celecoxib or placebo treatment arms was 
initiated in cognitively intact elderly with familial history of dementia. However, this trial 
was stopped because of cardiovascular safety concerns (Heneka et al., 2011). Clinical trials 
with nonselective NSAIDs or newer COX selective drugs were not found to be beneficial in 
acute treatment setup for AD symptoms. A COX-inactive NSAID, tarenflurbil (Flurizan), 
which is a R-enantiomer of flurbiprofen was shown to possess Aβ lowering effects. However, 
a multicenter, randomized, placebo-controlled phase 3 trial in mild AD patients failed to slow 
down cognitive decline or loss of activities of daily living in mild AD patients (Green et al., 
2009).  A detailed account of epidemiological, experimental, clinical details of various 
NSAIDs can be found in the comprehensive review by (Imbimbo et al., 2010).  
2.4.2 Peroxisome proliferator activated receptor gamma  
Immunomodulatory effects of NSAIDs can also be mediated by activation of PPARγ 
activity. In fact, typical NSAIDs like ibuprofen, indomethacin, fenoprofen and flufenamic acid 
are PPARγ ligands (Lehmann et al., 1997). PPARγ is widely present in adult and developing 
brain  as well as in spinal cord  (Heneka and Landreth, 2007). Of its two isoforms, PPARγ1 is 
specifically present in adipose tissue, whereas PPARγ2 is present in other tissues like liver 
and skeletal muscle Upon activation PPARγ forms heterodimers with retinoid X receptor; 
heterodimers then recruit co-activators and bind to PPAR responsive elements present in 
promoter regions of many genes. PPARγ can also inhibit gene expression without binding to 
gene promoters by transrepression of several genes regulated by NF-κB, activator protein 1 
(AP-1), signal transducers and activators of transcription (STAT-1) transcription factors 
(Heneka et al., 2010). PPARγ plays a critical role in controlling inflammatory processes and 
mediators. PPARγ agonists and ligands are known to inhibit expression of several 
proinflammatory genes, such as cytokines IL-1β, TNF and IL-6, chemokines like MCP-1, 
COX-2, and metalloproteinase 9 (Landreth and Heneka, 2001). Furthermore, iNOS mediated 
cell death in response to LPS treatment of cerebellar granule cells was prevented by activation 
of PPARγ (Heneka et al., 1999). Agonists of PPARγ also inhibited neurotoxicity associated 
with Aβ activated microglia by suppressing expression of IL-1β, TNF andCOX-2 (Combs et 
al., 2000). In addition, stimulation of neuroblastoma cells transfected with APP by cytokines 
was inhibited by ibuprofen and indomethacin treatment, which was further suppressed by 
PPARγ anatagonists (Sastre et al., 2003). Further in vivo studies demonstrated that acute 
treatment of APP transgenic mice with PPARγ agonist like pioglitazone suppressed 
activation of microglia and astrocytes, and reduced expression of COX-2 and iNOS along 
with suppression of BACE (Heneka et al., 2005);(Sastre et al., 2006), suggesting that acute 
effects of PPARγ involve rapid inhibition of inflammatory responses and negatively 
modulating amyloidogenesis. However, during chronic treatment paradigms, amyloid 
lowering properties of PPARγ activators was reported to be limited, although 
immunomodulatory negative effects on inflammation was replicated (Yan et al., 2003).  
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2.4.3 Vaccination strategies for Alzheimer’s disease 
Solomon and colleagues were the first to demonstrate that antibodies raised against Aβ 
protein prevented aggregation of Aβ monomers and disintegrated preformed Aβ fibrils 
(Solomon et al., 1996; Solomon et al., 1997). This in vitro observation laid foundations for 
future immunotherapeutic approaches for AD. This strategy received a major impetus with 
the first in vivo proof of concept reported by Schenk et al. (Bard et al., 2000; Schenk et al., 
1999). In PDAPP mice, vaccination with pre-aggregated synthetic Aβ1-42 peptide induced 
development of Aβ antibodies, which then prevented deposition of Aβ  and reduced 
preformed Aβ plaque load. In addition, treatment also decreased dystrophic neurites and 
inflammatory gliosis. These results were soon replicated by many groups independently 
(Weiner et al., 2000; Das et al., 2001) and were complemented by reports showing reversal of 
cognitive impairment in amyloid producing transgenic mice (Morgan et al., 2000)(Janus et al., 
2000). However, one study reported limited ability of Aβ vaccination to alleviate learning 
deficits in immunized mice in spite of 60% reduction in amyloid plaque pathology (Chen et 
al., 2007).  In this study only a subset of mice with low cortical Aβ levels displayed spatial 
memory benefits due to Aβ immunisation. Nevertheless, these initial studies demonstrated 
the potential of Aβ vaccination strategies to alleviate amyloid pathology and cognitive 
impairment in mice. In Tg2576 mice, however, active vaccination seemed to be efficient in 
preventing Aβ deposition in young mice but not in older mice with preformed amyloid 
plaques (Das et al., 2001). Also, in non-human primates like Caribbean vervets (Lemere et al., 
2004) and aged canines (Head et al., 2008), Aβ clearing effects with Aβ vaccination was 
demonstrated to be efficacious. Active Aβ vaccination with even non-fibrillar and non-toxic 
Aβ40 as well resulted in development of high titres of Aβ antibodies, which alleviated 
amyloid pathology in transgenic AD mice (Sigurdsson et al., 2001). 
Immune system of elderly patients might be less competent to induce immune response 
against Aβ peptide. In addition, sometimes immune responses to Aβ vaccine are exacerbated 
and difficult to control. Probably due to same reasons, a phase 2 clinical trial in AD patients 
with  Aβ vaccine AN 1792 (comprising of full length synthetic Aβ42 and QS-21- a strong Th1 
inducing adjuvant),  could induce Aβ antibodies only in 19% of patients, and more 
importantly, was prematurely stopped due to development of aseptic meningoencephalitis in 
6% of patients (Orgogozo et al., 2003).   
In an effort to improve safety and efficacy, many novel second generation vaccines have 
been developed. An optimal combination of antigen, adjuvant and route of delivery are 
critical for the success of active vaccination strategy (Lemere, 2009). The presence of adjuvants 
along with antigen stimulates the host immune system to effectively mount immune 
responses. Conventional adjuvants like complete and incomplete Freund’s adjuvant 
(Sigurdsson et al., 2001), Alum (Asuni et al., 2006) or heat shock protein 70 homolog of E.coli 
(Koller et al., 2004) were initially tested but lacked desired optimal efficiency.  T-cells 
recognize Aβ epitopes on the C-terminal end of Aβ peptide from 16-42 amino acids (Lemere, 
2009). Therefore, in order to avoid T-cell responses, N-terminal fragments of Aβ peptide from 
1-15 amino acids (constituting B-cell epitopes) were preferred as antigens with minor 
modifications to enhance immunogenicity (Cribbs et al., 2003); (Monsonego et al., 2003). 
Immunogens like dendrimeric Aβ1-15 (Seabrook et al., 2007) consisting of 16 copies of Aβ1-15 on 
a branched lysine tree, two tandem linear repeats of Aβ1-15 linked by two lysines with or 
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without N-terminal three amino acid sequence RGD or attachment of T1 T-helper cell epitope 
by two lysines to Aβ1-15 were also developed(Maier et al., 2006). It was already known that T 
cell responses based on their cytokine release profile can be characterized as Th1 (cell 
mediated and proinflammatory) or Th2 type (humoral and anti-inflammatory). In mice, 
induction of antibodies predominantly of IgG1 and IgG2b sub-classes are indicative of anti-
inflammatory Th2 cytokine signalling whereas IgG2a sub-class results from pro-
inflammatory cytokine signalling (Abbas et al., 1996). Th2 cytokine profiles were preferred 
over Th1 in order to avoid T-cell mediated meningoencephalitis. Vaccinations with 
papillomavirus-like particles expressing 1-9 amino acid region of Aβ on viral capsid surface 
(Aβ-VLP) resulted in efficient humoral response at the same time avoiding induction of T cell 
responses (Zamora et al., 2006), suggesting that viral based vaccines are potentially safe and 
effective alternative candidates for AD vaccine (Chackerian et al., 2006).  Add ravetch ref 
Furthermore, appropriate route of administration in addition to suitable adjuvant are 
important to achieve high titres of Aβ antibodies after vaccination in mice. Intranasal 
immunization with fibrillar Aβ40/42 plus adjuvant LT(R192G)  (a mutant form of E.coli heat 
labile enterotoxin) resulted in higher titres of Aβ antibodies than  in combination with 
adjuvants like monophosphoryl lipid A (MPL)/trehalose dicorynomycolate (TDM) emulsion 
or cholera toxin B subunit. However, subcutaneous vaccinations with the same antigen and 
adjuvants were not as efficient as intranasal routes (Maier et al., 2005). Transcutaneous route 
of vaccine delivery of aggregated Aβ1-42 with cholera toxin adjuvant as well resulted in higher 
titres of Aβ antibodies of IgG1 subclass and reduced brain Aβ loads by 50% without any pro-
inflammatory consequences of vaccination (Nikolic et al., 2007). Furthermore, this approach 
was not associated with any T-cell infiltration or cerebral microhemorrhage. Remarkably, one 
study reported decreased vascular amyloid and microhemorrhages with clinically approved 
Alum as adjuvant (Asuni et al., 2006).  
Limitations and side effects of active Aβ immunotherapy fostered development of passive 
immunisation methods. In passive immunisation strategy, either monoclonal or polyclonal 
antibodies reactive to Aβ peptide are administered by intravenous or intraperitoneal routes. 
In PDAPP mice, injection of N-terminal specific Aβ antibodies not only crossed blood-brain-
barrier but also decorated plaques and induced clearance of Aβ deposits by Fcγ receptor 
mediated microglial phagocytosis (Bard et al., 2000). However, in PDAPP mice, passive 
administration of m266 antibody directed towards the middle region of Aβ, prevented Aβ 
deposition, decreased biochemical levels of Aβ in brain, and increased Aβ immune complexes 
in plasma and CSF, indicating an efflux of Aβ from CNS in support of the peripheral sink 
mechanism (DeMattos et al., 2001).  More direct evidence came from studies with multi-
photon microscopy, where plaque clearance was demonstrated within 3 days of application 
of Aβ antibody directly to the cortex (Bacskai et al., 2001). Subsequent mechanistic studies 
revealed that Aβ N-terminally directed antibodies were efficient in clearing plaques, 
providing neuronal protection. Moreover, affinity of antibodies to FCγ receptors on microglia 
was found to be more important than affinity to Aβ itself (Bard et al., 2003). In triple 
transgenic AD mice, passive immunisation with Aβ antibodies not only cleared extracellular 
plaques but also decreased intracellular Aβ and tau pathologies (Oddo et al., 2004). 
Behavioural and memory benefits were also reported with passive immunisation protocols 
(Wilcock et al., 2004b). However, removal of Aβ plaques was not essential for obtaining 
cognitive benefits. (Kotilinek et al., 2002; Dodart et al., 2002). In addition, Aβ passive 
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immunotherapy prevented synaptic loss and reversed gliosis (Chauhan and Siegel, 2002), 
preserved dendritic morphology and structural plasticity in brains of PDAPP mice (Spires-
Jones et al., 2009), and finally also protected from Aβ oligomer mediated loss of neuronal 
function (Klyubin et al., 2005; Klyubin et al., 2008).  Passive immunisation with Aβ antibodies 
while efficacious in removal of Aβ plaques also resulted in Aβ antibody interactions with 
vascular amyloid causing cerebral amyloid angiopathy and microhemorrhages in mice 
(Wilcock et al., 2004b; Pfeifer et al., 2002; Racke et al., 2005).Microhemorrhages are 
consequences of antibodies reacting to Aβ present in the walls of cerebral blood vessels, thus  
triggering an inflammatory reaction. This is particularly critical in old people with frail blood 
vessels. All these AD mouse data indicate overall efficacy of passive immunisation strategy 
provided that the treatment begins before onset of robust plaque pathology in brain and 
blood vessels.   
Mechanistically, both active and passive immunisation strategies rely on efficient clearance 
of Aβ from brain. Three main prominent mechanisms for immunotherapy have been 
proposed (Weiner and Frenkel, 2006; Morgan, 2011; Morgan, 2009; Morgan, 2005). First, Aβ 
antibodies prevent and interfere with aggregation of Aβ monomers into amyloid fibrils or 
even disintegrate pre-established Aβ plaques.  Second, Aβ antibodies decorate plaques in the 
brain, which are subsequently recognized by Fcγ receptors on microglia.  Thus, activated 
microglia removes Aβ deposits by phagocytosis. The third mechanism relies on the fact that 
there is a dynamic equilibrium between Aβ within the brain and outside the brain, thus 
binding of Aβ in the periphery by antibodies instigates an efflux of Aβ from CNS into 
plasma.  The first two mechanisms will require antibodies to cross blood-brain-barrier while 
the third mechanism does not require antibodies to enter CNS parenchyma. All these 
mechanisms might be mutually exclusive and independent (Citron, 2004). Currently, nine 
passive immunisation trials and six active immunisation trials are in various stages of clinical 
development (Lemere and Masliah, 2010b) and trial results due in 2012-2013 will be critical in 
shaping future drug discovery programs in AD. Recently, antibodies have also been used to 
interfere with APP interaction with BACE1 site (Arbel-Ornath et al., 2010). 
Immunotherapeutic strategies for AD are destined to be disease modifying treatments as 
removal of Aβ from AD brains may delay or even reverse progression of this disease. 
Modulation of host immune system or influencing immune functions of microglia by Aβ 
antibodies irrespective of being passively transferred or actively produced constitutes their 
immunomodulation potential. 
 2.4.4 Miscellaneous immunomodulatory drugs   
Among the other potential immunomodulators for AD are interferon-β and glatiramer 
acetate. Interferon-β is a type I interferon immunomodulatory cytokine which can be induced 
by ligands for TLRs. There are very few studies which explored immunomodulatory effects 
of interferon-β in the context of AD pathology. Nevertheless, they are known to inhibit 
production of IL-1β by regulating imflammasome either by mechanisms downstream of 
STAT activation  or by induction of IL-10 (Gonzalez-Navajas et al., 2012). They are also 
known to shift proinflammatory Th1 cytokines milieu to Th2 anti-inflammatory profiles.  
Thus, their ability to influence innate immune responses and cytokines networks indicates 
their potential for use in AD. Glatiramer acetate has been tested in AD mice and was shown 
effective in clearing Aβ plaques and switch microglia phenotype by expressing CD11C 
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dendrite cell marker producing insulin growth factor 1 (IGF-1) (Butovsky et al., 2006). This 
treatment also induced neurogenesis and confered cognitive benefits to mice. 
Immunomodulatory effects of drugs on microglia can be monitored indirectly by measuring 
CSF levels of chitotriosidase, which is an indicator of activated microglia. Such 
immunomodulatory effects on microglia/ macrophages were previously reported by 
natalizumab treatment in multiple sclerosis patients (Olsson et al., 2012) and may be as well 
used for AD trials as biomarker of microglial activity. Anti-cancer drug mitoxantrone can 
block Aβ oligomerization (Colombo et al., 2009), and has been known to possess 
immunomodulatory properties by suppressing  proliferation of CNS inflammatory cells and 
inhibiting the regulation of pro-inflammatory cytokines (Derwenskus, 2011). 
Immunomodulatory properties of human umbilical cord blood-derived mesenchymal stem 
cells (hUCB-MSC) were reported to improve both memory impairments and neuropathology 
(Lee et al., 2012). These cells not only reduced Aβ deposition, BACE-1 levels and tau 
hyperphosphorylation but also suppressed proinflammatory cytokines, elevated anti-
inflammatory cytokines, and increased alternatively activated microglia (Lee et al., 2012). 
Similar anti-inflammatory and immunomodulatory effects were also reported by bone 
marrow-derived mesenchymal cells (Lee et al., 2010). Immunomodulators like thalidomide 
and its derivative supidimide were reported to favour nonamyloidogenic processing of APP 
via the α-secretase pathway (Avramovich et al., 2002). Further, neuronal and cognitive 
deficits associated with LPS induced chronic neuroinflammation was rescued by 3,6 
dithalidomide, an analog of thalidomide possessing anti-TNF activity, indicating behavioural 
benefits of immunomodulation (Belarbi et al., 2012). Temporal and dose-dependent 
production of many cytokines and chemokines by intracerebroventricular injection of Aβ 
peptide or LPS was also suppressed by treatment with immuonodulators like glucocorticoids 
or IL-10 (Szczepanik and Ringheim, 2003). Many novel synthetic and natural agonists of Toll-
like receptors are also being developed to specifically harness neuroprotective functions of 
innate immune system. Such immunomodulators may prevent detrimental effects of 
neuroinflammation and alter the course of disease progression, exemplifying a disease 
modification strategy in AD. 
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2.5 HUMAN INTRAVENOUS IMMUNOGLOBULIN FOR ALZHEIMER’S 
DISEASE 
   In 1991 Mönning et al. first reported Aβ immunoreactivity in human serum and 
CSF (Mönning et al., 1991). Subsequently, B-cells isolated from AD patients were reported to 
secrete antibodies that were reactive to Aβ plaques and blood vessels in AD brains (Gaskin et 
al., 1993). Several studies thereafter tried to characterize immune responses against Aβ by 
measuring autoantibodies in the brain, CSF and serum. So far, the evidence for the presence 
of Aβ autoantibodies in AD remains ambiguous. One study (Baril et al., 2004) demonstrated 
that subjects ranging from one-year-old to elderly showed low and variable titres of Aβ 
autoantibodies in the serum.  Furthermore, no significant difference Aβ antibody titres were 
found between AD and control subjects. Likewise, another study (Hyman et al., 2001) found 
it quite common for normal healthy people above 65 years age to show small titres of 
autoantibodies against Aβ. However, since titres of Aβ antibodies in this study were far 
below those acquired during experimental immunotherapy, it was concluded that low 
affinity interactions of these antibodies may not be clinically useful either for diagnostic 
purposes or to therapeutically impact Aβ in brain or CSF or plasma (Hyman et al., 2001). In 
contrast, a study using tissue microarrays on AD and control brains demonstrated that 
antibodies reactive to Aβ are common in the elderly and that these antibodies can decorate 
Aβ plaques inside the brain (Kellner et al., 2009), indicative of  therapeutic potential for 
autoantibodies against Aβ protein. Similarly, another  microarray study also reported the 
presence of natural antibodies against Aβ and other toxic amyloidogenic assemblies in the 
serum and CSF of AD patients and control subjects (Britschgi et al., 2009).  Interestingly, in 
one  study, Aβ antibodies in the CSF of AD patients were found to be 38% lower than those in 
healthy subjects (Du et al., 2001).  
 Several studies thereafter have also reported significantly lower serum Aβ 
antibodies in AD patients than in elderly controls (Weksler et al., 2002; (Yang et al., 2005) 
Song et al., 2007).  This phenomenon was not attributed to age-related decline in normal 
immune responses (Weksler et al., 2002). Not only serum titres, but also avidity of serum Aβ 
antibodies was significantly reduced in AD patients. However, the avidity of Aβ antibodies 
was not influenced by the age of the subjects in another study (Jianping et al., 2006). 
Interestingly, a study (Moir et al., 2005) showed significantly reduced titres of autoantibodies 
to oligomeric cross-linked Aβ protein species in AD patients but no differences in 
autoantibodies to unmodified Aβ monomers. Similartly, large immune complexes of 
autoantibodies against Aβ protein were selectively decreased in AD patients in another study 
(Henkel et al., 2007). In stark contrast to aforementioned studies, one study (Nath et al., 2003) 
reported significantly increased serum auto Aβ antibody titres in AD patients. However, only 
3 of 11 AD patients showed presence of Aβ antibodies in ventricular CSF (from autopsy). 
Furthermore, in this study none of the 31 normal control subjects showed any detectable 
antibodies to Aβ. Similarly, another study (Mruthinti et al., 2004) using affinity purified IgGs 
from plasma showed four-fold higher titres of Aβ antibody in AD patients than in unaffected 
individuals. Likewise, after applying appropriate ELISA dissociation protocols, levels of 
serum Aβ autoantibodies were significantly elevated in AD patients than controls in a third 
study (Gustaw et al., 2008).  
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Thus, currently available literature shows decreased, unchanged or increased Aβ 
autoantibody levels in AD patients compared to normal subjects. The discrepancy in these 
studies can in part ascribed to technical caveats associated with ELISA measurements of 
protein complexes under investigation. Significant quantities of both Aβ protein and Aβ 
autoantibodies are bound to complexes, and therefore measuring total amounts of antigen or 
antibody following unmasking is critical for their precise estimation (Weksler et al., 2005). 
Furthermore, recent studies indicated very high non-specific binding properties of human 
intravenous immunoglobulins (hIVIG), such that even the reverse sequence of Aβ1-42, BSA or 
plain buffer solution could show positive optical density values (Klaver et al., 2010b);(Klaver 
et al., 2010a)(Klaver et al., 2010a)(Klaver et al., 2010a)(Klaver et al., 2010a)(Klaver et al., 
2010a)(Klaver et al., 2010a)Klaver et al., 2010a);Klaver et al., 2010b). Notably, all the previous 
studies that measured Aβ autoantibodies (Dodel et al., 2002; Szabo et al., 2008) described no 
controls for the specificity of antibody binding to Aβ protein.  Despite all this ambiguity 
about Aβ autoantibodies in serum or CSF, there is little doubt about the central role for 
immune system in regulating Aβ homeostasis.  
 
Finally, Aβ antibodies in commercial preparations of hIVIG were investigated and shown 
to be reactive to Aβ monomers or oligomers (Klaver et al., 2010a). Detailed examination of 
epitope specificity of natural Aβ antibodies contained in human intravenous 
immunoglobulins (hIVIG) indicated the presence of conformational Aβ antibodies that were 
presumably formed from the neo-epitopes formed during aggregation of Aβ peptides to 
oligomers and fibrils (Szabo et al., 2008) (Britschgi et al., 2009). Roughly < 0.2% of antibodies 
in commercial hIVIG preparation has been reported (Gammagard S/D) to be reactive to Aβ 
protein (O'Nuallain et al., 2006). However, owing to the presence of antibodies reactive to 
toxic Aβ assemblies (O'Nuallain et al., 2008), therapeutic viability of hIVIG for treatment of 
AD was taken seriously by many investigators. 
 
hIVIG, is not a pharmaceutical product but a collection of pooled polyclonal natural and 
acquired IgG antibodies. The subset of Aβ antibodies in hIVIG  preparations are natural 
antibodies in the sense that they have not been produced in response to sensitization to any 
foreign antigen or due deliberate immunization. Much of the natural antibodies in healthy 
people are autoantibodies that are polyreactive to a wide array of self-antigens (Kazatchkine 
and Kaveri, 2001). Human body makes IgG which is purified by commercial fractionators 
from pooled plasma of more than 10000 healthy volunteers. Among the purification methods 
are Cohn-Oncley process (cold ethanol precipitation), Kistler-Nitschmann process, ion-
exchange chromatography methods, and caprylate treatment followed by ion-exchange 
chromatography (Martin, 2006)(Radosevich and Burnouf, 2010). Typical plasma pools range 
from 4000 to 50000 litres. The World Health Organisation (WHO) guidelines require more 
than 1000 donors per lot.  Hence, hIVIG represents a broad spectrum of antigenic repertoire 
that would be present in normal serum. Sometimes this property might as well cause dilution 
of any clinically useful components. Companies invest efforts and resources to minimise 
batch to batch variation, in order to maintain and ensure reproducible biological functions of 
purified immunoglobulins. Ensuring normal pharmacokinetics, pharmacodynamics and 
functional efficacy of hIVIG formulations largely depend on preservation of native molecular 
structure of Fab and Fc domains of IgG (Radosevich and Burnouf, 2010). According to a 
review comparing physic-biochemical properties of commercially available hIVIG 
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preparations (Boros et al., 2005),the half-life of hIVIG is approximately 21 days. Commercial 
preparations of hIVIG contain intact IgG molecules with trace amounts of IgM and IgA. For 
some IgA deficient patients there is risk of developing immune response (anaphylaxis) to IgA 
upon hIVIG infusion. These preparations are formulated as liquids with high IgG 
concentrations (100mg/ml) and are intended for intravenous use. Formulations also included 
stabilizers like polyols (sorbitol), sugars (maltose, glucose), or amino acids (glycine, L-proline, 
isoleucine) to prevent aggregate formation. Sodium content (0.9%) and osmolality of hIVIG 
preparations are controlled to reduce infusion-related adverse events. Optimal pH 4.0 to 4.5 
also prevented aggregation and which upon administration would be rapidly neutralized by 
buffering capacity of blood. Therefore, buffering agents are added to maintain stability and 
prevent aggregation. Typically, hIVIG preparations have approximately neutral pH. Recently, 
pure (>98%) high IgG concentration (200mg/ml) stabilized by proline was developed for 
subcutaneous  self-administration by patients with necessary training (Jolles and Sleasman, 
2011). Presence of L-proline in the formulation prevents IgG aggregation during storage and 
decreases viscousity of the liquid formulation. Such formulations with shorter infusion times 
and better patient compliance are commendable advances in the field of hIVIG therapies. 
  
hIVIG has a long history of being safe and effective therapy (van Doorn et al., 2010. 
Caution is exercised and all the necessary steps are taken in accordance with good 
manufacturing practice (GMP) protocols to avoid risk of viral transmission.  Currently hIVIG 
is used as replacement therapy for primary and secondary immune deficiencies.  It is also 
indicated in the treatment of autoimmune and systemic inflammatory diseases like idiopathic 
thrombocytopenic pupura (ITP), Guillian-Barré syndrome, multifocal motorneuropathy, 
chronic inflammatory demyelinating polyneuropathy(CIDP), and myasthenia gravis (Ballow, 
2005)(Kaveri et al., 2011). Adverse reactions to hIVIG are seen in less than 5% of the patients. 
They include headaches, chills, nausea, fatigue, myalgia, arthralgia and back pain (Ryan et al., 
1996)(Spurlock and Prittie, 2011). Patients with hypertension, diabetes, renal disease, age, 
hyperviscosity and dehydration are at higher risk for adverse events. More than 90% of 
hIVIG associated adverse acute renal failures was found to be due to sucrose containing 
hIVIG preparations (Orbach et al., 2005)(Cheng and Christmas, 2011). Decent safety profile 
and presence of Aβ reactive antibodies in hIVIG prompted many investigators to carry out 
clinical trials that were designed to test if hIVIG treatment will be beneficial for AD patients.  
 
Many small published clinical studies have suggested beneficial effects of hIVIG treatment 
in AD. In a small clinical study comprising of 7 patients with varying neurological disorders, 
treatment with 0.4 g/kg hIVIG (Octagam) for three consecutive days significantly decreased 
CSF Aβ levels and elevated serum levels of Aβ after hIVIG treatment (Dodel et al., 2002). In 
another study by the same group (Dodel et al., 2004), 5 AD patients were treated with 0.4 g/kg 
hIVIG (Octagam) for three consecutive days every 4 weeks for 6 months. Following hIVIG 
treatment, AD patients showed 30% decrease in CSF total Aβ levels, 233% increase in serum 
total Aβ levels and a modest improvement in ADAS-cog (Alzheimer’s Disease Assessment 
scale – Cognitive subscale) scores but no change in MMSE (Mini-mental State Examination) 
scores. This was the first demonstration that hIVIG treatment can bring about clinical benefits 
to AD patients. A subsequent open-label phase 1 trial in mild AD patients (Relkin et al., 2009) 
revealed many interesting clinical aspects of hIVIG treatment. This study comprised of hIVIG 
treatment for 6 months followed by a 3-month washout period and an additional 9 months of 
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hIVIG treatment. All 8 patients were initially given a test dose of hIVIG (0.4 g/kg) and then 
were randomly assigned to one of the doses (0.4 g/kg/2 weeks, 0.4 g/kg/week, 1 g/kg/2 weeks 
and 2 g/kg/4 weeks). After the first test dose all patients showed significantly higher Aβ 
antibodies in their serum. The half-life of serum Aβ antibodies was calculated to be 9.3 days 
which was much shorter than typical IgG (~21 days), suggesting that Aβ antibodies were 
engaging their endogenous ligands (probably Aβ). After 6 and 9 months of renewed hIVIG 
treatments, there was a significant decrease in CSF Aβ40 and Aβ42 from their baselines levels. 
Increased MMSE scores were also seen during this phase. However, during the 3-month 
washout period CSF Aβ40 and Aβ42 levels returned to baseline values and MMSE scores fell. 
In this study, lower doses of hIVIG were associated with higher MMSE scores than high ones 
suggesting an inverse dose-response relationship (Relkin et al., 2009). Stability and sometimes 
even improvement on neurocognitive test scores were also reported in another study (Devi et 
al., 2008), albeit in a small number of AD patients. Furthermore, data from a subsequent 
phase 2 trial (Fagan, 2004.) showed treatment effects on  brain atrophy, measured by 
calculating ventricular enlargements rates. Patients receiving hIVIG showed significantly 
reduced ventricular enlargement rates which also correlated with reduced cognitive decline 
as  measured by CGIC (Clinical Global Impression of Change) and ADAS-cog scores (Relkin 
et al., 2010).  Currently, a phase 3 multicenter clinical trial involving more than 300 patients is 
underway. 
 
Nearly, 30 years back Imbach and his collegues for the first time demonstrated clinical 
benefits of high dose IgG in acute ITP patients (Imbach et al., 1981). Since then, clinical usage 
of hIVIG expanded rapidly but its mechanism of action still remains elusive and mysterious. 
As only high dose hIVIG showed anti-inflammatory properties, it implied that only a small 
portion of polyclonal hIVIG were responsible for therapeutic effects. Much of the work done 
in this regard comes from various mouse models of human antibody-mediated autoimmune 
diseases such as ITP, RA, CIDP etc.  Subsequently, intravenous infusion of mere Fc fragments 
from hIVIG were also found to be sufficient to treat children with acute ITP (Debre et al., 
1993),thereby, implying  a role for  Fc fragments. Samuelsson and his collegues conclusively 
demonstrated that Fc fragments of IgG protected mice from experimental immune 
thrombocytopenia and this protective effect of hIVIG required surface expression of 
inhibitory FcγRIIB on spleenic macrophages (Samuelsson et al., 2001). Figure 2.5a describes 
antibody mediated regulation of macrophage activation in health and disease. Furthermore, 
IgG glycosylation was found to be of necessary for both FcγRIIB binding and anti-
inflammatory effects of hIVIG. A single N-linked glycan attached at aspragine 297 in Fc 
domain of IgG, consisted of a heptameric core with variable branching and terminal sugar 
residues such as galactose, sialic acid, N-acetylglucosamine and fucose. Nearly, 5% of serum 
IgG possessed this carbohydrate moiety. Ravetch and his collegues discovered that indeed 
terminal sialic acid residues of Fc fragments were responsible for anti-inflammatory 
properties of hIVIG (Kaneko et al., 2006b). Morever, deglycosylation of antibodies in hIVIG 
by neuraminidase treatment abolished anti-inflammatory effects and as expected upon 20% 
enrichment with sialylated IgG antibodies, potency of hIVIG to suppress inflammtion 
enhanced by 10 fold (Kaneko et al., 2006b). Discovery of Fc sialylated IgG antibodies initiated 
search for its cognate receptor. However, sialylated mouse and human IgG antibodies have 
less affinity for Fcγ receptors and were found to show high affinity for specific ICAM3-
grabbing nonintegrin, related 1  (SIGN-R1) and dendritic cell-specific ICAM-3-grabbing non-
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integrin 1(DC-SIGN) receptors. These receptors are present on subset of spleenic 
macrophages.  Consequently, op/op mice, Rag1 -/- mice and spleenectomized mice were not 
protected by hIVIG from induced experimental arthritis (Bruhns et al., 2003). Further 
blockade of a receptor, (SIGN-R1) expressed by spleenic marginal zone macrophages 
completely abrogated anti-inflammatory effects of hIVIG. Similarly, SIGN-R1-/- mice were not 
protected from induced arthritis either by hIVIG or sialylated Fc fragments (Anthony et al., 
2008). Human orthologue of SIGN-R1 is DC SIGN (hDC-SIGN). SIGN-R1 -/- mice when 
engineered to express human DC-SIGN were both responsive to hIVIG and sialylated Fc 
fragments. Lastly, hDC-SIGN receptor interaction with sialylated IgG antibodies induced IL-
33 in the spleen and blocking IL-33 receptor abolished protection of hIVIG from induced 
arthritis. IL-33 induces innate Th2 response by inducing IL-4 which in turn induced 
expression of inhibitory FcγRIIB on macrophages thereby increasing activation threshold for 
inflammation (Anthony et al., 2011). Thus, it appears that hIVIG exerts its anti-inflammatory 
effects via a novel innate Th2 mechanism initiated by sialylated antibodies (See figure 2.5b). 
This pathway explains hIVIG effects only in spleenic macrophages. Interestingly, B cells do 
not express Sign-R1 and DC-SIGN. hIVIG binds to B cells irrespective of CD22 ligand 
(terminal sialic acid ligand) and CD22 (expressed by B cells). Also, there are no Fcγ receptors 
on T cells and only a subset of spleenic and lymph node macrophages express Sign-R1. Yet, 
hIVIG binds to B cells, Tcells and myeloid cells, presumably interaction with yet to be 
discovered cell surface receptor/s for hIVIG.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5a. Regulation of macrophage activation by antibodies in health and disease. Adapted 
from Immunological Reviews (2010): 236 :265-275, 15. 
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Figure 2.5b. Putative mechanism of action of hIVIG. Adapted from Ann N Y Acad Sci. 
(2012)1253:170-180. 
 
Anti-inflammatory and immunomodulatory functions of hIVIG emerge from many 
independent and synergistic effects on immune system.  The Fab portion mediates antigen 
binding whereas the Fc portion mediates various effector functions of IgG, which include 
expression, function and modulation of Fc receptors (Samuelsson et al., 2001); and also 
inhibition of complement activation (Lutz et al., 1996). Anti-inflammatory effects are also 
mediated by interference with the cytokine networks (Bendtzen et al., 1993);(Andersson et al., 
1993),  constituent anti-idiotypic antibodies (Kazatchkine et al., 1994), and by modulation of 
T- and B-cell activation (Boros et al., 2005). For anti-inflammatory effects, high-dose 
immunoglobulin by intravenous route was found to be necessary. The mechanism is not yet 
fully understood but engagement of the Fc portion of IgG with Fcγ receptors on effector cells 
might be responsible (Vaitla and McDermott, 2010). Also, with higher doses of hIVIG (2 
g/kg), inhibition of complement fixation to target cells was proposed as one of the 
mechanisms working complimentary to microglia mediated changes in cytokine production 
(Hack and Scheltens, 2004). Neuroprotective potential of hIVIG from complement mediated 
neuronal death has also been reported (Arumugam et al., 2007). In a different study, same 
authors also demonstrated capacity of hIVIG to reduce activation of kinases like p38MAPK, c-
Jun NH(2) -terminal kinase and NFκB p65 in vitro (Widiapradja et al., 2012). In the same 
study, hIVIG also attenuated Aβ induced accumulation of lipid peroxidation products and 
upregulated anti-apoptotic protein Bcl-2 in cortical neurons. In vitro hIVIG prevented Aβ 
fibril formation and protected neurons from Aβ induced neurotoxicity (Du et al., 2003).  Istrin 
and colleagues (Istrin et al., 2006) also reported dose- dependent disintegration of fibrillar 
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Aβ40 by hIVIG. Using BV-2 microglial cell line they demonstrated a change in microglial 
phenotype with ramified morphology along with concomitant increase in CD45 expression. 
They also reported enhanced microglial phagocytosis of fibrillar Aβ40 in response to hIVIG 
treatment.  
 
In vivo studies of hIVIG in APP mice are scanty. In fact, the current thesis is the only 
comprehensive report of hIVIG in vivo effects in transgenic AD mice. Preliminary studies 
conducted with Aβ antibody enriched fractions of hIVIG were encouraging. One such study 
(Wei et al., 2006) showed an increase in serum Aβ levels and also lower CSF Aβ levels in APP 
mice after treatment with affinity purified Aβ antibodies (extracted from hIVIG). Recently, 
Dodel et al. reported also improvement in behavioural changes in transgenic AD mice treated 
with natural Aβ antibodies isolated from hIVIG (Dodel et al., 2011). In the present thesis, 
study 1 describes the in vivo treatment effects of hIVIG in APP/PS1dE9 mice. Various factors 
like dose of hIVIG, age of mice at treatment onset and treatment duration were considered in 
the experimental design. In our experiments we set out to find in vivo mechanisms of hIVIG 
in AD mice. Clearly, in the context of neuroinflammatory processes of AD, anti-inflammatory 
properties of hIVIG may drive inflammation around amyloid plaques towards 
neuroprotective direction and thereby mediate beneficial effect in AD patients. By preventing 
the toxicity of amyloid fibrils and modulating microglia function, hIVIG may prove to be 
helpful. Hence, there is an urgent need to test the mechanisms of hIVIG action in an animal 
model of AD. 
 
Clinical benefits described in phase 1 and 2 trials prompt for mechanistic explanations for 
hIVIG effects. In this study, we focused on amyloidocentric as well as amyloid-independent; 
anti-inflammatory, immunomodulatory effects of hIVIG. In spite of promising initial clinical 
outcomes, there are many unseen hurdles for hIVIG before it reaches patients.  For example, 
since hIVIG is a pool of polyclonal antibodies obtained from large population of healthy 
donors, every batch of hIVIG may not be similar with respect to its antibody pool and their 
biological activities. This variation inherent to vast repertoire of human IgG’s might actually 
limit reproducibility and reliability of any experimental data. However, companies 
manufacturing hIVIG undertake serious measures to reduce this biological variation between 
various batches of hIVIG.  
In our experimental setup, serious considerations were also needed to the possibility of 
mice developing neutralising antibodies or anti-human IgG antibodies in response to hIVIG 
treatment. Such antibodies are not commonly seen in humans and hence this limitation needs 
to be addressed if clinical implications of the present experimental study to remain valid. 
Antibodies are not conventionally known to cross the blood–brain-barrier. However, there 
are specific receptor mediated transport mechanisms like those involving LRP-1, human 
insulin receptor, transferrin receptor, diptheria toxin receptor and neonatal Fc receptor that 
can influence antibody movement across blood-brain-barrier (Proulx et al., 2012)(Boado et al., 
2007; Deane et al., 2005). Therefore, in order to show any effects inside brain, hIVIG needs to 
cross this barrier. This is a valid limitation in both humans (clinical studies) and mice (current 
study). A very small proportion of antibodies in hIVIG is reactive to Aβ; therefore, it will be 
interesting to see if this is sufficient to detect and opsonise Aβ deposits inside the brain. 
Furthermore, in our experiment, even if hIVIG crosses the blood-brain barrier and decorates 
Aβ deposits, the ability of Fcγ receptors present on mouse microglia to detect Fc portions of 
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human IgG will be under scrutiny, because it will bear implications on microglia mediated 
phagocytosis. If hIVIG passes all the above hurdles in our experimental setup, reduction in 
Aβ load should translate into cognitive benefits in mice. For testing cognition in mice, one 
potential issue is inflammation associated with multiple intraperitoneal injections of human 
protein during chronic treatment regimens. The abdominal discomfort related to 
inflammation associated with treatments (hIVIG or saline) can confound any subtle cognitive 
changes in mice during routine Morris water maze task. Last but not the least, antibody 
treatments in AD patients and mice were previously associated with vascular bleedings, and 
thus propensity of microhemorrhages with hIVIG treatment needs to be cautiously evaluated 
so as to ensure safety. The limitations presented above are mostly related to practical issues 
concerning our experimental setup.  
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2.6 NF-ΚB IN ALZHEIMER’S DISEASE 
Several studies point to an important role of NFκB in AD pathology. One study utilising a 
polyclonal antibody for p65 revealed prominent NFκB immunoreactivity in neurons, their 
processes, neurofibrillary tangles, and dystrophic neurites of AD patients. In control sections, 
only weak neuronal staining was noticed. However, this study did not reveal glial 
immunoreactivity suggesting enhanced expression of neuronal NFκB in areas affected by AD 
pathology(Terai et al., 1996). In another study, monoclonal p65 antibody was used to stain 
tissue from histopathologically confirmed AD patients. Among 300 Aβ immunopositive 
plaques roughly 65% were found to be strongly positive for p65 immunoreactivity. Neurons 
and astrocytes near the plaques were also positive. Furthermore, p65 staining intensity was 
correlated with plaque stage (primitive, diffuse, classic) (Kaltschmidt et al., 1997). 
Involvement of other NFκB family members, p105 and IκBγ, were also found to be elevated 
in AD brains as compared to age-matched controls (Huang et al., 2005). In addition, several 
reports identified NFκB in the AD brain tissue as well as in nuclear extracts prepared from 
AD patients (Boissiere et al., 1997; Lukiw and Bazan, 1998). Furthermore, enhanced 
expression of IκBα and other NFκB proteins was also found to be associated with 
neurofibrillary tangles (Yoshiyama et al., 2001). The reactive astrocytes located near the 
vicinity of Aβ plaques produce many pro-inflammatory mediators like cytokines, 
chemokines, and iNOS that have been shown to be neurotoxic (Akama et al., 1998; Lee and 
Brosnan, 1996).Examination of nuclear extracts from AD tissue samples revealed an enhanced 
NFκB DNA binding, which was shown to be associated with increased COX-2 expression, 
thus directly linking inflammation to NFκB signalling (Lukiw and Bazan, 1998). 
 
Molecular mechanisms implicating a role of NFκB in AD can be understood from its  
functional relationship with APP, Aβ, BACE, γ- secretase, RAGE, and Pin 1.   In brains of AD 
patients, both NFκB p65 expression and BACE1 levels were found to be increased. Further, 
NFκB signalling regulates BACE expression and APP processing, thereby implicating a 
central role for NFκB in AD(Chen et al., 2011) .In rat primary neurons and post-mitotic 
neuronal cells, stimulation with Aβ40 resulted in dose-dependent neuronal damage, 
reduction of anti-apoptotic protein Bcl-XL and selectively induced translocation of NFκB p65 
and p50 subunits. Furthermore, these Aβ40 mediated effects were inhibited by a kappaB 
decoy, acetylsalicylic acid (aspirin) and a selective IKK-2 inhibitor (Valerio et al., 2006). Also, 
certain NSAIDs like indomethacin have been shown to suppress NFκB resulting in reduction 
of Aβ in mice (Sung et al., 2004). Therefore, NFκB signalling may modulate production, 
deposition and clearance of Aβ. 
 
NFκB has been shown to play a role in transcriptional regulation of the APP gene. p50 
homodimers as well as p50/p65 and p50/c-Rel heterodimers interact with specific sequences 
located in 5’ regulatory region of the APP gene and act as transcription activators (Grilli et al., 
1995). Similar NFκB sites have also been found for presenilin and BACE, with NFκB acting as 
repressor for BACE in non-activated neurons and astrocytes. However, NFκB acts as 
transcription activator for Bace1 in activated astrocytes and Aβ-exposed neurons (Bourne et 
al., 2007). These findings suggest a dual role of NFκB in regulating Bace1 transcription in cell 
specific manner. Furthermore, in APP23 mice, deletion of Tnfrsf1a gene resulted in > 70% 
reduction of Aβ pathology, which was further shown to be due to decreased BACE1 levels 
and activity (He et al., 2007). Subsequent investigations with potent NFκB inhibitors 
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demonstrated significant reduction in TNF induced Bace1 promoter activity, indicating that 
NFκB plays a significant role in regulating transcription of Bace1 (He et al., 2007). 
 
Gamma-secretase is a critical enzyme for processing APP and to generation of Aβ protein. 
Presenilin 1, presenilin 2, nicastrin, Aph-1 and Pen-2 are the major constituents of this 
intramembrane protease (Iwatsubo, 2004).  Local and systemic modulation of γ- secretase was 
reported to induce NFκB induction along with pro-inflammatory molecular mediators like 
TNF and COX-2 (Nasoohi et al., 2012). Inhibitors of γ-secretase or Notch RNA interference 
reversed Notch hyperactivity that was typically associated with Nfkb1-/- mice. Furthermore, 
Notch 1 was shown to be an important upstream regulator of NFκB (Schwarzer et al., 2012), 
thus implying a significant role of NFκB in Notch mediated effects of γ-secretase inhibition. 
In macrophages following LPS stimulation, treatment with γ-secretase inhibitors prevented 
activation of Notch signalling, thereby diminishing NFκB mediated inflammatory activity 
(Monsalve et al., 2009). Therefore, NFκB activity is susceptible to functioning of γ-secretase, 
which is also the key enzyme for generation of Aβ peptide in AD. 
 
Aβ and tau proteins are known to undergo non-enzymatic glycation and form AGEs 
(Advanced Glycation End products). Binding of AGEs to Receptors for Advanced Glycation 
End Products (RAGEs) can initiate NFκB dependent gene transcription (Granic et al., 2009). 
AGEs also mediate release of cytokines like IL-1β and TNF, which in turn can further activate 
NFκB signalling (Granic et al., 2009). Levels of pro-inflammatory cytokines are increased in 
AD, and among these, TNF has been shown to activate NF-κB, which can be critical for 
neuronal survival (Kaltschmidt and Kaltschmidt, 2009). 
 
Another protein, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1), has been 
shown to bind both Aβ and phosphorylated tau proteins, stabilising them in their non-
pathogenic functional conformations (Lu and Zhou, 2007). Pin1 has been also shown to bind 
phosphorylated p65 upon TNF-α treatment, which subsequently results in increased NFκB 
activation.  Pin1 also inhibits ubiquitin-mediated proteolysis of p65 by SOCS1 (suppressor of 
cytokine signalling-1). Further, Pin1 binding to p65 inhibits IκBα from binding p65, which 
means more transcriptional activity of NFκB and promotion of neuronal survival (Ryo et al., 
2003).  
 
All mechanisms described above show complex consequences of NFκB activation in 
different physiological and pathological contexts like those related to memory, detrimental 
inflammatory responses and neuroprotective and cell survival capabilities. All these diverse 
functions are also tightly regulated by NFκB family transcription factors. 
 
Pharmacological inhibition of NFκB in transgenic AD mice has yielded some conflicting 
data. Pyrrolidine dithiocarbamate (PDTC) is a well-known NFκB inhibitor with anti-
inflammatory (Cuzzocrea et al., 2002) and antioxidant properties in several models of CNS 
injury (Nurmi et al., 2004; Ahtoniemi et al., 2007; La Rosa et al., 2004).  In rats, 
neuroinflammation induced by intracerebroventricular injection of Aβ were attenuated by 
PDTC and further conferred cognitive benefits (Cheng et al., 2006). Intraperitoneal daily 
treatment of APP/PS1dE9 mice with PDTC 50 mg/kg for 5 months suppressed TNF and COX-
2 induction and attenuated astrogliosis. However, treatment also resulted in elevation of 
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brain Aβ42 burden (Zhang et al., 2009). In the same AD mouse line, however, treatment with 
PDTC (20 mg/kg in drinking water) for 7 months conferred spatial memory benefits via Cu+2 
– activated Akt pathway with no accompanying changes to amyloid burden (Malm et al., 
2007).   Treatment with nonsteroidal anti-inflammatory drugs like indomethacin and 
flurbiprofen, which are known to reduce NFκB activity, showed marked reductions in Aβ 
pathologies in mice (Eriksen et al., 2003; Sung et al., 2004). Effects on amyloid and 
inflammatory pathologies can also be studied in genetic mouse models deficient in key 
components of the NFκB pathway, such as Nfkb1 knockout mice.   
 
2.6.1 Gene deletion of Nfkb1 and p50 subunit deficiency 
 
NFκB p65/p50 dimer is more common than any other homo- or heterodimers. It is also the 
major DNA binding dimer in the normal adult rodent brain (Kaltschmidt and Kaltschmidt, 
2009). Therefore, it looks temepting to either genetically remove p65 or Nfkb1 to block 
canonical NFκB pathway. Actually, p65 gene deletion is lethal for mice. However, gene 
deletion of Nfkb1 (precursor protein for p50) produces viable mice (Sha et al., 1995)that are 
deficient in both p105 and p50, and hence provide an opportunity to study functional and 
pathological consequences of inhibiting NFκB signalling in health and disease. Precursor 
protein p105 is processed by proteolytic mechanisms mediated by proteasome. Constitutively 
most cells maintain equal levels of p105 and p50. However, upon stimulation complete 
degradation of p105 ensues, thereby releasing all bound Rel subunits to freely translocate into 
nucleus. Typically, p105 can retain p65, p50 and c-Rel but not RelB in the cytoplasm(Beinke 
and Ley, 2004). In fact, in mice that lack p105 precursor  and IκBγ but express p50 (targeted 
deletion of COOH-terminal ankyrin domain of p105) indicate that p105 has a regulatory role 
on p50 homodimer activity and deregulated p50 homodimers in such p105-/-  mice might act 
as transcriptional activators or repressors depending on the cell type.  Thus, p105 might 
mainly function to retain p50 dimers in the cytoplasm (Ishikawa et al., 1998).   
 
The precursor protein p105 also binds to Tpl-2 with high affinity. Tpl-2 functions as MAP-3 
kinase that phosphorylates and activates the ERK-1/2 kinase MEK-1/2 kinase. Tpl-2 deficient 
macrophages display dramatically reduced expression of TNF and COX-2 when stimulated 
by LPS by virtue of defective ERK-1/2 activation (Waterfield et al., 2003). Furthermore, Tpl-2 
knockout mice are resistant to LPS induced endotoxin shock, suggesting an important role for 
Tpl-2 in both innate and adaptive immune responses. Furthermore, p105 maintains Tpl-2 
protein stability (p105 mice show very low levels of Tpl-2), and binding of p105 also inhibits 
Tpl-2 MEK kinase activity (Beinke et al., 2003). It was shown that upon LPS stimulation IKK 
complex also regulates ERK activation via p105 as illustrated in Figure 2.6a (Beinke and Ley, 
2004). Therefore, one has to be cautious when interpreting molecular phenotype of these 
Nfkb1 null mice, as deletion of Nfkb1 also results in secondary deficiency of proteins like Tpl-2, 
ABIN-2 causing combined defects in both NFκB and Tpl-2-MEK-ERK pathway. 
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Figure 2.6a. NFκB precursor protein p105 is involved in multiple downstream pathways leading to 
inflammatory gene exprssion.  
 
Mice deficient in p105 do not produce p50 and display multifocal defects in immune 
system (Sha et al., 1995). These mice fail to mount a normal humoral response to T-cell 
dependent antigens. In Nfkb1 null mice, the same antigen can elicit different patterns of 
cytokine induction in different cell types. These mice are susceptible to intracellular 
protozoan parasite Leishmania major. Their parasitic lesions fail to resolve, owing to defective 
Th1 responses.   Nfkb1 null mice are also resistant to both collagen-induced (chronic) arthritis 
and methylated BSA/IL-1-induced (acute) models of arthritis. In contrast, intragastric 
infection with Helicobacter hepaticus causes more severe colitis in these mice owing to 
overproduction of pro-inflammatory cytokines in the gut(Beinke and Ley, 2004; Beinke et al., 
2003). Homodimers of Nfkb1 lack transactivation domains and may act as repressors of gene 
transcription. Therefore, in Nfkb1 null mice some effects may arise, in addition to loss of Nfkb1 
function, also as a result of depression of NFκB target genes (Kaltschmidt and Kaltschmidt, 
2009). Cortical neurons of Nfkb1 null mice distinctly exhibited reduced neuritic branching, 
loss of varicosities and Notch 1 signalling hyperactivation. Treatment with γ-secretase 
inhibitor or Notch RNA interference reversed abnormal cortical morphology, suggesting 
cross-talk between NFκB and Notch signalling (Bonini et al., 2011). Lack of Nfkb1 gene also 
severely affected the survival of newborn cells in dentate gyrus implicating Nfkb1 gene 
functioning in survival of new neurons of dentate gyrus (Denis-Donini et al., 2008).  
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Mice with Nfkb1 gene deletion can provide us with a unique opportunity to study the 
effects of blocking canonical NFκB pathway, albeit with certain caveats. Studies investigating 
Aβ and neuroinflammatory mechanisms of AD in these genetically manipulated mice may 
further our understanding of the role of NFκB in AD pathogenesis.   
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3 Aims of the study 
The main objective of this study was to explore the therapeutic potential of experimental 
immunomodulation in the pathogenesis of Alzheimer’s disease using experimental mouse 
models. More specific aims of the thesis are listed below: 
1. To investigate in transgenic mouse model, the hypothesized mechanisms of action 
behind the beneficial effects of human polyclonal intravenous immunoglobulin 
(hIVIG) treatment  observed in early phase AD clinical trial patients? (hIVIG study) 
 
2. To assess the effect of hIVIG treatment on amyloid and inflammatory pathologies and 
cognition in a mouse model of Alzheimer’s disease (hIVIG study) 
 
3. To determine the role of  Nfkb1 gene on amyloid and inflammatory pathologies of 
genetically engineered APP/PS1 mice (NFκB study) 
 
4. To study the interaction between chronic neuroinflammation caused by amyloid 
pathology in APP/PS1 mice and acute neuroinflammation  induced by a local LPS 
injection, and the role of  NFκB Nfkb1 subnit in the inflammatory responses (NFκB 
study) 
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4 Materials and methods 
4.1 ANIMALS  
We employed two different genetically engineered mouse lines in our studies. To model 
AD we used APPswe/PS1dE9 (APP/PS1) mice that harbor human APPswe mutation (K595N 
and M596L) and human PSEN1 with deletion of exon 9 co-integrated in the same transgene 
(Jankowsky et al., 2004).  The mice were backcrossed for nine generations to C57BL/6J mice. 
APP/PS1 mice develop progressive amyloid pathology beginning as early as 4 months of age 
(Garcia-Alloza et al., 2006) and cognitive deficits around 12 months of age (Minkeviciene et 
al., 2008). Nontransgenic wild-type littermates (referred to as wild-type mice) were used as 
controls.  
To study the role of NFκB in neuroinflammation we purchased mice deficient in Nfkb1 
gene (p105) from Jackson laboratories (Sha et al., 1995). These mice were backcrossed to the 
C57BL/6J strain for 6 generations and maintained as homozygotes. We crossed Nfkb1 
knockout mice with APP/PS1 mice and established mouse lines carrying mutated APP and 
PSEN1 transgenes on Nfkb1 null (Nfkb1-/-) or wild-type (Nfkb1 wild-type) background. These 
novel mice were viable and did not show any overt physical or behavioural defects at birth.  
Homozygous Nfkb1 wild-type carriers (either on APP/PS1 or wild-type for this transgene) 
served as controls. The housing conditions (National Animal Center, Kuopio, Finland) were 
controlled (temperature +22C, light from 07:00 to 19:00; humidity 50-60%), and fresh food 
and water were freely available. The experiments were conducted according to the Council of 
Europe (Directive 86/609) and Finnish guidelines, and approved by the State Provincial Office 
of Eastern Finland.  
 
4.2 EXPERIMENTAL DESIGN  
Our hIVIG study comprised of four independent experiments, each of which differed with 
respect to age of mice at onset of treatment and treatment duration. The source of hIVIG used 
in this study was commercially available Gammagard Liquid (Baxter A/G, Austria). Table 
4.2a gives summary of all the experiemnts in this study and table 4.2b details all the 
parameters assessed in this study. Below are the details and design of individual 
experiments.  
Experiment 1 (IVIG-1):  Four-month-old APP/PS1 mice received a single injection of either 
0.1 g/kg (low dose) or 1 g/kg (high dose) of hIVIG intraperitoneally. Mice were sacrificed 
either one day or one week after hIVIG injection (N = 6 in each group). A separate group of 
mice received three weekly injections of hIVIG at the high dose (N=8). The control group 
received 0.01 ml/g of saline.  Mice received ~ 0.3 ml of either hIVIG solution or normal saline. 
Concentration of Aβ in the brain and serum was analysed by ELISA. Microglial reactivity was 
assessed by CD45 immunoreactivity. Table 4.2a gives more details about this experiment. 
Development of anti-human IgG antibodies in serum was assessed from the hIVIG group that 
had 3 weekly injections (group 6). 
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Experiment 2 (IVIG-3): Aged mice (14-months) were treated with bi-weekly intraperitoneal 
injections of either highdose hIVIG (N = 18), control IgG (N = 8) or saline (N= 15) for 3 weeks. 
Control IgG is hIVIG depleted with anti-Aβ antibodies. Acute treatment effects on spatial 
memory were assessed by the Morris water maze task. Mice were sacrificed at the age of 15 
months a week after they received the last injection. Development of anti-human IgG 
antibodies was assessed from serum samples. Amyloid and microglial pathologies were 
evaluated in histological sections. Vascular microbleedings were assessed by Perl’s 
hemosiderin staining.  
Experiment 3 (IVIG-6a): Young (4-months) APP/PS1 mice received once weekly 
intraperitoneal injection of either high dose hIVIG (N = 16) or saline (N = 14) for 3 months. 
After testing cognitive functions, mice were sacrificed a week after last injection. 
Development of anti-human IgG antibodies was assessed in serum samples. Brain sections 
were evaluated for amyloid and microglial pathologies. See table 4.2b for more details. 
Experiment 4 (IVIG-6b): Young (4-months) APP/PS1 mice received once weekly 
intraperitoneal injection of either high dose hIVIG (N = 14-16) or saline (N = 15) for 8 months. 
After carrying out behavioural tests for cognition, mice were sacrificed a week after last 
injection. Development of anti-human IgG antibodies was assessed in serum samples. Brain 
sections were evaluated for amyloid and inflammatory pathologies.See table 4.2b for more 
details. 
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Table 4.2a.  Summary of experiments in hIVIG study. 
 
 
Experiment Group Treatment Dose 
Injection   
schedule sacrifice N 
IVIG-1 
4-month old 
APP/PS1 mice 
1 Saline 10ml/kg 1 1 day after last 
injection 
6 
2 hIVIG 0.1g/kg 1 1 day after last 
injection 
6 
3 hIVIG 0.1g/kg 1 1 week after last 
injection 
6 
4 hIVIG 1g/kg 1 1 day after last 
injection 
6 
5 hIVIG 1g/kg 1 1 week after last 
injection 
6 
6 hIVIG 1g/kg Once weekly; 
3 weeks 
1 day after last 
injection 
8 
IVIG-3 
14-month old 
APP/PS1 mice 
1 Saline 10ml/kg Twice weekly; 
3 weeks 
1 week after last 
injection 
15 
2 hIVIG 1g/kg 18 
3 Control IgG 1g/kg 8 
IVIG-6a 
4-month old 
APP/PS1 mice 
1 Saline 10ml/kg Once weekly; 
14 weeks 
1 week after last 
injection 
14 
 2 hIVIG 1g/kg   16 
IVIG-6b 
4-month old 
APP/PS1 mice 
1 Saline 10ml/kg Once weekly; 
40 weeks 
1 week after last 
injection 
15 
 2 hIVIG 1g/kg 16 
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Table 4.2b Summary of tests/analyses carried out in hIVIG Study  
Tests/analyses IVIG-1 IVIG-3 IVIG-6a IVIG-6b 
Behavioural Tests  
Marble test X 
Exploratory activity X 
Novel objection recognition  X 
Morris water maze X X X 
 
ELISA measurements  
Anti-human IgG antibodies X X X 
Soluble Aβ40 X X X 
Insoluble Aβ40 X X X 
Soluble Aβ42 X X X X 
Insoluble Aβ42 X X X X 
Serum Aβ40 X X X X 
 
Histology  
Congo Red staining X X 
microhaemorrhage staining X  
 
Immunohistochemistry  
Anti-human IgG  X X X X 
Amyloid beta  X X X 
CD45 X X X X 
Iba-1a X 
CD68 X 
GFAP X 
Confocal analysis of microglia X 
Doublecortin X 
RT-PCR  analysis for Tnf and Il1b X 
 
Our NFκB study comprised two individual experiments. In both experiments, we used our 
novel mouse line deficient in Nfkb1 gene on APP/PS1 background (Nfkb1-/-). Mice with intact 
Nfkb1 gene on APP/PS1 background (Nfkb1 wild-type) served as littermates controls. The two 
experiments differed from each other with respect to chronic stimuli arising from age-
dependent Aβ deposition and acute stimuli from LPS injection. Table 4.2c gives summary of 
all the experiments in NFκB study and table 4.2d details all the parameters assessed in this 
study. 
In the first experiment (age series), we followed Nfkb1-/- and Nfkb1 wild-type mice (both on 
APP/PS1 background) for progression of amyloid and microglia pathologies across three 
ages: 3.5, 8 and 12 months. Mice from the last cohort also participated in behavioural tests to 
reveal any possible abnormal behavioural phenotypes.Availability of mice of either 
genotypes and sex was considered carefully.  Female APP/PS1mice were used at 3.5 months 
age because they devlop higher magnitude of amyloid pathology much earlier  than male 
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mice. Also, at 12 months age, subtle effects of  Nfkb1-/- on amyloid pathology might be easier 
to detect in male APP/PS1 mice rather than in female mice with robust amyloid pathologies. 
Table 4.2c provides further details. 
In our second experiment (LPS injection), we gave intrahippocampal LPS and saline 
injections to Nfkb1-/- and Nfkb1 wild-type mice (both on APP/PS1 background). Mice were 
sacrificed 7 days after injections and their brains were evaluated for Aβ and microglial 
pathologies using immunohistochemistry. 
Table 4.2c. Summary of experiments in NFκB Study  
Experiment 
Age 
(months) Sex 
N for each genotype 
   
APP/PS1 
Wild-type & 
Nfkb1 wild-
type 
APP/PS1 
Wild-type & 
Nfkb1 -/- 
APP/PS1 
& Nfkb1 
wild-type 
 
APP/PS1 
& Nfkb1 -/- 
Age series 3.5  Females 
 
  11 11 
8 Males   7 8 
 Females 
 
  11 6 
12 Males 14 9 15 8 
LPS injection 12 Female   10 5 
 
 
Table 4.2d. Summary of tests/analyses carried out in NFκB Study  
Tests/analyses Age series LPS Injection 
 3.5 months 8 months 12months 
Behavioural Tests 
Marble test X
Exploratory activity X
Rotarod test  X
Elevated plus maze X
Morris water maze 
 
X
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ELISA measurements 
Soluble Aβ40 
Insoluble Aβ40 X
Soluble Aβ42 X
Insoluble Aβ42 X X X
Congo red staining X
Immunohistochemistry 
Amyloid beta  X X X X
CD45 X X
Iba-1a X X
CD68 X X
RT-PCR  analysis for Tnf and Il1b X
 
4.3 BEHAVIOURAL TESTS  
Mice were caged individually and were allowed to adopt to laboratory conditions for 
about a week before initiating any behavioural tests. During this time the person running the 
behavioural tests got acquainted with the mice, and vice versa, and the mice got used to 
human handling. We used clean tissue paper for mouse handling. Also the person handling 
the mice were advised not to apply any strong deodorants or perfumes, and care was taken 
that their clothes did not emit strong odours (e.g. garlic, ginger, other food materials ). A 
placid mouse  comfortable feeling  mouse will not bite or elicit a quick escape response 
(jump) when placed smoothly on handler’s palm but rather will leisurely explore restrain 
boundaries in order to find exit route towards its home cage. During the first day of handling 
almost every mouse jumped off the palm or tried to bite, or defecated and urinated. However, 
over 2-3 days they got used to human handling. Loud noise, startling sounds, or pungent 
smells from adjoining rooms were taken into account before beginning the behavioural tests. 
Any abnormal events encountered during the tests, either related to mice or test system, were 
documented for future reference.  
4.3.1 Marble burying test 
This is a very simple test for neophobia, where one can easily spot anxious mice in a 
cohort. Mice were caged individually and the cage was filled with double bedding. Nine glass 
marbles (diameter 1 cm) were arranged in a 3 x 3 array (figure. 4.1-A) and left overnight in 
the cage. During the night the mouse will typically hide the marbles under the bedding. Next 
morning, the number of visible marbles was counted. A marble with less than 10% of its 
visible surface were considered hidden. An anxious mouse should cover more marbles than a 
mouse that is at ease with the novel objects. However, a highly anxious mouse will not touch 
any of the marbles. Another task confounder is that some mice carry marbles to their nests. 
4.3.2 Exploratory Activity 
Mice were tested in a dimly lit and quiet room. Observation cages (26 cm x 26 cm x 39 cm, 
TruScan® Coulbourn Instruments, CO, USA) equipped with two rings of photodetectors 
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enabled separate monitoring of horizontal (XY-move time) and vertical activity (rearing). 
Attached computer software detected spontaneous locomotor activity of the mice and 
computed various parameters such as ambulatory distance, time engaged in stereotypic 
movement and number and time of vertical entries (rearing). After gently placing the mouse 
in the observation cage, the investigator left the room. Activity was measured for 10 min 
(figure 4.1-B ). At the end, mouse was gently returned to its home cage.  Faeces /urine were 
removed and the cage floor was cleaned with 70% alcohol before placing the next mouse in 
the test cage. Ambulatory distance, rearing time, and stereotypy time were measured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. (A) Mouse home cage displaying arrangement of marbles. (B) Test chambers for 
monitoring exploratory behaviour of mouse. (C) Rotarod apparatus with mouse on trial. (D) 
Elevated plus maze set up for testing anxiety in mice 
 
4.3.3 Rotarod test 
Motor coordination of mice was tested by using the Rotarod apparatus, which consists of a 
horizontal rotating rod with vertical dividers (figure 4.1-C). Test was carried out in a quiet 
and well-lit room. The mouse was gently placed on the rod facing away from the investigator 
and allowed to adopt to the stationary rod for 30 s. For the next 30 s, the rod revolved with a 
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constant speed to let the mouse get accustomed to a rotating rod. Then, for the next 8 min, the 
speed of rotation was increased stepwise to challenge the mouse’s balance. The test ended 
when the mouse fell off the rod or when a cut-off time of 8 min had passed. The apparatus 
was cleaned of faeces /urine stains with 70% alcohol before placing the next mouse on the 
rod.  
4.3.4 Elevated plus maze 
Fear and anxiety of mice was assessed by elevated plus maze. The maze comprised a plus- 
shaped elevated platform (40 cm from floor), with two opposite arms open (length 30 cm, 
width 5 cm, ledge 0.25 cm) and two opposite arms enclosed with high walls (30 cm x 5 cm x 
15 cm). All four arms merged into a square platform (5 cm x 5 cm) in the center (figure 4.1-
D,). A camera mounted on top allowed the investigator sitting in adjacent room to monitor 
the movements of mice on the maze. This test was carried out in a quiet, dimly lit room. The 
mouse was gently placed on the maze centre, and the investigator left the room. Each mouse 
was allowed to explore the maze for 5 min. Mice typically spent most of the time in the closed 
arms and made only short visits to the open arms. Highly anxious or stressed mice would 
remain in the closed arms, while mice treated with anxiolytics would spend more time 
exploring the open arms. The number of visits and percentage of total time spent in open and 
closed arms were calculated and reported. Data from only those mice making more than 5 
moves between arms during the 5-min test period were included in the statistical analysis.  
4.3.5 Novel object recognition test 
To test recognition memory, we used novel object recognition task which is based on the 
spontaneous tendency of mice to preferentially explore novel objects. A pair of exactly similar 
looking objects were kept overnight in the home cage, leaving the mouse with enough time to 
explore and acquaint themselves with the objects. Next morning the objects were removed for 
4 h before the commencement of actual test. The Test was carried out in a well-lit room. In the 
actual test, a new pair of objects was introduced into the mouse cage. Among these two 
objects, one was identical to the object introduced during the previous night while the other 
one was novel. The number of visits to explore the object was recorded. The test was repeated 
in total with three different pairs of objects during 4 successive days. 
4.3.6 Morris water maze 
Morris swim task (‘water maze’) is a classic test for assessing spatial learning and memory 
in rodents. This test was carried out in a quiet and well lit-room. The apparatus consists of a 
black cylindrical plastic water tank (Figure 4.2-A) of 120 cm diameter. A black square escape 
platform (14 cm x14 cm) was located 1 cm below the water surface. The water temperature 
was maintained at 21°C. The pool was filled on the evening before the scheduled test day.  
Two days before the actual test, mice received alley training. The mice were gently 
dropped into water at one end of a black plastic alley (10 cm x 14 cm x 25 cm). A hidden 
platform (below surface of water) was placed half-way inside alley. This way the mice 
learned to climb onto the platform and find that it provided an escape from the water. If the 
mouse did not find the platform in 20 seconds, it  was gently guided towards the hidden 
platform. The mouse was allowed to stay on the platform for 10 s before it was returned to 
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their home cage. Each mouse received 5 daily trials for two days. The mouse was gently dried 
with a paper towel and kept under a heater before replacing into the home cage to prevent 
hypothermia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Morris water maze set up (A) for testing spatial memory in mice. (F) Swim tracks of 
mouse that did not learn to find platform and that of mouse (C) that remembered to locate the 
platform. (D) IVIG-3 spatial memory test protocol. First 5 days, each mouse received 5 trials/day 
during which they learned to remember the platform location. On day8-9, platform was moved to 
new location, mice had to learn the new platform location. Tretament begins and acute effects on 
memory were evaluated on day 23-24 and day 30-31. 
A
B C
D
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In the learning phase of the task, each mouse received 5 trials per day for 5 days. Each trial 
started from one of the four randomly selected locations on the pool periphery (North, East, 
West, and South), so that the mouse was facing the wall. The position of the hidden platform 
was fixed during all trials on the first 5 days. If the mouse failed to find the platform within 
60 s, it was gently guided towards it. After reaching the platform, the mouse was let to stay 
there for 10 s before transferred to warm waiting area to wait for the next trial. A ceiling 
camera connected to a video tracker recorded the swim pattern which was recorded and 
analyzed by a computer software (HVS Image, Hampton, UK) Typically the mice were tested 
in groups of five, so that each mouse got at least  5-minutes of rest between the trials. On first 
day, it took for the mouse long to reach the platform (figure 4.2-B), but by day 5 all mice 
learned to reach the platform by taking the shortest route (figure 4.2-C). In IVIG-6 
experiments, day 5 was a probe trial without the platform to determine the search bias of the 
mouse. A target zone was defined as a 30 cm diameter circle centered on the previous 
platform location. Since target zone comprised 6.25% of the total surface area of tank, in a 
probe trial of 60 s, a randomly swimming mouse would spend 3.75 s in the target area. If 
significantly exceeding this time, it was considered to have a learned search bias.  Escape 
latency, swim path length, swimming speed, and the time spent in target zone (vicinity of 
platform area) during probe trial were determined by the HVS software. 
In the IVIG-3 experiment, a more complicated test protocol was applied (figure 4.2.D). We 
first let the mice to learn the location of the hidden platform during 5 daily trials over 5 days 
as described above. Instead of the probe trial without the platform, the platform was moved 
to a new location on days 8 and 9 to assess learning of a new platform location while the task 
principle should already be familiar to the mice. All this was first done without any 
treatment. After three weeks of hIVIG treatment we tested learning to two more new 
platform positions over two days (days 23-24 and 30-31). This protocol was successfully 
applied to testing the impact of amyloid plaque deposition in very old APP transgenic mice 
(Chen et al., 2000). 
 
4.4 INTRAHIPPOCAMPAL LPS AND SALINE MICROINJECTIONS 
Under general anesthesia (halothane, 4% for induction, 1.3 % for maintenance). the mouse 
was placed in a stereotactic apparatus (David Kopf, model 940, Tujunga, CA, USA). The level 
of inhaled gases was monitored on capnometer (Capnomac Ultima, GE healthcare, UK; O2: 
25-26% ; N2O: 68%). A rectal thermometer probe was inserted and body temperature was 
maintained with the aid heating pad.  The skull was exposed and a small burr hole was 
drilled on the skull. The injection needle connected to a Hamilton (Reno, NV, USA) syringe 
was aimed at the following coordinates: A/P -2.7 mm and M/L ± 3.0 mm from bregma, and ,  
D/V -2.7 mm from dura. After inserting the needle to the desired D/V coordinates, we waited 
for 30 s before beginning the injection at a rate of 0.2 μl/min. A total volume of 1 μl is injected 
during 5 min. After finishing the injection we waited for 2 min before slowly pulling the 
needle up. The injections were made bilaterally. The left hippocampus received saline and the 
right hippocampus received 4 μg/μl LPS (Sigma-Aldrich St. Louis, MO, USA; L6511) 
injection. The wound was then cleaned and sutured. The animal was allowed to recover in an 
incubator overnight. Mice did not receive any post-operative analgesic drugs. 
76 
 
 
 
Female mice (~12 months age) from Nfkb1 wild-type (N=10) and Nfkb1-ko (N = 5) 
genotypes under APP/PS1 background were used. A week after injections mice were 
sacrificed and their brains were retrieved for routine immunohistochemistry. 
 
4.5 SAMPLING PROCEDURES  
On the day of sacrifice, mice were weighed. They were euthanized with excess dose of 
pentobarbiturate-chloralhydrate (Equithesin i.p injection, ~0.3 ml).  In the hIVIG study, 
terminal blood samples by cardiac puncture (~0.4 ml or more) were collected into Eppendorf 
tubes (Sarstedt,Numbrecht, germany) and stored on ice (no more than 3 h), centrifuged  at 
9000 rpm for 20 min(Eppendorf centrifuge 5415D,NY,USA), after which the serum was 
separated and stored in a -70 °C freezer. Roughly, 50μl was collected for estimation of 
antihuman IgG antibodies and rest was used for ELISA measurements of serum Aβ40. In 
IVIG-6b experiment, additional blood sample was taken from mice at 7.5 month age by 
saphenous vein puncture method for estimation of anti-human IgG titres.  
After terminal blood sampling, the mouse was transcardially perfused with ice-cold saline 
(0.2 ml heparin added) for 7 min. The brain was removed, divided into left and right 
hemibrains, and the left hemibrain including the intact olfactory bulb and cerebellum was cut 
on a ice cold iron block.  Hippocampus was retrieved and three cortical blocks dissected 
(frontal, parietal and temporal) and stored at -70 °C. The right hemibrain was immersion 
fixed in a freshly prepared 4% paraformaldehyde for 4 h, transferred to 30% sucrose solution 
overnight and further transferred to an antifreeze solution where it was stored at -20 °C.  For 
the hIVIG study, coronal sections of 35 μm were cut with a freezing slide microtome, while 
for the NFκB study, brains were cut with a cryostat into 20μm thick coronal (LPS injection 
experiment) or sagittal (age series) sections.  
 
4.6 IMMUNOHISTOCHEMISTRY 
Following systematic random sampling scheme, four free-floating sections 400 μm apart 
from each other, starting from septal hippocampus (-1.3 mm from bregma) were collected for 
various immunostainings. Similarly, six to seven sections each 210 μm apart starting from 
septal hippocampus (-1.3 mm from bregma) were collected for doublecortin immunostaining. 
For NFκB study, four to six sections at 400 μm intervals per animal were sampled. All 
immunostainings were made with free-floating sections except for LPS experiment in NFκB 
study were immunostaining was performed on mounted sections. Briefly, free floating 
sections were washed in phosphate buffered solution (PBS) overnight. Next day, after 
washing in PBS, sections were treated with 0.3 % H2O2 in methanol for 30 min to block 
endogenous peroxidase. For Aβ immunostaining, sections were additionally boiled with 0.05 
M sodium citrate (85 °C) for 30 min after which they were cooled in PBS. Free-floating 
sections were later blocked with 10 % normal goat serum for 30 min. After washing with TBS-
T (Tris-buffered saline with triton) for 5 min, sections were incubated overnight with primary 
antibodies at room temperature as shown in Table 4.2. After ~18 h of incubation, sections 
were washed in TBS-T and  incubated for 2 h with corresponding biotinylated anti-rat, anti-
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mouse, anti-rabbit, and anti-goat secondary antibodies (1:500), followed by incubation with 
horseradish peroxidise (HRP) labelled streptavidin.  Color was developed by reacting nickel 
diaminobenzidine (Sigma) with hydrogen peroxide for 3 min. Reaction was stopped with 
phosphate buffer and sections were then mounted, air-dried, cleared in xylene and cover 
slipped in Depex mounting medium.  All staining batches had control sections that followed 
the same procedures except for omitting primary antibodies. 
For LPS experiment, four to six 20 μm thick coronal sections at 400 μm intervals from each 
animal were mounted on superfrost slides. After blocking endogenous peroxidase with H2O2 
and blocking with normal goat serum, slides were incubated overnight in primary antibodies: 
Iba1 (1:250, Wako, Osaka , Japan), CD68 (1:200, AbD serotec, Kidlington, Oxford,UK), CD45 
(1:100, Serotec AbD serotec, Kidlington, Oxford,UK), 6E10 (1:1000; Covance, Princeton, New 
Jersey,USA). Following day, slides were washed with TBS-T and incubated for 2 h with 
corresponding corresponding anti-rat, anti-mouse, anti-rabbit Alexa-Fluor 568 - conjugated 
secondary antibodies (1:200, Molecular Probes). Slides were then washed and mounted with 
Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI) and cover 
slipped. 
For double fluorescent immunostaining, sections were sequentially incubated with CD45 
followed by Iba-1 primary antibodies.  Tyramide signal amplification kit (Molecular Probes, 
paisley,UK) was used for visualizing CD45 with cy-3 label, whereas Alexa Fluor 488 
conjugated secondary antibody (1:400; Molecular Probes, paisley,UK) was used for Iba-1 
staining. Sections were mounted with Vectashield mounting medium containing DAPI. 
For detecting human IgG in mouse brain, free floating sections sections were treated with 
0.1 % hydrogen peroxide in methanol, and incubated overnight with rabbit anti-human HRP-
labelled antibody.  Immunoreactivity was visualized with 0.25 % nickel enhanced 
diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA).  
For triple immunofluorescent staining to study co-localization of Aβ, microglia and human 
IgG, free-floating sections were washed with 0.1 M  Tris-buffered saline (TBS), pH 7.4 and 
nonspecific binding sites in the tissue were blocked with 5 % normal donkey serum in TBS, to 
which 0.3 % Triton X-100 had been added (NDS-TBS-T), for 1 h. The sections were then 
incubated overnight with a mixture of biotinylated monoclonal mouse anti-Aβ17-24 (clone 
4G8, Covance Princeton, New Jersey, 1:100 in NDS-TBS-T) and rabbit anti-Iba-1 (Wako 
Chemicals GmbH, 1:400). Next, the sections were rinsed with TBS and applied to a cocktail of 
highly purified, carbocyanine (Cy)-conjugated secondary antibodies (all from Jackson 
ImmunoResearch,Philadelphia,USA, 20 μg/ml in TBS containing 2% BSA): Cy3-coupled 
streptavidin, Cy5-coupled donkey anti-rabbit IgG and Cy2-coupled donkey anti-human IgG.  
Sections were washed and mounted in Mowiol. 
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Table 4.2. Primary antibodies used in immunohistochemistry 
Antibody 
& host 
Target Dilution Catalogue 
number & 
Company 
Notes 
Anti-human 
IgG/HRP 
Rabbit 
polyclonal  
Reacts with gamma-
chains of human IgG 
1:7500 P0214 
DAKO, 
Denmark 
May cross react with 
mouse IgG. 
 
 
 
6E10 
Mouse 
monoclonal  
Reactive to 1-16 amino 
acid residues for human 
APP protein. Epitope 
lies within amino acids 
3-8 of Aβ (EFRHDS). 
1:2000 SIG-39320 
COVANCE, USA 
Needs citrate pre-
treatment and stains Aβ 
deposits as well as 
neurons. Works nicely 
even with alexa- 
flourophores. 
 
 
W02 
Mouse 
monoclonal 
Recognizes 4-10 amino 
acid residues of human 
Aβ protein. 
1:30000 MABN10 
MILLIPORE, 
USA 
Highly potent antibody 
for visualizing Aβ 
deposits. 
 
CD45 
Rat  
Mouse CD45 1:1000 MCA 1388 AbD 
SEROTEC, UK 
Robust marker for 
activated spider-like 
microglia. 
 
Iba-1a 
Rabbit 
polyclonal 
Reactive to carboxy 
terminal sequence of 
human, mouse and rat 
Iba1 molecule (Ionized 
calcium binding adaptor 
molecule 1). 
1:5000 01-1974 
WAKO, JAPAN 
Good marker for both 
activated and quiescent 
microglia. Cell bodies 
and microglia processes 
are distinctly stained. 
Works well with alexa- 
flourophores. 
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4.7 HISTOLOGICAL STAININGS 
For Congo red staining, sections mounted on slides were incubated in saturated alcoholic 
alkaline NaCl solution for 20 min, followed by incubation in alkaline solution of 0.2% 
alcoholic Congo red solution. Slides were then washed, dehydrated, cleared in xylene, and 
coverslipped. 
For the microhaemorrhage staining, eight 35 μm coronal brain sections from each mouse 
were used.  Sections were first stained with 2% potassium ferrocyanide in 2% hydrochloric 
acid for 15 min, followed by a counter stain in a 1% neutral red solution for 10 min. 
4.8 IMAGE ACQUISITION, PROCESSING AND DIGITAL IMAGE ANALYSIS 
Images (2074×2074) from hippocampi were acquired at 2× (Plan N2×/0.06) objective using 
an upright optical microscope (OLYMPUS BX40, Tokyo, Japan) with Olympus optical DP50 
camera. A flat field image was also acquired in order to correct uneven illumination. 
Immunopositive areas were quantified using Photoshop CS3 Extended version 10 software 
(Adobe Systems Incorporated, San Jose, CA, USA). Briefly, hippocampus (the region of 
interest) was outlined and the immunopositive areas were thresholded for measurements and 
reported as mean percent immunopositive area for each brain. For double-stained fluorescent 
sections, images were acquired with confocal Zeiss LSM 700 microscope (Jena, Germany). 
Eight bit images stacks (1024×1024) were taken with Plan-Apochromat 40×/1.3 oil DIC M27 
objective. Individual pixel size in x-y direction was 0.31 μm and 0.41 to 0.49 μm along the z-
axis. Subsequent image analysis was done by Image J software. After background subtraction, 
CD68 
Rat  
Macrosialin is murine 
homologue of human 
CD68, both members of 
lysosomal-associated 
membrane protein. 
 
 
1:5000 MCA 1957 
AbD SEROTEC, 
UK 
Marker for 
macrophages. Also, used 
as marker for 
phagocytosis. 
GFAP  
Mouse 
monoclonal 
 
Recognizes human, rat 
pig GFAP (Principle 
intermediate filament 
protein in astrocytes)  
 
 
1:1000 Clone G-A-5 
Sigma-Aldrich, 
USA 
Specific marker for 
astrocytes. 
Doublecortin 
Goat polyclonal 
Reactive to human, 
mouse, rat 
doublecortin. 
1:1000 Sc-8066 
SANATACRUZ 
USA 
Specific marker for 
newborn adult neurons. 
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individual microglial cell stacks were outlined and separated in x-, y-, and z-planes. Each 
stack comprising of only one microglial cell was then split into its constituent green, red, and 
blue channels. A simple Image J macro then applied a threshold value for red and green 
channels, and created selections for measurements from all the slices of a stack.  Integrated 
intensities, area and volume were then calculated. Maximum intensity projections of 
microglial cell stacks were then used to measure circularity value for each microglial cell. 
4.9 ASSAY FOR ESTIMATING ANTI-HUMAN IgG ANTIBODIES 
Microtiter plates (PolySorp, Nunc, MLS, Menen, Belgium) were coated with Gammagard 
Liquid (Baxter AG, Austria) diluted to 1 μg/mL with coating buffer containing NaHCO3 
(0.1 M; Merck,NJ, USA) and Na2CO3 (0.1 M; Merck, NJ, USA), adjusted to pH9.6. After 
overnight incubation and washing with a buffer of Dulbecco’s PBS (Gibco, Life Technologies) 
supplemented with Tween20 (0.05%; Merck,NJ, USA), the plates were blocked with the same 
buffer plus 1% BSA for 2 h at room temperature. After further washing, dilutions of serum 
samples and controls were added to the plates and incubated for 2 h at room temperature. 
Serum samples and the negative control (serum pooled from untreated mice) were pre-
diluted at 1:50 in the same buffer but with 0.5% BSA and further serially diluted by a factor of 
2. Purified mouse anti-human IgG Fc (Jackson ImmunoResearch,Philadelphia,USA) was pre-
diluted 1:250,000 and further serially diluted by a factor of 2 for the positive control of the 
assay. After washings, the plates were incubated with HRP-conjugated goat anti-murine IgG 
(1:2,000; Southern Biotech, Alabama, USA) for 1 h at room temperature. Further washing and 
incubation with enzyme substrate (substrate buffer: Na2HPO4.2H2O (0.1 M; Merck,NJ,USA), 
C6H8O7.H2O (0.05 M; Merck), pH5.0, o-phenylenediamine-dihydrochloride (1 mg/mL; Sigma-
Aldrich, USA), and H2O2 (0.03 %; Merck)) for 30 min at room temperature produced a color 
reaction. The reaction was stopped with H2SO4 (2 N; Merck,NJ,USA) and the color intensity 
was measured with an ELISA plate reader (Synergy BioTek,Winooski,USA) set at a 492-nm 
wavelength (wavelength correction set to 630 nm). All samples where the difference between 
the samples’ optical density (OD) and the blank OD was ≥0.3 were considered positive. The 
highest dilution to show a positive result was specified as the titre. 
4.10 ESTIMATION OF SERUM AND BRAIN AΒ LEVELS 
For estimating serum Aβ40 levels, samples were diluted at 1:3 with diluting buffer in 
accordance to the manufacturer’s instructions (The Genetics Company,Basel, Switzerland). 
Standards or diluted samples and antibody conjugate comprising of a detection antibody 
were applied to the 96-well microtiter plates precoated with capture antibody. Following 
overnight incubations at 4°C and washings, biotin-streptavidin enzyme conjugate was 
incubated at room temperature for 30 min. A further incubation with enzyme substrate at 
room temperature  for 30 min gave a colored reaction product. After stopping the reaction, 
color intensity was measured with a microtiter ELISA plate reader (Multiskan MS, 
Labsystem, Helsinki, Finland) set at 450 nm wavelength. Standard curve was prepared and 
sample concentrations of Aβ40 were extracted from standard curve and expressed as pg per 
ml of serum. 
Levels of soluble and insoluble Aβ40 and Aβ42 were determined from the hippocampus 
block. The tissue was weighed and homogenized in 10× volume of Dulbecco’s PBS buffer 
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(Sigma-Aldrich, St.Louis,USA), containing complete inhibitory mixture (Roche Diagnostics, 
Mannheim, Germany). Samples were centrifuged at 45,000 rpm (Beckman Ultrafuge, 
Fullerton, CA,USA) for 2 h at 4°C. Supernatant was diluted at 1:2 and used to analyze soluble 
levels of Aβ40 and Aβ42. The remaining pellet was resuspended in 5 M guanidine-
HCl/50 mM Tris·HCl, pH 8.0 and mixed on a shaker for 3 h at RT. Samples were then diluted 
at 1:50 with reaction buffer (Dulbecco’s PBS with 5% BSA, 0.03% tween-20, supplemented 
with protease inhibitor cocktail) and centrifuged at 16,000 × g for 20 min at 4°C. Decanted 
supernantant is further diluted at 1:400 with dilution buffer. Diluted samples were then used 
to analyze insoluble Aβ40 and42 species. Aβ40 and Aβ42 levels were estimated using ELISA 
kits (Biosource International,Life technologies, Paisley,UK) in accordance to manufacturer’s 
instructions. Aβ40 andAβ42 levels were standardized to tissue weight and expressed as 
picograms of Aβ per gram ± SEM. 
4.11 QUANTITATIVE REALTIME-PCR 
Total RNA was extracted from frozen frontal cortices by TRIzol reagent (Invitrogen, Life 
technologies, Paisley,UK) according to the manufacturer’s instructions. RNA concentration 
and purity was measured with Nanodrop 1,000 spectrophotometer (Thermo Fisher 
Scientific,Delaware, USA). cDNA was synthesized from 500 ng of total RNA using random 
hexamer primers (Promega, Madison, USA) as a template and Maxima reverse transcriptase 
(Fermentas, Thermo Fisher Scientific,Delaware, USA). The relative expression levels of 
mRNA encoding mouse Tnf and Il1b were measured according to manufacturer's protocol by 
quantitative RT-PCR (StepOnePlus; Applied Biosystems, Life technologies, Paisley,UK) by 
using specific assays-on-demand (Applied Biosystems, Life technologies, Paisley,UK) target 
mixes. The expression levels were normalized to ribosomal RNA and presented as fold 
change in the expression ± SEM. 
4.12 STATISTICAL ANALYSIS 
All data are given as mean ± SEM. For comparing means of two treatment groups or 
genotypes, independent-sample Student’s t-test was employed. For testing genotype and 
treatment interaction, two-way ANOVA was employed. For non-parametric data, Mann-
Whitney U-test was employed. Two-step cluster analysis was used to segregate microglia 
populations. All statistical analysis were performed by GraphPad Prism version 5.03 for 
Windows (GraphPad Software, La Jolla, CA, USA, www.graphpad.com) and IBM SPSS 
statistics version 19 for Windows (New York, USA). For LPS experiment, Linear mixed model 
analysis was performed on  IBM SPSS statistics version 19 for Windows  to test within subject 
(saline vs. LPS) and between subject differences (Nfkb1 wild-type Vs. Nfkb1-/-). Statistical 
significance was set at P < 0.05. 
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5 Results 
5.1 HUMAN INTRAVENOUS IMMUNOGLOBULIN (hIVIG ) STUDY  
We treated APP/PS1 mice with intraperitoneal injections of hIVIG in a series of 
experiments with different treatment regimens. In general, mice well tolerated both single 
and multiple hIVIG injections. In chronic treatment regimens, repeated hIVIG injections did 
result in local tenderness around the injection site, but no peritonitis or swelling was noticed 
and no abnormal behaviour indicating significant pain. Overall, hIVIG treated mice showed 
no significant side effects. Table 5.1 summarizes all the key findings of hIVIG study. 
Table 5.1. Bird’s eye view of key hIVIG study findings. 
Assessments 
 
IVIG-1 
 
IVIG-3 
 
IVIG-6a 
 
IVIG-6b 
 
General mouse behaviour Normal Normal Normal Normal and heightened 
sensitivity to touch near 
site of injection. No signs 
of distress or pain. 
 
Anti-human IgG  titres Present Present Absent in 
majority of 
mice. 
 
Present but highly 
variable. 
Brain Penetration of 
human IgG 
No No Yes. 
Hippocampus 
showed human 
IgG gradient 
along rostro-
caudal axis. 
Yes. 
1. Hippocampus and 
cortex show human 
IgG signal. 
2. Rostro-caudal human 
IgG gradient in 
hippocampus. 
3. Aβ Plaque 
decoration. 
 
Cognitive Tests -- No treatment 
effect 
hIVIG treated 
APP/PS1 mice 
performed 
better on probe 
trial. 
 
1. No cognitive benefits.
2. APP/PS1mice more 
active. 
Amyloid pathology No 
change 
No change No change 1. Soluble Aβ increased 
by 30-50%. 
2. No change in Aβ 
plaques. 
 
Microglia pathology No 
change 
No change. No change. 1. Decrease in CD45 
microglia by 36% 
2. Statistically 
significant increase in 
Iba-1 by >38% 
3. Changes in type B 
and type C microglial 
cells. 
 
 
Proinflammatory gene -- -- -- 1. Suppression of Tnf 
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expression gene expression. 
2. CD45 microglia 
correlate inversely 
with Tnf and Il1b 
gene expression. 
 
 
Neurogenesis -- -- -- 1. Increase in 
doublecortin positive 
cells by ~60% in 
both wild and 
APP/PS1 mice. 
2. Inverse correlation 
between  CD 45 
microglia and 
doublecortin positive 
cells. 
 
Microhemorrhages -- No 
microhemorhages
Detected 
 
-- -- 
 
5.1.1 Effect of hIVIG in young mice (IVIG-1 study)  
In this dose-finding experiment, mice well-tolerated hIVIG injections and there were no 
signs of peritoneal inflammation or pain around the site of injection. Behaviour of mice post-
hIVIG treatment was as well unremarkable. 
5.1.1a Effects on brain and serum levels of Aβ protein 
At 4 months of age APP/PS1 mice show a few scattered plaques as detected by 6E10 
immunostaining in the cortex and hippocampus. ELISA assays were used to determine levels 
of Aβ40 and Aβ42 in the parietal cortex. One or three, once weekly injections of either a high or 
a low dose of hIVIG did not significantly change cortical levels of soluble or insoluble Aβ40 
and Aβ42 (figure 5.1.1a-A-D).  Similarly, serum levels of Aβ40 were assessed to see if hIVIG 
treatment caused efflux of Aβ from the brain into the peripheral circulation. As evident from 
Figure 5.1.1a-E, mice treated with high-dose hIVIG and sacrificed a week after injection 
showed significantly higher Aβ40 levels than saline group (F(4,12) = 3.54, p = 0.04). 
Unfortunately, we ran short of serum samples from group 6 that had 3 weekly injections of 
high-dose hIVIG. Serum Aβ42 levels were below the level of detection. This increase in serum 
Aβ40 in the high-dose group prompted us to further evaluate its effects with longer treatment 
durations. 
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Figure5.1.1a. ELISA measurements of  cortical levels of (A)soluble Aβ40 & (B) Aβ42 and (C) 
Insoluble Aβ40  & (D) Aβ42. (E) Serum Aβ40  levels from high hIVIG 3w group is missing.Treatment 
groups varied with respect to hIVIG dose either low (0.1 g/kg) or high (1g/kg) and time of 
sacrifice  after treatment:either 1day(1d), 1week (1w) or 3 weeks (3w) after treatment. 
 
5.1.1b Effect on microgliosis 
In order to assess the acute effects of hIVIG on microglia, CD45 immunostaining was 
performed and the number of microglial clusters quantified. CD45 signal dovetailed Aβ 
pathology in young APP/PS1 mice. Usually the immunopositive areas of 6E10 and CD45 
staining were overlapping, which indicates an efficient microglial response to Aβ deposition. 
However, as evident from figure 5.1.1b-A&B, hIVIG treatment with varying dose and 
duration did not bring about any significant change to microglial responses in either the 
cortex or the hippocampus (cortex: F (5, 32) = 0.44, p = 0.81; hippocampus: F (5, 32) = 0.21, p = 0.95). 
Again this may be explained by insufficient penetration of hIVIG into the brain. Therefore we 
proceeded to further test hIVIG with longer treatment regimens. 
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Figure5.1.1b. Number of CD45 positive microglial clusters in (A) cortex and (B) hippocampus. 
Treatment groups varied with respect to hIVIG dose either low (0.1 g/kg) or high (1g/kg) and 
time of sacrifice  after treatment: either 1day(1d), 1week (1w) or 3 weeks (3w)after treatment. 
 
5.1.2 Effects of hIVIG in 15-month-old mice (IVIG-3 study) 
In this experiment, aged (14-month old APP/PS1) mice well-tolerated high dose hIVIG 
injections and there were no signs of peritoneal inflammation or pain around the site of 
injection. Also, there were no noticeable abnormal mouse behaviour post-hIVIG treatments. 
5.1.2a Development of anti-human IgG antibodies in APP/PS1 mice 
Anti-human IgG neutralising antibodies were analysed by BaxterA/G, Austria. Only titres 
above 200 were considered significant. None of the mice in saline group developed significant 
neutralising antibodies (figure 5.1.2a). However, the remaining mice, irrespective of age or 
number of injections, developed anti-human IgG antibodies. Peak titres in young mice (4 
months) were of an order of magnitude lower compared to aged mice (15 months).  
 
 
 
 
 
 
 
Figure5.1.2a. Titres of anti-human IgG antibodies or neutralising antibodies from IVIG-1 and 
IVIG-3 experiments.Treaments and corresponding number of injections are displayed on X-axis. 
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5.1.2b Anti-human IgG staining in hIVIG treated mice 
Based on this tentative observation we made plans to initiate our treatments at the age of 4 
months in our subsequent experiments.  An advantage of treating mice with a human protein 
is that it should be feasible to locate the human IgG inside the brain by immunostaining. Mere 
presence of human IgG signal within the brain parenchyma would thus confirm brain 
penetration of hIVIG. A very nonspecific anti-human IgG staining can be clearly appreciated 
in brain sections from hIVIG and control IgG groups whereas saline treated sections are 
completely clean of any signal in figure 5.1.3c-B. Ventricular linings, fimbriae, choroid plexus 
and some adjoining blood vessels showed strong 3, 3'-diaminobenzidine (DAB) signal 
indicating that human IgG was inside the brain vasculature but failed to enter brain 
parenchyma. There was no evidence of Aβ plaque decoration in these mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.2c. Spatial navigation test by Morris water maze. (A) Mice in all treatment groups 
displayed no differences in swimming speeds. (B) Escape latencies did not differ among the 
treatment groups during pre-treatment phase and post treatment phase. (C) Trial by trial 
visualization of escape latencies across treatment groups are also similar.  
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5.1.2c Cognitive effects of hIVIG on 15-month-old mice 
The treatment groups did not differ in their swimming speeds (figure 5.1.2c-A). As evident 
from the escape latencies (figure 5.1.2c-B), all mice learned the task to the same extent during 
the first 5 days. Overall, the escape latencies were longer after the platform had been moved 
to a new position. Figure 5.1.2c-C illustrates the escape latencies on each separate trial for 
saline and hIVIG treated groups. On some days (D24 and D31), the escape latency was 
significantly longer than on the previous day, after the platform had been moved to a new 
location. However, in half of the days (D23 and D30) this was not the case. In addition, one 
can see an overall trend for escape latencies to shorten towards the end of the experiment. 
This trend suggests that instead of learning the particular new platform location each day, the 
mice just learned a more and more efficient general search strategy. Furthermore, the mean 
latencies of different treatment groups were almost 100 % overlapping, speaking against 
treatment effect. 
5.1.2d Effects of hIVIG on amyloid and microglial pathologies in 15-month-old mice 
One week after the last injection, brains and sera were collected for immunohistochemical 
and ELISA analysis, respectively. As illustrated in figure 5.1.2d-A to D, statistical analysis 
showed no significant group differences in soluble and insoluble levels of Aβ40 and Aβ42 
(soluble Aβ40: t (18) = 0.20, p = 0.85; insoluble Aβ40: t (18) = 0.20, p = 0.85; soluble Aβ42: t (18) = 0.85, p 
= 0.40; insoluble Aβ42: t (18) = 0.02, p = 0.99). Similarly, one-way ANOVA analysis of serum 
levels of Aβ40 (figure 5.1.2d-E) revealed no treatment effects (F (2, 16) = 0.30, p = 0.74). We next 
assessed brain Aβ plaque load with 6E10 immunohistochemistry. Monoclonal antibody 6E10 
recognizes N-terminal 4-9 amino acid residues of Aβ peptide. As shown in figure 5.1.2d-F 
roughly 8 - 10 % of the cortical area had Aβ positive plaques. However, one-way ANOVA 
revealed no statistically significant treatment effects (F (2, 37) = 0.69, p = 0.51). Microglial 
reactivity (figure 5.1.2d-G) as assessed by CD45 immunostaining, did not differ between the 
treatments (F (2, 37) = 1.46, p = 0.25). Inadequate brain penetration of hIVIG, coupled with high 
anti-human IgG titres in this study might account for for the lack of effects on amyloid and 
microglial measurements. 
5.1.2e Microhemorrhages with hIVIG treatment 
 See figure 5.1.2e-A to G for some examples of positive profiles of microhemorrhages. 
Overall, there were 13 positive profiles which were highly suspicious for microhemorrhages. 
Of these only eight were inside the brain parenchyma and the rest were noticed in choroid 
plexus. Only one positive profile was noticed in the cortex of saline treated mouse whereas 
two such profiles were noticed from hIVIG treated mice. Overall, there was no significant 
difference between groups indicating hIVIG treatment did not significantly increase the risk 
of microhemorrhages (figure  5.1.2e-H).  
5.1.3 Effects of weekly hIVIG treatment for 3 months (IVIG-6a study) 
The hIVIG treatments so far had failed to induce any change in the brain amyloid load or 
alleviate the cognitive impairment of APP/PS1 mice. However, two important factors may 
explain the poor treatment outcome. Firstly, the magnitude of anti-human IgG titres 
developed by 15-month-old mice was far higher than those in 4-month-old mice. Secondly, it 
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was clear that in previous studies there was little brain penetration of hIVIG. Three weeks of 
treatment was obviously too short for aged mice with massive cerebral amyloid pathology.  
In this experiment, aged (4-month old APP/PS1) mice well-tolerated chronic weekly high 
dose hIVIG injections and there were no signs of peritoneal inflammation. Heightened 
sensitivity to touch was evident around the sites of injection. Also, there were no indications 
of abdominal pain or distress or abnormal behaviour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure5.1.2d.Quantitative data related to amyloid and microglial pathologies in 15-month old mice 
from IVIG-3 study. No treatment effects in any of the measured parameters. Biochemical levels of 
(A) soluble Aβ40  (B)soluble Aβ42 (C) Insoluble Aβ40  (D) Insoluble Aβ42 (E) serum Aβ40 from 
cortex of mice treated with hIVIG or saline.Quantitative immunohistochemical analysis of (F) Aβ 
burden and (G) microglial reactivity. 
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Figure5.1.2e. (A-G) Representative images of positve iron staining patterns in mice treated with 
hIVIG. Mostly, there were common in fimbriae and thalamus regions. (H) Quantification of 
positive microhemorrhage profiles per section. 
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5.1.3a Effect of 3-month hIVIG treatment on cognition of APP/PS1 mice 
As shown in figure5.1.3a-A there were no significant differences between the treatment 
groups with regard to escape latency on all the four days (F (2, 45) = 0.88; p = 0.42). On day 4, 
only a trend for wild-type mice to perform better than APP/PS1 mice emerged. However, a 
probe trial on day 5 showed a significant difference (F (2, 47) = 4.53; p = 0.16), such that saline 
treated wild-type mice (p = 0.02), and hIVIG treated APP/PS1 mice (p = 0.04) performed 
statistically better than saline treated APP/PS1 mice (figure5.1.3a-B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure5.1.3a. Morris water maze data from mice treated with hIVIG for 3 months. (A) On Day 4 
APP/PS1 mice took longer to reach platform than wild mice. (B) Probe trial on day 5, showed that 
saline treated wild and hIVIG treated APP/PS1 mice crossed the platform location significantly 
more number of times than saline treated APP/PS1 mice.  
* indicates p < 0.05. 
 
5.1.3b Development of anti-human antibodies during 3-month hIVIG treatment 
As shown in figure 5.1.3b, out of 17 mice hIVIG treated mice, only three developed 
neutralising antibody titres higher than 200. Rest had titres similar to that of saline treated 
mice suggestive of abated cross-species immune response. 
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Figure5.1.3b. Anti-human antibodies titres from sera of hIVIG treated mice as estimated by 
ELISA. Note only 2 mice developed  significant titres. Titres > 200 were considered positive. 
 
5.1.3c Successful penetration of human IgG into the hippocampus of APP/PS1 mice   
As shown in figure 5.1.3c-A and B, anti-human IgG signal in IVIG-1 and IVIG-3 was quite 
weak, yet distinctly different from saline treated mice. Notably, even sections from mice 
treated with control human IgG in the IVIG-3 experiment exhibited a weak signal akin to 
hIVIG treated mice. Upon careful observation, one could actually identify a clear human IgG 
signal inside the blood vessels but very scanty staining outside the vessels, indicating that 
human IgG was indeed present inside the blood vessels but never made its way out in 
significant quantities into the surrounding brain parenchyma. In the IVIG-6a experiment 
(figure 5.1.3c-C), where mice received weekly hIVIG injections for 3 months, a clear human 
IgG signal could be observed within the hippocampus. Importantly, saline treated mice were 
devoid of any immunoreactivity. Interestingly, not only human IgG signal was concentrated 
in the hippocampus but there was also a clear gradient in staining intensity across the rostro-
caudal axis (figure 5.1.4a-F). Furthermore, Figure 5.1.3c-D also shows scattered intensely 
stained human IgG aggregates as discrete deposits on the lower blade of dentate gyrus 
indicative of putative plaque decoration. Overall, anti-human IgG immunostaining in brain 
sections of these mice indicate successful penetration of human IgG into mouse 
hippocampus.  
5.1.3d Amyloid pathology and reactive microglia assessment after 3-month hIVIG 
treatment    
At the end of experiment, brains were processed and stained with 6E10 antibody to 
evaluate the total volume of diffuse amyloid plaques and Congo red to stain for dense core 
plaques. In addition, we used CD45 antibody in order to evaluate microglial activation. As 
shown in figure 5.1.3d-D and E, treatment did not bring about any significant changes to 
either 6E10 (t (28) = 0.44; p = 0.66) or Congo red positive amyloid deposits (t (28) = 1.60; p = 0.12). 
CD45 immunopositive area (figure 5.1.3d-F) did not differ between the treatments, either (t (28) 
= 0.12; p = 0.90) or similarly, microglial reaction relative to Aβ plaque area did not differ 
between the treatments (t (28) = 0.29; p = 0.77). Furthermore, as illustrated in figure 5.1.3d-A to 
C, no statistically significant differences were found in measurements of soluble (t (27) = 0.33; p 
= 0.74) or insoluble levels of Aβ42 (t (27) = 0.09; p = 0.93), or serum Aβ40 levels (t (22) = 0.44; p = 
0.67).  
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     Figure 5.1.3c continued.. 
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Figure5.1.3c. Anti-human IgG immunostainings. Mouse sections from (A) IVIG-1 and (B) IVIG-3 
experiments showed  very weak human IgG signal whereas sections from (C) IVIG-6a clearly 
showed human IgG signal emerging predominantely from hippocampus. Control animals treated 
with saline were devoid of any anti-human IgG signal. Under high magnification one can clearly 
see (D) dark intensly stained aggregates ofhuman IgG in dentate gyrus. 
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Figure5.1.3d. Hippocampal levels of (A) soluble Aβ42 (B) insoluble Aβ42 and (C) serum levels of 
Aβ40 measured from  IVIg-6a experiment. Mice were 7.5 month old at the end of treatment 
schedule. (D, E and F) show quantitative immunohistochemistry data related to Aβ burden, 
amyloid burden and microglial reactivity, respectively. 
 
5.1.4 Effects of weekly hIVIG treatment for 8 months (IVIG-6b study) 
In this experiment, aged (4-month old APP/PS1) mice well-tolerated chronic 8-month weekly 
high dose hIVIG injections and there were no signs of peritoneal inflammation. Heightened 
sensitivity to touch was evident around the sites of injection. Also, there was no noticeable 
abnormal mouse behaviour indicative of abdominal pain or distress. All the mice irrespective 
of treatment were well groomed and  were active in their home-cages. 
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5.1.4a Development of anti-human IgG titres and brain penetration of human IgG 
We took lifetime blood samples at 7.5 month of age and terminal samples at 12-month age 
in order to assess the development of neutralising antibodies. Interestingly, this time the titres 
were much more variable than our previous experiment. In contrast to our previous belief, 
even mice with no detectable anti-human IgG titres at 7.5 months developed high titres by 12-
month age and vice versa. This indicates that age of mice or the duration of treatment had 
limited influence over development of neutralising antibodies (figure 5.1.4a-A). We also 
carried out anti-human IgG immunostainings in mouse brain sections and compared them 
with anti-human IgG titres measured from sera. As evident from figure 5.1.4a-B, human IgG 
staining intensity was more or less the same in mice with either low or high anti-human IgG 
titres. One can see dark deposits of human IgG even in mice with the highest antibody titres. 
Figure 5.1.4a-C shows the full extent of human IgG deposition and decoration around 
putative plaques in both the cortex and hippocampus of mouse 389, which developed the 
highest titres of anti-human IgG antibodies in this experiment. A double staining with congo 
red and anti-human IgG (figure 5.1.4a-D) shows that this human IgG staining is specific to 
amyloid plaques.   
 
 
 
 
 
 
 
 
 
      
 
 
 
     
 
 
     Figure 5.1.4a continued.. 
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Figure 5.1.4a. (A) Development of anti-human antibodies in mice treated  hIVIG for 8 months. 
Circles represent wild and triangles represent APP/PS1 mice. Titires > 200 are only considered 
significant.(B) Comparision  of anti-human IgG stained mouse brain sections with anti-human IgG 
titres in sera. Scale bar denotes 100µm. (C) Anti-human IgG stained section from  mouse 389 
shows putative human IgG deposits in cortex (red arrows) and hippocampus (black arrows). Scale 
bar denotes 500µm. (D) High magnification image from  serial sections stained with congo red 
(black arrows)and anti-human IgG immunostain (red arrows). Scale bar denotes 50µm. (E) Anti-
human IgG staining on a mouse brain section treated with saline. This control section is 
completely devoid of human IgG signal. (F) Human IgG gradient present across rostral-caudal 
axis of hippocampus. (G) Triple  flourescencent staining of mouse section with Aβ, huma hIgG 
and microglia. 
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In contrast, brain sections of saline treated control mice were devoid of any 
immunoreactivity to human IgG (figure 5.1.4a-E). This indicates that the human IgG 
immunoreactivity signal in mice cannot be an artefact of the human APP transgene. 
Furthermore, one can clearly appreciate the existence of a human IgG gradient within the 
hippocampus across rostro-caudal axis (figure 5.1.4a-F), which indicates accumulation or 
sequestration of hIVIG within the hippocampus as a consequence of chronic treatment.  
Finally, a triple immunofluorescent labelling showed amyloid plaque, human IgG and 
microglia all located within the same microenvironment (figure 5.1.4a-G). 
Finally, we tried to correlate the important measured outcome parameters with titres of 
anti-human IgG antibodies. Serum Aβ40 (Pearson r = 0.035, p = 0.91), hippocampal soluble 
Aβ40 (Pearson r = - 0.11, p = 0.68), hippocampal CD45 immunoreactivity (Pearson r = - 0.29, p 
= 0.27),   TNF (Pearson r = 0.01, p = 0.98) and Doublecortin positive cells in the dentate gyrus 
(Pearson r = - 0.11, p = 0.76) all yielded statistically nonsignificant correlations with anti-
human IgG titres. Among the 16 mice that received hIVIG only 7 mice produced significant 
titres of neutralizing antibodies (titres >200). After removing data from these mice, the 
outcome of the study remained unchanged.  
5.1.4b Effect of 8-month hIVIG treatment on behaviour of APP/PS1 mice 
In the marble burying test for neophobia, the number of visible marbles was counted 24 h 
after placing them inside the home cage. Two-way ANOVA showed no statistically 
significant effect (figure5.1.4b-A) of either genotype (F (1, 56) = 0.89; p = 0.35) or treatment (F (1, 56) 
= 0.007; p = 0.93). Next, in exploratory activity as assessed by ambulatory distance (figure 
5.1.4b-B), we noticed a significant genotype effect (F (1, 56) = 5.33; p = 0.025), but no significant 
treatment effects (F (1, 56) = 0.71; p = 0.40) or their interaction (F (1, 56) = 0.26; p = 0.61). This was 
consistent with our previous findings that APP/PS1 mice are hyper-active. In the novel object 
recognition test, APP/PS1 mice made significantly more exploratory visits to the objects than 
their wild-type-type littermates (F (1, 56) = 5.21; p = 0.026). However, neither a treatment effect (F 
(1, 56) = 0.91; p = 0.36) nor an interaction between the genotype and treatment were found (F (1, 56) 
= 0.18; p = 0.67). As for novelty preference, there was no treatment (F (1, 56) = 0.31; p = 0.58) or 
genotype (F (1, 56) = 0.64; p = 0.43) effect, or an interaction between the genotype and treatment 
(F (1, 56) = 0.02; p = 0.89). In Morris water maze test for spatial memory, there was no genotype 
or treatment effect on the swimming speed. Unfortunately, escape latencies (figure 5.1.4b-C) 
to reach the platform over the five test days did not reveal any genotype or treatment effects 
(genotype: F (1, 56) = 1.01; p = 0.32; treatment: (F (1, 56) = 0.1; p = 0.89). Only when considering 
learning within day 1, APP/PS1 mice proved to be inferior to their wild-type littermates (F (1, 
56) = 4.1; p < 0.05), but no treatment effect was found on this initial learning, either (p = 0.46).  
 
 
 
 
     Figure5.1.4b continued.. 
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Figure 5.1.4b. Mice were subjected to a battery of behavioural tests assessing (A)neophobia 
(marble test), (B) locomotor activity (TrueScan) and (C) spatial memory (Morris water maze). * 
indicates significant difference between wild and APdE9 genotypes, p < 0.05 
 
5.1.4c Effects of 8-month hIVIG treatment on amyloid pathology 
Interestingly, when compared to saline group, chronic hIVIG treatment resulted in 
significant elevation of soluble Aβ40 (t (29) = 2.32; p = 0.03) and Aβ42 levels (t (29) = 2.78; p = 0.009) 
by 36.3 % and 50.3 % respectively (figure5.1.4c-A, B). After removing data from mice that 
produced significant titres of anti-human antibodies, elevation of soluble Aβ42 levels still 
remained significant (t (22) = 2.2; p = 0.038), displaying  a 49.4 % increase compared to saline 
group. However, soluble Aβ40 levels, even though displaying a 29.5 % increase, did not reach 
statistical significance. The levels of insoluble Aβ40 and Aβ42 in hIVIG treated group were 
elevated by 11 % and 10 %, respectively, when compared to saline groups. This change did 
not reach statistical significance (insoluble Aβ40: t (29) = 1.28; p = 0.21 and insoluble Aβ42: t (29) = 
1.85; p = 0.07) (figure5.1.4c-C, D).  Despite a significant increase in the biochemical levels of 
Aβ, the volume of diffuse amyloid plaques (figure 5.1.4c-E) and dense-core amyloid deposits 
(figure 5.1.4c-F) in the hippocampus did not differ significantly between saline and hIVIG 
groups (diffuse plaques: t (29) = 0.91; p = 0.37 and dense-core plaques: t (28) = 0.73; p = 0.47). 
Similarly, serum levels of Aβ40 (figure 5.1.4c-G) did not show significant differences between 
saline and hIVIG treated groups (t (26) = 0.09; p = 0.92). Furthermore, hippocampal levels of 
Aβ40 and Aβ42 showed no correlation with serum Aβ40 levels (Pearson r (12) = 0.29, p = 0.31; 
Pearson r (12)   = 0.32, p = 0.26, respectively). 
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Figure 5.1.4c. Chronic hIVIg treatment (hIVIG-6b study) elevated hippocampal (A) soluble Aβ40 
and (B) Aβ42 levels. (C) Insoluble Aβ40 and (D) Aβ42  levels (E) Aβ plaque burden as measured by 
WO2 immunohistology, (F) amyloid burden as measured by congo red staining and (G) serum 
Aβ40 levels did not show statistically significant changes due to chronic hIVIG treatment. * 
indicates p<0.05, ** indicates p<0.01. Mice were 12 month old at the time of sacrifice. 
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5.1.4d Effects of 8-month hIVIG treatment on glial pathology 
We next went on to assess chronic 8-month hIVIG treatment effects on astrocytes and 
microglia.  Astrocyte reactivity in the hippocampus as detected by GFAP immunostaining 
(figure 5.1.4d-A) did not differ between saline and hIVIG treated animals (t (27) = 1.03; p = 0.31). 
Microglial reactivity was assessed by three different markers, Iba-1, CD68 and CD45. Iba-1, a 
structural marker for microglia, displayed a 39.2 % elevation in hIVIG treated mice compared 
to saline controls (figure 5.1.4d-B), but this difference did not reach statistical significance (t (28) 
= 1.54; p = 0.13). Macrophage lysosomal marker CD68 immunohistochemistry (figure 5.1.4d-
C) as well did not differ between saline and hIVIG treatments (t (27) = 0.41; p = 0.68). In 
contrast, CD45, a marker for activated microglia (figure 5.1.4d-D) revealed a statistically 
significant difference between saline and hIVIG treated groups (t (28) = 3.57; p = 0.001). CD45 
immunoreactive area of hIVIG group (2.79 ± 0.22, mean ± SEM) was 36.4% lower than the 
mean of the saline group (4.39 ± 0.40). To rule out the possibility that this suppression of 
CD45 immunoreactivity was a consequence of development of anti-human IgG antibodies in 
hIVIG treated mice, we excluded data from hIVIG treated mice that developed anti-human 
IgG antibodies (titres > 200). However, suppression of CD45 immunoreactivity (by 38 %) still 
remained statistically significant (t (22) = 3.01; p = 0.006). Furthermore, a moderate inverse 
correlation was detected between CD45 immunoreactive areas and soluble Aβ42 levels 
(Spearman r (28)   = -0.43, p = 0.02). 
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Figure 5.1.4d. Scale bars represe 200µm. Astrocytes reactivity was assessed by (A) GFAP 
imuunostaining and microglia were quantified by (B) Iba-1, (C) CD68 and (D) CD45 
immunohistology. ** indicates p<0.01. All quantifications were in hippocampal region and mice 
were 12 month old at end of treatment period. 
 
5.1.4e Chronic 8-month hIVIG treatment brings subtype specific changes to microglia 
In our brain sections, microglia residing both far and near the Aβ deposits were stained by 
Iba-1 marker, although with different staining intensities (figure  5.1.4e-A & B). Microglia 
near Aβ plaques (activated) were much more intensely stained than those away from plaques 
(quiescent). Additionally, microglia near amyloid plaques exhibited larger cell bodies with 
short, thick processes, whereas those away from plaques display cell bodies that are smaller 
in size with relatively much thinner processes. Quiescent (resting) microglia could be found 
scattered ubiquitously in brain parenchyma that is devoid of any Aβ plaques whereas 
activated microglia can be found clumped together as clusters in the immediate vicinity of 
amyloid plaque microenvironment, resembling a barricade of cells contiguous to Aβ deposits. 
In short, Iba-1 antibody identified two distinct populations of microglia, activated and 
quiescent (resting) microglia (figure 5.1.4e-A, B). Another microglia marker, CD45, identified 
specifically activated microglia. One can easily notice intensely immunostained CD45 
microglia surrounding Congo red positive amyloid deposits (figure 5.1.4e-C). Under light 
microscope, these usually appear as clusters of large spider-like cells with short and thick 
processes. Microglia of this kind of phenotype were not found in areas devoid of plaques or 
even in normal wild-type type mice.  Additionally, CD45 marker identified small round cells 
(figure 5.1.4e-D, E, F) with extremely intense CD45 immunoreactive signal (many-fold higher 
than spider-like microglia), largely in clusters or sometimes singly scattered in the cortex, 
hippocampus and white matter. These cells were found in large numbers surrounding 
fimbria, and in areas adjoining choroid plexus, ventricles and meninges. These seemingly 
migratory cells were also frequently found in close proximity to blood vessels. In short, CD45 
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identifies two morphologically dissimilar phenotypes of activated microglia. Taken together, 
both Iba-1 and CD45 antibody markers label different sub-populations of microglia with 
distinct morphologies and activation phenotypes. This largely conforms to previously 
reported microglial heterogeneity (Lawson et al., 1990).  
In order to separate treatment effects in different cell populations, we immunostained 
microglia with CD45 and Iba-1 fluorescent markers then, measured individual microglial 
cells on confocal Z-stacks for their CD45 and Iba-1 intensities (figure 5.1.4e-G, H).  The mean 
integrated intensities of CD45 and Iba-1 markers across the entire Z-axis of each microglia 
were plotted against the circularity (morphological parameter). This 3-D scatter plot 
identified three different sub-populations of microglia as shown in figure 5.1.4e-I. 
Statistically, two-step cluster analysis as well revealed three different clusters of cells with an 
average silhouette equal to 0.7.  In addition, the nonparametric Kruskal-Wallis H-test rejected 
the null hypothesis (p < 0.001) that there are no sub-populations of microglia. We call these 
three clusters of cells simply as type A, B and C (figure 5.1.4e-I). Type A cells seen in the plot 
have a round soma with no processes, and exhibit very high CD45 immunostaining intensity 
but negligible Iba-1a staining.  These cells correspond to round cells illustrated in figure 
5.1.4e-D, E, F.Their number increased dramatically from 4 to 12 months of age, and much 
faster in APP/PS1 mice than in wild-type-type control mice (figure 5.1.4e-J). Prima facie, they 
might be infiltrating immune cells, although it is difficult to ascertain their exact peripheral 
origin in this particular experimental setup. Chronic hIVIG treatment did not significantly 
affect CD45 expression in type A cells (U = 2117, p = 0.99, Mann-Whitney U test). Type B cells 
were characterized by large oval cell bodies and thick branching processes, and exhibit 
substantial CD45 and Iba-1 signal. These cells were located in the immediate 
microenvironment of amyloid plaques and likely represent activated microglia around Aβ 
deposits (Naert and Rivest, 2011). Mann-Whitney U-test revealed significantly reduced 
expression of CD45 (U = 15605, p < 0.02) and elevated expression of Iba-1 (U = 13972, p < 
0.0001) in type B cells as a result of chronic hIVIG treatment. Lastly, Type C cells showed a 
much more variable cell morphology. The cell bodies were relatively small and the processes 
much thinner than in type B cells. Type C cells exhibited substantial Iba-1a expression but 
practically no CD45 signal. These cells were found equally often around Aβ deposits and in 
plaque-free tissue. Those away from the plaques likely represent cells referred to in the 
literature as quiescent microglia (Kettenmann et al., 2011; Naert and Rivest, 2011). Iba-1a 
expression was significantly elevated in Type C cells as a consequence of chronic hIVIG 
treatment (U = 12795, p = 0.0001). Especially, the cells appeared to possess much longer 
processes. Collectively, these observations indicate that chronic hIVIG treatment brings about 
specific changes in subpopulations of microglia/macrophages.  
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Figure 5.1.4e. Scale bars represent 500 µm unless otherwise stated. Iba-1 marker for microglia 
stains both (A) activated and (B) non-activated microglia phenotypes. See black arrows. (C) 
Only activated spider-like phenotype of microglia are identified by CD45 marker. In addition, 
CD45 also identifies a phenotype of round microglial cells (D,E,F) near blood vessels, meninges 
and ventricles. Double immunoflourescent stainings (G, H, Scale bar 50 µm) with both Iba-1 
(green) and CD45 (Red) markers  reveal all the above microglia phenotypes simultaneously. 
Quantification of complete single cell confocal images across the Z-axis for integrated intensties 
and plotting them on a 3-D scatter plot (I, Scale bar = 5 µm) reveals three different sub-
populations of microglia namely, Type A, Type B and Type C cells. (J) Age dependent increase of 
Type A cells in both wild and APdE9 mice. 
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5.1.4f Chronic hIVIG treatment suppresses Tnf gene expression 
Having uncovered a subpopulation specific effect of hIVIG on microglia, which are 
important cellular source of inflammatory cytokines, we utilised RT-PCR technique to assess 
the gene expression of two most important pro-inflammatory cytokines, Tnf and Il1b. Two-
way ANOVA revealed a significant genotype (F (1, 30) = 34.3; p < 0.0001) and treatment effects 
(F (1, 30) = 8.57; p = 0.0065) for Tnf (figure 5.1.4f-A); however no significant interaction between 
the factors (F (1, 30) = 0.46; p = 0.5) was seen. For Il1b (figure 5.1.4f-B), a significant genotype 
effect (F (1, 31) = 7.24; p = 0.01) was found but no significant treatment effect (F (1, 31) = 0.07; p = 
0.79) or interaction between the factors (F (1, 31) = 0.86; p = 0.36). Interestingly, in saline treated 
mice a trend for positive correlation (figure 5.1.4f-C) was seen between CD45 microglia 
(immunopositive areas) and Tnf expression (Pearson r (7) = 0.66, p = 0.05). In contrast, chronic 
hIVIG treatment flipped this to a negative correlation (figure 5.1.4f-D) which was statistically 
significant (Pearson r (7) = -0.85, p = 0.003). Similarly for Il1b, a trend for positive correlation 
(Pearson r (8) = 0.59, p = 0.09) in saline treated mice changed to a statistically significant 
negative correlation (Pearson r (8) = -0.76, p = 0.01) in hIVIG treated mice (figure 5.1.4f-E, F). 
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Figure 5.1.4f. Quantitative gene expression analysis  by RT-PCR of  (A)Tnf and (B) Il1b. Positive 
correlation in saline treated mice (C) between  TNF-α expression and CD45 microglia flips towards 
a negative correlation in hIVIG treated mice (D). Similarly, positive correlation in saline treated 
mice (E) between  IL-1β gene expression and CD45 microglia flips towards a negative correlation 
in hIVIG treated mice (F). * indicates p<0.05,  ** indicates p<0.01 and *** indicates  p<0.001 
 
5.1.4g Chronic hIVIG treatment increases the number of newborn cells in the dentate gyrus 
We immunostained mouse brain sections with doublecortin, a marker for newborn 
neurons. Two-way ANOVA revealed statistically significant genotype (F (1, 34) = 18.9, p = 
0.0001) and treatment effects (F (1, 34) = 10.0, p = 0.003) in the number of doublecortin positive 
neurons (figure 5.1.4g-A). However, the interaction between the factors (F (1, 34) = 1.18, p = 0.3) 
was not significant. A 8-month high-dose hIVIG treatment resulted in nearly 60 % increase in 
the number of doublecortin positive neurons in both APP/PS1 and wild-type mice to a similar 
extent, indicating that this strong neurogenic effect is independent of APP or PSEN1 
transgenes or associated amyloid deposition. Furthermore, there was a significant inverse 
correlation (figure 5.1.4g-B) between hippocampal CD45 microglia (immunoreactive area) 
and the number of doublecortin positive cells in the dentate gyrus (Spearman r (18) = - 0.50, p = 
0.02), suggesting that these two variables are associated with each other. In other words, a 
high number of activated microglia associates with a low number of newborn neurons. 
 
 
 
 
 
 
 
 
 
Figure 5.1.4g. (A) Number of new born neurons as identified by doublecortin antibody marker. 
(B) A negative correlation can be seen between CD45 positive microglia and the number of new 
born cells as marked by doublecortin immunohistochemistry. ** indicates p<0.01 and *** 
indicates  p<0.001 
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5.2 ROLE OF Nfkb1 GENE ON PROGRESSION OF AMYLOID AND 
INFLAMMATORY PATHOLOGY (NFΚB STUDY) 
In this study we crossed NFκB gene knockout (Nfkb1-/-) mice with APP/PS1 mice, thereby 
creating a mouse line deficient in Nfkb1 gene on the APP/PS1 background. This allowed us to 
study the effects of Nfkb1 gene on the development of AD pathology. Since Nfkb1 gene is 
ubiquitously knocked out from all cells, it will be hard to ascribe the effects solely either to 
neurons or microglia.  In addition, NFκB regulates a number of functions in astrocytes, 
endothelial cells and the peripheral organs that regulate systemic immune reactions and 
inflammation. Moreover, there also exists considerable functional redundancy among the 
various subunits of NFκB transcription factors. Lastly, beneficial or detrimental effects of 
NFκB activation depend on a variety of factors, such as  spatial and temporal relationships of 
the activating stimuli, cell type, and the presence of molecular mediators which might result 
in signalling cross-talks. Table 5.2 summarizes all key findings of NFκB study. Nfkb1 gene 
deficiency in resulted in a distinct behavioural phenotype. Nfkb1-/- mice displayed smaller 
body weights, better motor coordination and were less anxious than their controls. However, 
gene deletion did not worsen or improve spatial memory deficits associated with APP/PS1 
genotype. Effects of Nfkb1 gene deletion had very limited effects on development and 
progression of amyloid pathology. Interestingly, at 12 month age, Nfkb1 gene deficiency 
caused a dramatic decrease in CD45 microglia activation with concominant increase in Tnf 
gene expression.  
Table 5.2. Bird’s eye view of key NFκB study findings. 
Experiment Mouse 
behavioural 
phenotype 
 
Amyloid 
pathology 
Microglial 
pathology 
Proinflammatory 
gene expression 
3.5 month Normal 
 
 
No changes -- -- 
8 month Normal 
 
1. Female 
APP/PS1 mice 
show more Aβ 
pathology. 
2. No effect of 
Nfkb1-/- 
genotype. 
 
1. Female 
APP/PS1 mice 
show more 
CD45 microglial 
activation. 
2. No effect of 
Nfkb1-/- 
genotype. 
 
 
-- 
12 month 1. Normal  
behaviour.  
2. Both  APP/PS1 
and Nfkb1-/-  
genotypes 
resulted in lesser 
body weights. 
3. APP/PS1 mice 
more active. 
4. Nfkb1-/- 
genotype display 
better motor 
cordination on 
1. Insoluble Aβ42
decreased in  
Nfkb1-/- 
genotype  by 
14%. 
2. No changes in 
Aβ plaques. 
1. CD45 microglial 
activation 
decreased by 
56% in Nfkb1-/- 
genotype. 
2. No change in 
CD68 microglia 
marker. 
3. Iba-1 more in 
APP/PS1 mice. 
4. No Nfkb1-/-
effect on Iba-1 
microglial 
1. Both Nfkb1-/-
and APP/PS1 
genotype 
elevated Tnf 
gene 
expression. 
Significant 
interaction 
between 
genotypes. 
2.  Nfkb1-/-
genotype 
displayed 
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rotating rod. 
5. Nfkb1-/- 
genotype  
display 
decreased 
anxiety. 
6. Nfkb1-/- 
genotype did not 
improve  or 
worsen spatial 
memory deficits 
of APP/PS1 mice. 
 
 
marker. significant 
interaction with 
APP/PS1 
genotype. 
 
 
LPS experiment Higher mortality in 
Nfkb1-/- genotype   
LPS reduced 
diffuse Aβ but no 
effect of  Nfkb1-/-
genotype.  
1. Significant 
decrease in 
Iba-1 signal 
due to LPS 
injection in 
Nfkb1-/- 
genotype. 
2. No changes to 
CD68 microglia 
marker in 
Nfkb1-/- mice.  
-- 
 
5.2.1a Behavioral phenotype of Nfkb1 gene knockout 
Breeding of Nfkb1-/- and APP/PS1 mice was successful, and pups were viable. These mice 
appeared normal, although they were much leaner than their wild-type-type controls. Indeed 
at 12 months of age, two-way ANOVA displayed a significant effect on body weight 
(decrease) of both APP/PS1 (F (1, 42) = 4.42, p = 0.042) and Nfkb1-/- genotypes (F (1, 42) = 20.67, p < 
0.0001; figure 5.2.1a-A). However, there was no interaction between the two genotypes      (F (1, 
42) = 0.56, p = 0.46).   
Spontaneous motor/exploratory activity of mice was determined by automated activity 
monitor based on infrared detection (TrueScan). Two-way ANOVA revealed hyperactivity 
(figure 5.2.1a-C) due to the APP/PS1 genotype (F (1, 41) = 15.18, p < 0.0001) but not effect of the 
Nfkb1 genotype (APP/PS1: (F (1, 41) = 0.50, p = 0.48). As seen in figure 5.2.1a-D APP/PS1 
genotype was also associated with less time engaged in stereotypic movements (F (1, 41) = 19.5, 
p < 0.0001) and decreased rearing times (F (1, 41) = 7.76, p = 0.008), while the Nfkb1-/- genotype 
had no effect on either parameter (Stereotypy: F (1, 41) = 0.12, p = 0.73 & rearing time: F (1, 41) = 2.1, 
p = 0.15). Motor coordination and balance were evaluated in the rotarod test. The Nfkb1-/- 
genotype was associated with a longer time (F (1, 42) = 20.84, p < 0.0001) on the rotating rod 
figure 5.2.1a-E, while the APP/PS1 genotype had no effect on the performance of this test 
(APP/PS1: F (1, 42) = 0.70, p = 0.40). Also, there was no interaction between the genotypes (F (1, 42) 
= 0.03, p = 0.86).  
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Figure 5.2.1a. Behavioural assessment  of  Nfkb1 gene deficiency in APP/PS1 mice. (A) Body 
weights of  male mice at 12-month age. (B) Marble test for neophobia. Locomotor activity  of 
mice as indicated by (C) ambulatory distance  travelled and (D) time spent on stereotypy. (E) 
Motor coordination as evaluated by Rotarod Test. (F) Anxiety evaluated by elevated plus maze 
test. (G)Evaluation of spatial memory by Morrs water maze.  
 
Anxiety-like behaviour was assessed with a simple marble burying test that relies on 
innate behaviour of mice to cover potentially dangerous novel objects with the cage bedding. 
The numbers of visible or untouched marbles overnight were counted. There was no effect 
figure 5.2.1a-B of APP/PS1 (F (1, 42) = 0.89, p = 0.35) or Nfkb1-/- (F (1, 42) = 1.280, p = 0.26) genotype 
nor any interaction between the genotypes (F (1, 42) = 2.39, p = 0.13). In elevated plus maze, 
another test for anxiety, the Nfkb1-/- genotype was associated with increased time on the open 
arm (F (1, 42) = 6.42, p = 0.015), indicating decreased anxiety (figure 5.2.1a-F). In contrast, the 
APP/PS1 genotype was without effect on this parameter (F (1, 42) = 0.9, p = 0.35). 
In Morris water maze test for spatial learning and memory figure 5.2.1a-G, as expected the 
APP/PS1 genotype was associated with significantly increased escape latencies (F (1, 42) = 11.79, 
p = 0.001), indicative of impaired learning. In contrast, the Nfkb1-/- genotype did not affect the 
escape latency  (F (1, 42) = 0.002, p = 0.96), and there was no interaction between the two 
genotypes (F (1, 42) = 0.5, p = 0.49). Based on this behavioural test battery, knocking down the 
Nfkb1 gene did induce a characteristic phenotype (decreased anxiety and improved motor 
coordination and balance). However, the effect of Nfkb1-/- on behavioural was independent of 
APP/PS1 transgene effects.  
5.2.1b Impact of Nfkb1 gene knockout on amyloid pathology 
Mice with APP/PS1 transgene deposit their first Aβ plaques around 3-4 months of age 
(Garcia-Alloza et al., 2006). In order to see whether knocking down the Nfkb1 gene had any 
impact on early plaque deposition, fresh brain samples from mice at 3.5 months of age were 
processed with routine biochemical and immunohistochemistry procedures. At this age, 
brain levels of insoluble Aβ42 from females mice showed no statistically significant genotype 
differences (figure 5.2.1b-A), although there was a trend towards decreased levels in Nfkb1-/-  
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mice ( t (21) = 1.97; p = 0.06). Counting the number of W02 positive Aβ plaques in the cortex and 
hippocampus of APP/PS1 mice (figure 5.2.1b-B&C) revealed no statistically significant 
differences between Nfkb1-/- mice and Nfkb1 wild-type carriers (cortex: t (20) = 0.65; p = 0.52; 
hippocampus: t (20) = 1.72; p = 0.1). Fibrillar Aβ as detected by Congo red staining was not 
performed for mice of this age group. Overall,this indicates that lack of Nfkb1 gene may have 
a very limited role in early Aβ plaque deposition.  
We next went on to check amyloid pathology at 8 months of age. Levels of insoluble Aβ40 
and Aβ42  (figure 5.2.1b-D&E) in the hippocampus of male APP/PS1 mice revealed no 
statistically significant differences due to the Nfkb1 genotype (Aβ40: t (13) = 0.75; p = 0.46; Aβ42: t 
(13) = 0.42; p = 0.68). Cortical and hippocampal Aβ plaque burden in male and female APP/PS1 
mice was assessed with W02 immunohistology (figure 5.2.1b-F&G). Two-way ANOVA 
revealed a significant main effect of sex (F (1, 28) = 40.08, p < 0.0001) but no main effect of Nfkb1 
genotype (F (1, 28) = 0.04, p = 0.85) or an interaction between sex and Nfkb1 genotype (F (1, 28) = 
0.008, p = 0.93) on amyoid plaque burden. Interestingly, hippocampal W02 burden revealed 
significant main effects of both sex (F (1, 28) = 11.32, p = 0.002) and Nfkb1 genotype (F (1, 28) = 6.41, 
p = 0.02), but there no interaction between these factors (F (1, 28) = 0.12, p = 0.73). Fibrillar Aβ as 
detected by Congo red staining was not performed for mice of this age group. 
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     Figure 5.2.1b continued.. 
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Figure 5.2.1b. Age dependent progression of amyloid pathology. Biochemical  levels of (A) 
insoluble Aβ 42  levels and (B) WO2 positive deposits in cortex and (C) hippocampus of 3.5 month 
old female APdE9 mice. Insoluble levels of hippocampal (D) Aβ40 and (E) Aβ42 from 8-month old 
male mice. Quantification of Aβ plaques from (F) cortex and (G) hippocampus of 8-month old 
mice. ELISA measurements of hippocampal (H) soluble and (I) insoluble Aβ42 levels from 12-
month old mice. Similarly, quantification of Aβ plaques at 12-month detected  by (J) pan-Aβ 
immunostaining and (K) amyloid deposits by congo red histological stain. * indicates p< 0.05,  ** 
indicates p<0.01 and *** indicates  p<0.001. 
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At the age of 12 months (figure 5.2.1b-H), hippocampal soluble Aβ42 in male APP/PS1 mice 
did not differ significantly between Nfkb1-/- and Nfkb1 wild-type carriers (t (19) = 1.56; p = 0.14). 
Interestingly, insoluble Aβ42 (figure 5.2.1b-I) showed a 14 % drop in Nfkb1-/- mice, which was 
statistically significant (t (19) = 2.70; p = 0.01). However, immunohistochemical quantification of 
plaque burden (figure 5.2.1b-J&K) in these mice showed no statistically significant difference 
between the Nfkb1 genotypes (Pan Aβ antibody: t (21) = 1.96; p = 0.07; Congo red amyloid 
staining: t (21) = 0.99; p = 0.33). In conclusion, there was only a slight and age-dependent effect 
of Nfkb1 deficiency on brain amyloid levels. 
5.2.1c Impact of Nfkb1 gene knockout on microglia and pro-inflammatory cytokine gene 
expression 
To assess if microglial activation was influenced by absence of Nfkb1 gene, we 
immunostained free-floating brain sections with microglia specific CD45, Iba-1a and CD68 
primary antibodies. Two-way ANOVA of CD45 immunoreactivity in the cortex and 
hippocampus of 8-month-old APP/PS1 mice (figure 5.2.1c-A&B)  revealed no statistically 
differences between Nfkb1-/- and Nfkb1 wild-type carriers (cortex, F (1, 28) = 1.33, p = 0.26; 
hippocampus, F (1, 28) = 2.62, p = 0.12), but revealed a significant gender effect, with females 
exhibiting elevated CD45 immunoreactivities (cortex, F (1, 28) = 11.74, p = 0.001; hippocampus F 
(1, 28) = 11.64, p = 0.002). Also, there was no interaction between gender and Nfkb1 genotype 
(cortex: F (1, 28) = 1.25, p = 0.27; hippocampus: F (1, 28) = 0.32, p = 0.57).  
A) 
 
 
 
 
 
B) 
 
 
 
 
 
 
Figure 5.2.1c. Microglial reactivity in 8-month old APP/PS1 mice from NFκB age series experiment 
as measured by CD45 immunoreactivity in (A) cortex and (B) hippocampus. ** indicates p<0.01. 
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 In 12-month-old mice (figure 5.2.1c-C), quantification of the immunostained sections 
revealed a statistically significant 56 % decrease in the CD45 marker for activated microglia in 
Nfkb1-/- mice (t (21) = 3.34; p = 0.003). In contrast, the lysosomal macrophage marker CD68  
(figure 5.2.1c-E), did not differ between the Nfkb1 genotypes (t (21) = 1.26; p = 0.24). Two-way 
ANOVA on 12-month-old APP/PS1 and wild-type mice showed a significantly higher Iba-1 
signal (figure 5.2.1c-D) in APP/PS1 mice (F (1, 36) = 51.66, p < 0.0001), but no effect of the Nfkb1 
genotype (F (1, 36) = 1.05, p = 0.31).  Also, there was no significant interaction between the 
APP/PS1 and Nfkb1 genotypes (F (1, 36) = 0.02, p = 0.87).  A strong drop in CD45 
immunopositive signal prompted us to check pro-inflammatory gene expression (Tnf and 
Il1b) in these mice. Two-way ANOVA for Tnf gene expression (figure 5.2.1c-F) showed a 
statistically significant increase due to both APP/PS1 (F (1, 20) = 19.07, p = 0.003) and Nfkb1 (F (1, 
20) = 14.17, p = 0.001) genotypes. Moreover, there was a significant interaction between these 
factors (F (1, 20) = 5.00, p = 0.03). Similarly, Il1b (figure 5.2.1c-G)   showed a significant increase 
associated with the APP/PS1 (F (1, 20) = 5.24, p = 0.03), but the Nfkb1 genotype showed no 
significant effect (F (1, 20) = 2.43, p = 0.13). However, there was a significant interaction between 
the genotypes (F (1, 20) = 5.06, p = 0.04).   
C)            D)    
 
 
 
 
 
 
 
                E) 
 
 
 
 
 
 
 
 
Figure 5.2.1c. Microglial reactivity in 12-month old mice from NFκB age series experiment as 
measured by (C) CD45, (D) Iba-1 and (E) CD68 immunoreactivity in 12-month old mice. ** 
indicates p<0.01 and *** indicates  p<0.001.  
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 G) 
 
 
 
   
 
Figure 5.2.1c. Quantitative RT-PCR of proinflammatory cytokines (F) Tnf and (G) Il1b. 
* indicates p< 0.05,  ** indicates p<0.01 and *** indicates  p<0.001.  
 
In conclusion, Nfkb1-/- at an early stage of amyloid pathology (or at an adult age) did not 
significantly alter activation of microglia. However, at the age of 12 months, Nfkb1-/- had a 
significant effect on microglia activation as measured by CD45 immunoreactivity as well as 
on the brain levels of pro-inflammatory cytokines. Importantly, we also observed significant 
interactions between the APP/PS1 and Nfkb1-/- genotypes, indicating that knocking out the 
p50 NFkB subunit may modify the progression of neuroinflammation in AD. 
5.2.2 Impact of intrahippocampal injection of LPS on APP/PS1 mice with Nfkb1 deficiency 
We injected saline in the left hippocampus and LPS (4 μg) in the right hippocampus, and 
evaluated amyloid load and microglia activation 7 days after the injection (figure 5.2.2A). 
ANOVA for repeated measures (linear mixed model) was used to test within-subject (saline 
vs. LPS) and between-subject differences (Nfkb1 wild-type and Nfkb1-/-). Quantification of 
amyloid plaque load with 6E10 primary antibody revealed a significant decrease due to LPS 
injection (F (1, 13.4) = 48.1, p < 0.001). However, Nfkb1 deficiency had no significant impact on 
6E10 signal  in either saline (F (1, 25.3) = 0.89, p = 0.35)  or LPS  (F (1, 25.1) = 0.14, p = 0.71) treated 
hemibrains (figure 5.2.2B). Microglial reactivity as measured by Iba-1 significantly increased 
due to LPS injection (F (1, 14.1) = 10, p = 0.007).  Furthermore, Nfkb1 deficiency significantly 
decreased Iba-1 signal from LPS hemibrains (F (1, 26.4) = 4.5, p = 0.04)   but not from saline 
treated hemibrains (F (1, 26.2) = 0.54, p = 0.47) (figure 5.2.2C).  Similarly, lysosomal marker CD68 
indicative of phagocytosis, showed significant elevation due to LPS injection (F (1, 13.5) = 20.5, p 
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= 0.001) but revealed no Nfkb1 genotype effects in either saline (F (1, 17.6) = 0.001, p = 0.98) or LPS 
(F (1, 17.6) = 0.14, p = 0.71) treated hemibrains (figure 5.2.2D). 
 
 
 
Figure 5.2.2. (A) Intrahippocampal  coordinates for LPS/saline injection. Quantitative analysis of 
(B) 6E10 , (C) Iba-1 and (D) CD68 immunostainings. * indicates p< 0.05  
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6 Discussions 
6.1 EFFECTS OF HUMAN INTRAVENOUS IMMUNOGLOBULIN  IN A MOUSE 
MODEL OF ALZHEIMER’S DISEASE 
To our knowledge, this is the first study which systematically investigates the efficacy and 
safety of hIVIG therapy in a transgenic mouse model of Alzheimer’s disease (AD). At present, 
a phase-3 clinical trial is testing hIVIG in mild to moderate AD patients (Mangialasche et al., 
2010). Even though mechanisms of immunotherapy for AD are well documented (Wilcock et 
al., 2004a), there are hardly any reports that delve on in vivo effects and mechanisms of hIVIG 
in AD. Previous studies, including our own, tested various potential mechanisms for hIVIG in 
a variety of in vitro and ex vivo experimental setups (Istrin et al., 2006; Magga et al., 2010).  As 
of now, mechanisms of action for hIVIG still remain elusive. Table 5.1 summarized the key 
findings of this study. Importantly, in these experiments, we show that development of anti-
human IgG antibodies may not prevent us from using mouse models to test hIVIG. We report 
clear penetration and accumulation of human IgG across rostro-caudal axis of hippocampus 
in APP/PS1 mice after chronic hIVIG treatments. Further, we also noticed evidence for in vivo 
Aβ plaque decoration with human IgG. Eventhough, we could not notice any congnitive 
benefits with hIVIG treatment, we saw a remarkable elevation of soluble Aβ levels with out 
any concominant changes to diffuse and fibrillar Aβ deposits in hippocampus. Despite 
limited changes to Aβ pathology, we noticed profound changes in microglial activation and 
Tnf gene expression. Finally, we report neurogenic properties of human intravenous 
immunoglobulins which further correspond to  changes in microglial activation. 
6.1.1 IMPACT OF DOSE AND DURATION OF hIVIG TREATMENTS 
 We used highly concentrated hIVIG preparation (Gammagard Liquid,10%) to maximize 
the dose of putative anti-Aβ antibodies in chronic experiments. In a human study on patients 
with mild AD, a lower dose (0.4 g/kg) of hIVIG was found to be associated with higher 
MMSE scores than the higher  1 g/kg dose, which points to an inverted dose-response for in 
vivo hIVIG effects (Relkin et al., 2009). Therefore, it appears logical to expect more robust 
effects at a lower dose of hIVIG also in an AD mouse model. However, in IVIG-1 experiment 
either a low dose (0.1 g/kg) or shorter treatment durations (1-3 weeks) yielded no effects on 
amyloid or glial pathology.  In addition, our data indicate that either a lower dose and or a 
shorter treatment duration likely yielded insufficient brain penetration of hIVIG. 
Furthermore, the brain bioavailability of hIVIG is likely to be much higher in elderly humans 
than in young adult mice, and with intravenous administration as used in human trials, one 
may end up with a dose comparable to intraperitoneal administration of the high dose used 
in this study.  Owing to limitations of brain penetration and miniscule proportions of Aβ 
reactive antibodies in hIVIG (O'Nuallain et al., 2008), we stretched treatment durations to 3 
and 8 months in IVIG-6a and IVIG-6b respectively.  
6.1.2 IMPACT OF ANTI-HUMAN ANTIBODIES ON hIVIG STUDY  
Mouse immune system reacts to intraperitoneal injections by mounting an immune 
response against the injected human antibodies (Loeffler et al., 2012). Development of these 
anti-human antibodies (also referred as neutralising antibodies) may seriously compromise 
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the circulating amount of antibodies and impede brain penetration as well. From our initial 
experiments (IVIG-1 and IVIG-3), we assumed that aged mice develop higher titres of 
neutralising antibodies than young mice.  Our assumption was vindicated by the results of 
the IVIG-6a experiment, where we initiated treatments at 4months of age (in order to 
overcome a cross-species immune response) and noticed development of immune tolerance 
in all except three mice. This is consistent with pilot studies carried out by Elisabeth Maier at 
Baxter Innovation (Vienna, Austria) showing that anti-human IgG titres reach their peak 
around 3 weeks after hIVIG injections and subside thereafter. Data so far suggested that 
young adult mice develop immune tolerance after a prolonged hIVIG treatment and 
importantly age of mice was very critical for the development of neutralising antibodies. 
However, in IVIG-6b (8-month treatment) we came to know that this was actually not the 
case.  Mice in this experiment developed highly variable titres of neutralising antibodies. This 
is in agreement with a recent report describing murine anti-human antibody response of 
natural human antibodies in a mouse model of Alzheimer’s disease (Dodel et al., 2011).  
The formation of anti-human antibodies is a serious concern in the interpretation of the 
present results. However, all available data in our study indicate that their role is of little 
significance. We offer the following explanations to support our inference.  Firstly, not all 
mice developed anti-human antibodies. In IVIG-6a only three mice and in IVIG-6b only 44% 
of mice treated with hIVIG developed neutralizing antibodies.  From Figure 5.1.4a-B on can 
appreciate that human IgG immunoreactivity in the brain does not correspond to serum titres 
of anti-human antibodies. As an extreme example, one mouse that developed the highest 
anti-human antibody titres (Fig. 5.1.4a-C) clearly demonstrated cortical and hippocampal 
localization of human IgG. These observations support the assumption that neutralising 
antibodies are not hampering brain penetration of human IgG. Secondly, none of the test 
parameters in this study showed a significant correlation with anti-human antibodies, 
indicating that these neutralising antibodies may not be associated with the primary 
outcomes of the present study. Lastly, to ensure that those anti-human antibodies are not 
confounding the results we removed data from all mice that produced significant titres of 
neutralizing antibodies and reperformed statistical analysis. In IVIG-6b, among the 16 mice 
that received hIVIG only 7 mice produced significant titres of neutralizing antibodies (titres 
>200). Even after data from these 7 mice were removed, the main outcome, suppression of 
CD45 still remained statistically significant (t (22) = 3.0, p = 0.0064). In contrast, the data from 
these 7 mice with high titres alone did not show a statistically significanct effect on CD45 
immunoreactivity (t (20) = 1.7, p = 0.10). Furthermore, outcomes related to amyloid pathologies 
did not change, either. Data provides ample evidence that development of neutralising 
antibodies did not affect brain penetration of human IgG and also did not influence the 
outcome of our experiments.Therefore one can reasonably infer that development of cross-
species immune response is a serious limitation but at the same time, anti-human antibodies 
did not hamper hIVIG penetration nor counfound the results of the present study. 
6.1.3 BRAIN PENETRATION OF hIVIG IN A MOUSE MODEL OF 
ALZHEIMER’S DISEASE 
Immunoglobulins have traditionally been known to have limited entry into CNS. Only less 
than 1% of total injected protein can be traced into the brain (O'Nuallain et al., 2008). In order 
to ascertain brain localization of human IgG, we carried out anti-human IgG immunostaining 
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on free floating coronal sections of mice treated with hIVIG. Control sections from saline 
treated mice were devoid of any immunoreactivity whereas mouse sections from hIVIG 
treated mice showed clear human IgG immunoreactivity in the hippocampus. Anti-human 
IgG immunoreactivity signal in APP/PS1 mice was persistent upon changing fixation method. 
It was also noticed in hIVIG treated wild-type-type mice albeit to a lesser extent. In addition, 
strong immunoreactivity was also noticed in ventricles, and occasionally, within ill perfused 
blood vessels, indicating that human IgG was indeed present in brain vasculature but had 
restricted entry into brain parenchyma. Interestingly, penetration of human IgG was 
dependent on the duration of treatment. Very faint human IgG signal was noticed in 
experiments with durations up to 3 weeks (IVIG-1 and IVIG-3).  In the 3-month experiment 
(IVIG-6a), there was not only a detectable hIVIG signal within the hippocampus, but also a 
gradient of immunoreactivity across the rostro-caudal axis, with the highest intensity of 
human IgG signal coming from the septal end adjoining choroid plexus.  Vasculature in the 
anterior wall of choroid plexus might be one of the entry routes for human IgG into mouse 
brain. Apart from occasional presence of human IgG aggregates or deposits in the 
hippocampus, there was limited evidence for cortical localization. However, in the 8-month 
experiment (IVIG-6b), in addition to antero-posterior gradient of human IgG, one can clearly 
see human IgG deposits decorating amyloid plaques in the hippocampus and cortex. Double 
staining with Congo red shows that these amyloid deposits were covered by stippled 
aggregates of human IgG deposits and further fluorescent triple staining clearly showed Aβ, 
human IgG and microglia within the same microenvironment. We thus conclusively show 
evidence for brain penetration of human IgG in spite of development of anti-human 
antibodies. To our knowledge this is the first study systematically reporting in in vivo brain 
penetration of immunoglobulins in a transgenic mouse model of AD. 
6.1.4 EFFECT OF hIVIG ON BEHAVIOR OF APP/PS1 MICE  
Mice tolerated intraperitoneal injections of hIVIG well and did not exhibit any adverse 
effects in their general behaviour or well-being. Mice that had prolonged treatment durations 
showed tenderness around the injection site. Otherwise, mice were no different from those 
treated with saline. We assessed the behaviour of hIVIG treated mice with a neurological test 
battery in each experiment. Consistent with our previous studies (Kemppainen et al., 2012) 
APP/PS1 mice showed increased locomotor activity, which was not alleviated by the 
treatment. Morris water maze is a sensitive test to reveal hippocampal based spatial learning 
in mice. In spite of robust accumulation of hIVIG in the hippocampus, we could not 
conclusively detect any cognitive benefits of hIVIG treatment in APP/PS1 mice. Certain 
inherent limitations of our study design might have contributed for this poor show on Morris 
water maze test.  In IVIG-1 and IVIG-6a, APP/PS1 mice were too young to show any 
impairment. In IVIG-3 even though mice were older, the test paradigm did not work as 
expected because a change in platform position did not always lead to prolonged escape 
latencies. Further, mere six injections of hIVIG might be too little to influence robust Aβ 
plaque pathology in APP/PS1 mice at this age. So, at hindsight only IVIG-6b may have had 
reasonably good chance to reveal any effects of hIVIG on spatial learning and memory. 
Consistent with our previous reports (Kemppainen et al., 2012), our transgenic mice 
developed cognitive deficits around 12 months of age (age series experiment). However, even 
in IVIG-6b experiment Morris water maze did not reveal any changes in spatial learning and 
memory. This limitation might be in part due to the stress associated with repeated 
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intraperitoneal injections for months. In addition, very low concentrations of Aβ reactive 
antibodies in hIVIG preparations together with no reduction of brain Aβ levels due to 
treatment might be responsible for the lack of cognitive treatment effects.  
6.1.5 EFFECTS OF hIVIG TREATMENT ON AMYLOID PATHOLOGY OF 
APP/PS1 MICE 
Human IVIG has been reported to possess antibodies reactive not only to Aβ epitopes but 
also to Aβ conformation (O'Nuallain et al., 2008).  Furthermore, both epitope and 
conformation specific Aβ antibodies have been reported in sera from healthy humans 
irrespective of age or gender (O'Nuallain et al., 2010). These antibodies present in hIVIG are 
hypothesized to augment the clearance of Aβ from the brains of APP/PS1 mice by various 
established mechanisms, such as antibody-mediated disaggregation of Aβ deposits, antibody 
mediated microglial phagocytosis of Aβ deposits, and antibody-mediated efflux of Aβ 
protein from CNS into peripheral circulation due to peripheral sink. Notably, all these 
mutually exclusive mechanisms should ultimately result in decrease in brain total Aβ levels, 
and the peripheral sink effect in addition to an increase in serum Aβ levels (Solomon, 2007). 
Development of anti-human IgG antibodies in IVIG-1 and IVIG-3 might have hindered any 
changes to brain Aβ levels. However, after 3 months of treatment with hIVIG (IVIG-6a) we 
noticed no change in either brain or serum Aβ levels. This might be due to very low 
concentration of anti-Aβ antibodies of the total IgG (~ 0.1 %, (O'Nuallain et al., 2008)) and 
insufficient accumulation in the brain with a short duration of treatment. More surprisingly, 
we noticed an elevation of soluble brain Aβ levels with the present chronic 8-month 
treatment(IVIG-6b). The underlying mechanisms for the selective elevation of brain Aβ levels 
is not clear at present, but  interestingly, microglia may play some role in regulating brain Aβ 
levels. Microglia  ablation  in APP transgenic mice  resulted in   similar elevation in soluble 
Aβ levels (Grathwohl et al., 2009).  Furthermore, APP transgenic mice with CD45 deficiency 
also exhibited elevation of soluble Aβ levels (Zhu et al., 2011) and then in our hIVIG study, 
chronic 8-month hIVIG treatment caused suppression of the CD45 microglia marker by 30%, 
which correlated with elevated soluble Aβ levels. This may be an emerging evidence for the 
role of microglia in modulating the soluble levels of Aβ.  Nonetheless, this observation 
together with no changes in plaque-associated Aβ burden clearly points to an inefficient 
disintegration of pre-existing Aβ deposits due to hIVIG treatment.  Immunostainings with N-
terminal specific antibodies or Congo red staining for fibrillar Aβ deposits also revealed no 
treatment effects. Our 8-month study (IVIG-6b) had an 80% power to detect a 19% change in 
mean Aβ immunopositive area and 30% change in mean Congo red positive area with a 
significance level (alpha) of 0.05 (two-tailed). This together with no changes in CD68 
immunostaining speaks against enhanced Aβ phagocytosis by microglia due to hIVIG 
treatment.  
According to the peripheral sink hypothesis, bidirectional transfer of Aβ between CNS and 
periphery would lead to elevated serum Aβ levels (DeMattos et al., 2001). However, 
irrespective of the dose used or treatment duration, we noticed no significant elevation of 
serum Aβ levels in our studies. Furthermore, there was no correlation between brain Aβ and 
serum Aβ levels. Statistically, our chronic 8-month study (IVIG-6b) had an 80% power to 
detect a 22% change in mean serum Aβ40 levels with a significance level (alpha) of 0.05 (two-
tailed). Furthermore, in IVIG -1 and IVIG -3,  no difference in amyloid plaque burden or in 
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biochemical levels of Aβ in brain and serum was noticed after three weekly hIVIG injections 
in 3-month-old APP/PS1 mice or after bi-weekly hIVIG treatment for 3 weeks in 15-month-old 
APP/PS1 mice. These findings indicate that the outcome of Aβ related measurements was not 
dependent on age or amyloid plaque burden at the onset of hIVIG treatment. A recent in vivo 
study reported that natural Aβ-antibodies (Nabs-Aβ) isolated from hIVIG reduced amyloid 
plaque burden in 3-month-old mice but not in 12-month-old APP transgenic mice (Dodel et 
al., 2011). This reduction was ascribed to the peripheral sink mechanism. However, even in 
that study elevated plasma Aβ levels were not statistically significant outcome of the 
treatment, and in the absence of correlations between brain/CSF and plasma levels of Aβ, it 
will be difficult to acknowledge the presence of a peripheral mechanism. Moreover, mere 
increase in plasma Aβ due to antibody treatment might also be a consequence of stabilization 
of Aβ-antibody complexes in plasma (Winkler et al., 2010; Levites et al., 2006). Interestingly, a 
recently published report on anti-Aβ monoclonal  antibody (bapineuzumab) indicates that in 
spite of antibodies engaging brain Aβ, it may not necessarily be reflected in CSF or serum 
(Blennow et al., 2012). 
Even though we found no amyloid reduction with hIVIG, a recent in vivo study reported 
that natural Aβ-antibodies (Nabs-Aβ) isolated from hIVIG confer protection from Aβ toxicity 
along with beneficial effects on cognition in an APP transgenic mouse model of AD (Dodel et 
al., 2011).  However, in that report absence of hIVIG treated group makes it difficult to 
delineate the effects of constituent anti-Aβ antibodies and non-specific polyclonal IgG 
antibodies from those arising from extraction procedure itself. As expected, four weeks of 
treatment with natural Aβ-antibodies did not alter plaque pathology in 12-month-old mice 
but reduced amyloid plaque burden in 3-month-old mice. However, the plaque reduction 
effect in young animals did not differ significantly between low and high doses of Nabs-Aβ. 
In addition, a recent meeting abstract also reported no significant changes in PIB retention in 
brains of small number of human patients treated with hIVIG (Kondo et al., 2011). 
Collectively, these findings suggest that hIVIG unlikely would substantially affect brain Aβ 
deposition or clearance.  
6.1.6 EFFECTS OF hIVIG TREATMENT ON ASTROCYTES AND MICROGLIA 
OF APP/PS1 MICE 
After finding no evidence for amyloid lowering mechanisms for hIVIG in our study, we 
shifted our focus to anti-inflammatory actions of hIVIG.  Anti-inflammatory properties of 
hIVIG are well known and polyclonal antibodies of hIVIG are reactive to a wide array of 
inflammatory proteins including cytokines and chemokines (Nimmerjahn and Ravetch, 2008). 
Mean GFAP immunopositive area for astrocyte reactivity was lower in hIVIG treated mice 
than in the saline group, but failed to reach statistical significance. Similarly, increase in Iba-1 
due to hIVIG treatment was not statistically significant inspite of increase in mean Iba-1 
immunopositive area in hIVIG treated mice. A change in microglia phenotype (or activation 
state) was indicated by increased expression of microglial markers around the Aβ 
microenvironment, with CD45 measuring only activated microglia (Masliah et al., 1991) and 
Iba-1 measuring both activated and quiescent microglia. In addition, the CD68 marker has 
been associated with phagocytosis (Morgan, 2009). The lack of significant changes in CD68 
immunopositive microglia confirmed limited effects of hIVIG treatment on Aβ phagocytosis. 
Whilst 8-month chronic hIVIG treatment suppressed CD45 expression, Iba-1 expression 
124 
 
 
 
increased in a subset of microglial cells as demonstrated by confocal analysis.  The fact that 
different subtypes of microglia cells responded differently, strongly indicates that hIVIG has 
a highly specific immunomodulatory effect and not just a general suppression of the brain 
inflammatory reaction. Notably, we measured Iba-1 signal from individual microglial cells 
across the entire z-stack along the section thickness, so there was no interference from 
microglia in other activation levels that could confound quantification of this signal. In 
contrast, with nickel-DAB developed sections, the immunopositive Iba-1 signal from 
microglia often were influenced by neighbouring microglial cells present in various levels of 
activation. Therefore, this approach allowed us to measure integrated intensities of more than 
one activation marker in a single individual microglial cell and relate this information to the 
morphological features (in this case, circularity). To our knowledge, this is the first study to 
report segregation of microglial cells based on both morphology and activation markers.  A 
change in microglial activation as a consequence of hIVIG treatment has been reported in one 
previous in vitro study (Istrin et al., 2006). In this study, BV-2 microglia cell line displayed a 
more ramified morphology and increased expression of CD45 in response to hIVIG treatment. 
In contrast, our in vivo study found decreased CD45 expression (only in Type B microglial 
cells) and increased Iba-1 expression (in Type B and Type C microglial cells) along with a shift 
towards more ramified microglia morphology. 
6.1.7 EFFECTS OF hIVIG TREATMENT ON PRO-INFLAMMATORY CYTOKINE 
GENE EXPERESSION 
After finding clues for differential activation of microglial cells, we focused further on 
classic inflammation regulatory actions of hIVIG. Many in vitro and in vivo studies have 
indicated the ability of hIVIG preparations to modulate cytokine induction and release 
(Murakami et al., 2012; Toungouz et al., 1995; Andersson and Andersson, 1990; Yang et al., 
2011; Wu et al., 2006)(Toyoda et al., 1994; Aukrust et al., 1994; Ling et al., 1993). In addition to 
direct cytokine neutralizing antibodies in hIVIG, there are also other plausible mechanisms 
(Wadhwa et al., 2000; Andersson et al., 1996; Le Pottier et al., 2007). Since pro-inflammatory 
cytokines like TNF and IL-1β are important contributors of neuroinflammation, there is an 
opportunity for hIVIG to cease, decrease or suppress amyloid induced cytokine release by 
microglia. Tnf gene expression has been reported to be increased in various transgenic mouse 
models of AD, including the APP/PS1 mouse (Ruan et al., 2009). In our study, hIVIG 
treatment caused a significant reduction in Tnf gene expression (and a similar trend in Il1b 
expression). Moreover, this suppression of pro-inflammatory gene expression due to hIVIG 
treatment was not genotype specific or an artifact of the APP transgene as it was also present 
in wild-type-type littermates. One would expect a straightforward correlation between the 
expression levels of pro-inflammatory cytokines and CD45 marker of activated microglia. 
Indeed, in saline treated mice, a trend towards positive correlation was found between CD45 
microglial marker and Tnf gene expression. However, chronic hIVIG treatment shifted this 
correlation to opposite direction, and a similar shift after hIVIG treatment was observed in 
the correlation between CD45 and Il1b gene expression. This inverse relationship between 
pro-inflammatory cytokine and CD45 expression suggests that hIVIG treatment may change 
the brain immune response, so that microglia may maintain a high activity despite a decrease 
in generalized inflammatory response mediated through pro-inflammatory cytokines. This 
profile of immunomodulation works against the profile associated with aging (Hickman et 
al., 2008) and may confer neuroprotection in the AD brain. Pro-inflammatory cytokine 
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regulatory effects of hIVIG are further supported by a report, where circulating levels of TNF 
and IL-1β cytokines dropped upon hIVIG treatment in Guillian-Barre syndrome patients 
(Sharief et al., 1999). More detailed experiments are still needed to fully elucidate the 
mechanisms involved and judge the therapeutic potential of cytokine regulatory effects of 
hIVIG in the context of AD and other neurodegenerative pathologies. 
6.1.8 EFFECTS OF hIVIG TREATMENT ON NEUROGENESIS 
Paucity of any previous studies pointing towards neurogenesis by hIVIG compelled us to 
discuss this novel finding indirectly within the context of microglia and inflammation. In fact, 
to our knowledge this is the first scientific evidence of hIVIG therapy augmenting 
hippocampal neurogenesis.  In diverse experimental setups, several studies connect 
suppression of microglia and pro-inflammatory markers to various stages of neurogenesis 
(Zunszain et al., 2012; Seguin et al., 2009; Monje et al., 2002). Inflammation has been long 
known to be a negative regulator of neurogenesis (Monje et al., 2003; Ekdahl et al., 2003). 
Cellular mediators of neuroinflammation, astrocytes and microglia, may impact neurogenesis 
negatively via HPA axis mediated release of glucocorticoids that supress neurogenesis or by 
decreasing neurotrophin support or by excessive release of reactive oxygen species and pro-
inflammatory cytokines (Song and Wang, 2011; Cameron and Gould, 1994).  In addition, pro-
inflammatory cytokines released by microglia are known to play role in in vitro differentiation 
of hippocampal progenitor cells (Mehler et al., 1993). Furthermore, in diverse animal models 
of disease pro-inflammatory cytokines TNF (van der Borght et al., 2011; Iosif et al., 2006), IL-
1β (Goshen et al., 2008; Koo and Duman, 2008), IFN-α (Kaneko et al., 2006a) and IL-6 
(Vallieres et al., 2002) have been shown to suppress adult neurogenesis, while in one study 
blockade of IL-6 alone restored it (Monje et al., 2003). On the other hand, a recent report 
provides stronger links between microglia and neurogenesis (Vukovic et al., 2012). In this 
study, microglia isolated from mice that had undergone running exercise for two weeks, 
mediated enhanced neural precursor cell activity in neurosphere preparations from sedentary 
aged mice. This study also revealed a novel CX3CL1–CX3CR1 axis capable of changing 
microglia phenotype towards one that supports neurogenesis in ageing brains (Vukovic et al., 
2012).   
In the context of AD, neurogenesis has been extensively studied in various transgenic AD 
mouse models, and Aβ itself has been shown to suppress adult neurogenesis in the 
hippocampus. Passive immunization with Aβ antibodies has been previously shown to 
modulate microglial phenotype (Wilcock et al., 2004a; Wilcock et al., 2011) and very recently 
Aβ immunotherapy has also been linked to neurogenesis as well (Biscaro et al., 2009). Similar 
to other models of experimental neuroinflammation, suppression of activated microglia in 
transgenic AD mouse models was also found to be sufficient to maintain hippocampal 
neurogenesis (Biscaro et al., 2012). Strikingly, even in our AD mouse model, chronic hIVIG 
treatment not only altered activation status of microglia and suppressed pro-inflammatory 
TNFα gene expression, but also significantly enhanced the number of doublecortin positive 
cells in the dentate gyrus irrespective of the genotype of mice. This effect may be selectively 
beneficial for aged mice in which neurogenesis is about to fade out. Moreover, the negative 
correlation between CD45 microglia and number of doublecortin positive cells in our study 
also points towards an inverse relationship between activated microglia and neurogenesis. 
While microglial cells activated by TNF-α and IL-6 inhibited neurogenesis, microglial cells 
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activated by IL-4 and T-cells have also been reported to contribute to hippocampal 
neurogenesis (Butovsky et al., 2006; Ziv et al., 2006).  Such alternatively activated microglia 
were shown to express MHCII proteins and co-localize with IGF-1, a growth factor known for 
neuroprotection and neurogenesis (Carro et al., 2001; Trejo et al., 2001). Therefore, 
modulation of microglia by hIVIG and subsequent suppression of proinflammatory cytokines 
might restore and foster hippocampal neurogenesis, thereby representing a mechanism to 
compensate for the loss of neurons observed during AD progression. However, it is also 
possible that fostering neurogenesis might be a direct exclusive property of hIVIG, 
irrespective of other indirect mechanisms discussed here. 
6.1.9 MECHANISM OF ACTION FOR HUMAN INTRAVENOUS 
IMMUNOGLOBULIN THERAPY  
Our study was designed to test amyloidocentric mechanisms for hIVIG; in fact we began 
our experiments hoping to find evidence for reduction of brain Aβ protein by hIVIG 
treatment. But we clearly present evidence for hIVIG effects independent of Aβ clearance. 
This is the first passive immunotherapy data in AD transgenic mice that describes 
modulation of microglial activation, suppression of pro-inflammatory cytokine gene 
expression, and enhancement of neurogenesis as a consequence of hIVIG treatment 
independent of amyloid clearance in the brain. However, it is unclear whether these are 
mutually exclusive and independent effects. This combination of effects makes hIVIG a 
unique treatment candidate that targets multiple inflammatory antigens and 
immunomodulatory factors associated with neurogenesis (Schnabel, 2011). At the onset of 
our studies, Aβ (or toxic assemblies) was putative target for hIVIG, but towards the end of 
our experiments, our data consistently defied this and brought in “microglia and 
inflammation” as potential targets of hIVIG therapy. It will be interesting to investigate if 
mere modulation of CD45 microglial protein expression could as well change cytokine 
profiles and support neurogenesis. A recent report described alterations in plasma cytokines 
levels in mild to moderate AD patients treated chronically with hIVIG, and further that these 
changes correlated with clinical outcomes, suggesting that immunomodulation by cytokines 
may be one of the therapeutic mechanisms for hIVIG (Relkin et al., 2011). While Aβ 
(oligomers) delivers the kiss of death by a thousand tiny blows to neurons (Selkoe, 2011), 
hIVIG reserves the potential to deliver relief by plethora of mechanisms (Ballow, 2011) such 
as influencing the activation state of microglia, suppressing proinflammatory gene 
expression, immunomodulation, regulating cytokine networks, and fostering neurogenesis in 
a manner independent of constituent anti-Aβ antibodies. Therefore, enriching hIVIG 
preparations with anti-Aβ antibodies may not be necessary to unmask the beneficial effects of 
hIVIG. In view of the limited supply of hIVIG (Bayry et al., 2007) it will be of enormous 
benefit to further explore the anti-inflammatory, immunomodulatory and neurogenic 
mechanisms of hIVIG in the context of Alzheimer’s pathology. Changes observed in 
microglia phenotype and their inverse correlation to proinflammatory gene expression 
advocate anti-inflammatory properties of hIVIG in AD mice. It would be tempting to check if 
these anti-inflammatory effects of hIVIg are related to recently discovered novel Th-2 
pathway (Anthony et al., 2011).  A small fraction of sialylated IgG antibodies in hIVIG 
interact with SIGN-R1 or hDC-SIGN receptors on spleenic macrophages to release IL-33 
thereby, initiating a IL-4 driven Th-2 response (Anthony et al., 2012). 
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6-1.10  IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE - PROSPECTS AND 
CAVEATS 
Immunotherapy for AD has been at the forefront of experimental AD therapeutics. 
bapineuzumab and  solaneuzumab both have failed in their pivotal phase 3 clinical trials. 
Gammagard Liquid (hIVIG) is currently in the phase-3 clinical trial and is expected to report 
its outcome by 2013. The first two are monoclonal antibodies whereas the last one is a 
polyclonal IgG antibody. Interestingly, all the three antibody candidates were supposedly 
expected to halt or slow down cognitive decline in AD patients by reducing brain amyloid 
protein. Treatment with high dose has already been discontinued for bapineuzumab because 
of vascular bleedings and amyloid related-imaging abnormalities (Sperling et al., 2012). As 
for hIVIG, lower doses were found to be associated with beneficial MMSE scores (Relkin et 
al., 2009), whereas higher doses of hIVIG are needed for its immunomodulatory effects 
(Nimmerjahn and Ravetch, 2008). Therefore, selecting a right dose which engages the target 
without precipitating any serious side effects will be a critical factor for the ongoing trials. 
Clinical data from bapineuzumab phase-2 trials provided the first evidence that getting rid of 
brain amyloid may not be sufficient to offer cognitive benefits. This might be an indication 
that either our target (Aβ) is wrong or we are too late to rescue already degenerated brain 
(Lemere and Masliah, 2010a). Clinical data from a small hIVIG trial, however, indicates that at 
hIVIG therapy slows down cognitive deterioration (Relkin et al., 2009). Based on our rodent 
experiments, we know that hIVIG may not be able to reduce brain amyloid but may show 
profound neurogenic immunomodulatory effects in and around amyloid plaque 
microenvironment. Therefore, drugs may confer benefits in AD even without removing brain 
amyloid.   
Even if we happen to choose the right target, and an effective drug and its right dose, we 
may still fail if we start the treatment at a wrong time (Sperling et al., 2011a). There is 
evidence to postulate that outcomes of many clinical trials would have been better if the 
therapy had been started at a very early stage, well before massive neuronal loss ensued. In 
fact, researchers are now contemplating to begin large therapeutic preventive trials in 
cognitively healthy people.  A sensitive issue here is how early one should begin treatment, 
and in the absence of a sufficient evidence proving the causality of Aβ protein in Alzheimer’s 
disease, it will be potentially dangerous to immunize otherwise healthy people. Arguments 
for testing AD drug candidates in early stage patients or at mild cognitive impairment stage 
is reasonable, but again when the drug target is elusive, it will be unethical to expose 
prospective AD patients until the drug target is pinpointed and validated by multiple 
independent studies. In any case, immunotherapy trials may be regarded as ultimate test for 
the amyloid cascade hypothesis, only when treatment starts in early presymptomatic phases 
of AD.  
In addition, one seriously undermined issue that will eventually pop up once hIVIG clears 
phase 3 trials is of significant concern.  The issue is about long-term viability of hIVIG as 
treatment option for AD patients. It takes decades for AD to develop and thus it is very 
reasonable to expect longer treatment regimens for hIVIG in order to see some benefits. 
Equity research report by RBC Capital Markets® (Henry Brandon, January 23rd, 2012), 
suggests a conservative estimate of 45000 dollars per annum per AD patient in USA alone. 
This clearly indicates a very expensive and economically unviable treatment option. 
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Furthermore, as more than 10000 donations from healthy people are required to enrich single 
hIVIG lot, one can extrapolate how many healthy donations will be needed to meet global 
demand by AD patients. Eventually, as the production demand continues to rise, 
immunodefecient and immunocompromised patients who rely critically on availability of 
hIVIG infusions for their survival will also face its acute shortage. For instance, mortality 
rates were reduced significantly in CVID patients receiving replacement immunoglobulin 
therapy and further such intervention added 30-40 years of productive life to patients (Chapel 
et al., 2008). This might also open a moral  and ethical dilemma for those who advocate hIVIG 
therapy to AD patients because mostly these patients are in their last years of their lives. If the 
production issues are not addressed now, one might end up with acute shortage thereby not 
only affecting patients with AD but also patients suffering from primary immunodeficiency 
disorders (Bayry et al., 2007). However, as the numbers of patients with conditions like CVID 
are much smaller when compared to AD, it would be also possible to secure supplies of 
hIVIG to patients critically in need for their survival.  
One naive possible solution to meet this increasing demand is to collect plasma from 
people when young and then use their own antibodies when they need during later part of 
their lives. Recombinantly manufacturing sialylated IgG antibodies is also an interesting 
avenue to proceed. Therefore, in view of these scientific, technical, economical and 
commercial limitations associated with hIVIG usage, it is in the best interest of everyone to 
investigate the inherent mechanisms underlying hIVIG effects with an objective to identify 
novel drug targets.  
6.2 ROLE OF NUCLEAR FACTOR KAPPA-B IN PATHOGENESIS OF 
ALZHEIMER’S DISEASE 
Nuclear factor kappa-B plays a major role in regulating inflammatory responses of brain 
with AD (Granic et al., 2009). NFκB activation in neurons and glial cells can be both beneficial 
and detrimental. We established a novel mouse line expressing APP/PS1 transgene under 
Nfkb1 null background to see whether Nfkb1 gene deficiency in APP/PS1 alleviates age-related 
memory impairment by reducing levels of inflammatory modulators that might have 
negative effect on learning and memory. On the other hand, we hypothesized that 
suppression of microglia, and thereby, phagocytosis in Nfkb1 knockout mice may result in 
higher brain amyloid burden. Table 5.2 summarizes key findings from this study. To our 
knowledge this is the first transgenic AD mouse line that is deficient in a key component of 
NFκB signalling. One cautionary note while interpreting the phenotype of Nfkb1-/- mice is that 
roughly one-third of p105 protein (precursor protein of Nfkb1) acts as scaffold for MEK kinase 
Tpl2 protein (Beinke and Ley, 2004). In Nfkb1-/- mice, the absence of p105 results in rapid 
degradation of Tpl2. Therefore, deficient NFκB signalling (via p105 deficiency) is also 
reflected as deficiency in ERK MAP kinase pathway (via deficiency of Tpl2). This compound 
signalling defect makes it difficult to attribute the observed phenotypes of Nfkb1 deficient 
mice to either loss of Nfkb1 function or Tpl2, or both (Gerondakis et al., 2006). 
We performed two experiments with these mice. In the first age series experiment we 
followed these mice at 3.5, 8 and 12 months of age. Both APP/PS1 and Nfkb1-/- mice displayed 
significantly lower body weights than controls, which was consistent with previous report 
(Jhaveri et al., 2006)(Lu et al., 2006).  Our data from behavioural test battery show that these 
mice do not show any deleterious effects of Nfkb1 gene deletion. Interestingly, decreased 
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anxiety and increased motor coordination as noticed in Nfkb1-/- mice can be viewed as 
beneficial outcome in the context of Alzheimer’s patients.  Although both the APP/PS1 and 
Nfkb1-/- genotypes had significant manifestation in behavioural phenotypes none of the 
outcomes of APP/PS1 genotype interacted with Nfkb1 knockout genotype, indicating that 
their phenotypes did not influence each other.  Like Nfkb1 knockout mice reported earlier 
(Kassed and Herkenham, 2004), Nfkb1-/- mice under APP/PS1 background as well displayed 
reduced anxiety-like behaviour. Our data from Morris water maze test shows that at the age 
of 12 months age APP/PS1 mice exhibited impaired spatial learning , but Nfkb1 gene deletion 
neither increased nor decreased latencies to reach the hidden platform. Thus, we accept our 
null hypothesis that there is no effect of Nfkb1 gene on memory impairments of APP/PS1 mice 
in current experimental setup.  In light of a recent report (Lu et al., 2006), detailing 
neurodegenerative changes in the hippocampus, cortex and optic nerve of Nfkb1-/- mice, it 
becomes interesting to see whether our new Nfkb1-/- mouse line under APP/PS1 background 
exhibits neuronal loss as they age. However, due to breeding problems we could not 
accumulate enough mice to carry out a systematic stereological assessment of neuronal 
number in the hippocampus and cortex. 
6.2.2 IMPACT OF Nfkb1 GENE KNOCKOUT ON AMYLOID PATHOLOGY 
NFκB activity has been shown to mediate APP processing and BACE-1 expression (Chen et 
al., 2011). Modulating NFκB pathway also resulted in decreased Aβ burden in transgenic APP 
mice (Sung et al., 2004). In our experiments, we used Nfkb1-/- mice to inhibit NFκB pathway. 
Neuronal inhibition of NFκB signalling, via regulation of BACE-1 expression can be 
hypothesized to cause lower Aβ burden in Nfkb1 null mice with APP/PS1 background. On the 
other hand, inhibition of NFκB signalling in microglia may also result in defective Aβ 
clearance via phagocytosis, thus resulting in higher Aβ burden. So we set out to test both 
hypotheses with our current model. Across three ages, we evaluated brain amyloid burden in 
Nfkb1 wild-type and Nfkb1 knockout mice under APP/PS1 background. Our data from 3.5-
month-old mice do not support any significant role of Nfkb1 gene in early stages of   Aβ 
plaque pathology, albeit a trend towards lower insoluble levels of Aβ42 in Nfkb1-/- mice was 
noted (Fig.  5.2.1b-A).  BACE-1 modulation by neuronal NFκB (Chen et al., 2011) could have 
contributed to this effect, although we did not check BACE-1 expression. A larger sample size 
for ELISA measurements might have revealed whether this trend (p = 0.06) would reach 
statistical significance. At 8 months APP/PS1 mice exhibited moderate amounts of Aβ plaque 
pathology in both cortex and hippocampus. In addition, gender differences become apparent, 
with females exhibiting more severe pathology. Importantly, at this age, Nfkb1 gene 
deficiency did not bring about any differences in biochemical levels of Aβ4o or Aβ42 between 
Nfkb1-/- and wild-type-type carriers. Quantification of Aβ burden by immunohistochemistry 
revealed a significant gender differences in both cortical and hippocampal plaque load but 
interestingly only the hippocampus showed elevated Aβ burdens in Nfkb1-/- mice. Variable, 
non-uniform, local deposition of Aβ plaques in different anatomical subregions in the cortex 
as evaluated in coronal sections might be responsible for seeing no overall Nfkb1 gene effect 
here. In contrast, this variation is comparatively small in hippocampus. At 12 months of age, 
both the cortex and the hippocampus are fully engrossed in severe Aβ plaque pathology. 
However, Aβ ELISA assays and amyloid plaque quantification revealed noNfkb1-/- effects. 
Our sample had an 80% power to detect a 33% change in mean Aβ immunopositive area and 
35% change in mean Congo red positive area with a significance level (alpha) of 0.05 (two-
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tailed). So, it is unlikely that our sample was underpowered to detect a clinically meaningful 
change in Aβ pathology.  However, insoluble Aβ42 levels in ELISA in Nfkb1 knockout mice 
were significantly lower than Nfkb1 wild-type mice (Fig.  5.2.1b-I).  
Overall, there was a trend for decreased Aβ at an early (3.5 months) and a late (12months) 
stage of amyloid pathology in Nfkb1-/- mice.  Only during intermediate stages of amyloid 
pathology (8 months), Nfkb1-/- mice showed increased Aβ plaque immunoreactivity. Basal 
expression levels of APP transgene did not differ significantly between Nfkb1 wild-type and 
Nfkb1-/- groups at 12 months, indicating that changes in APP transgene expression might not 
be the reason for this variability (data not shown). If we ignore the suppression of insoluble 
Aβ42 levels at 3.5 and 12months of age and the elevation of Aβ plaques at 8 months of age as 
random effect due to a small sample size, then one can conclude that Nfkb1 gene does not 
have any significant role in the development and progression of Aβ pathology. However, it 
should be noted that the ages of 3.5 and 12 months represent opposite ends of the rapid 
amyloid accumulation process in APP/PS1 mice and that many changes associated with 
ageing take place in a mouse between these age point. Thus, microglia at 3.5 and 12-month 
age might be totally different with respect to their activation and functions like phagocytosis, 
which may account in part for the age dependency of these findings. One can also consider 
giving an extra LPS stimulus to 3.5-month-old mice, in order to delineate Nfkb1 gene 
dependent functions in microglia. During intermediate stages of amyloid pathology (8 
months of age), insufficient phagocytosis by Nfkb1 deficient microglia might have caused 
elevation of Aβ plaques in the Nfkb1-/- group. However, this is in stark contrast to our data 
from ex vivo assays where Nfkb1 deficient microglia exhibited enhanced phagocytosis (data 
not shown). At the age of 12 months, combined influences of ageing, severe plaque burden, 
and elevated levels of TNF and IL-1β in APP/PS1 mice might have influenced microglial 
Nfkb1 associated functions. In addition, recent evidence suggests that mechanisms responsible 
for phagocytosis of Aβ plaques might be different from those regulating soluble/insoluble 
levels of Aβ (Zhu et al., 2011; Grathwohl et al., 2009). This provides explanation for decreased 
levels of insoluble Aβ42 in 12-month-old Nfkb1-/- mice without any changes in amyloid plaque 
load. The data from the age series experiment show that the age of mice as well as quality of 
stimulus (plaque severity and cytokine milieu) influence biochemical and neuropathological 
readouts of Nfkb1 gene functions.  
We further provided an acute LPS stimulus (4μg) in addition to chronic stimuli (Aβ 
deposits) to 12-month-old mice and examined their brains for changes in Aβ plaque 
pathology by immunohistochemistry. Due to increased mortality of Nfkb1-/- mice after acute 
LPS injections (Duckworth et al., 2006), we were left with only 5 mice compared to 10 mice in 
the corresponding Nfkb1 wild-type group. As expected and previously reported (Malm et al., 
2005a), LPS injection reduced Aβ plaque burden when compared to saline injections on the 
contralateral side. However, there was no difference in plaque burden between the Nfkb1 
wild-type and knockout APP/PS1 mice. All the above data provide evidence for a limited role 
of Nfkb1 gene in the development and progression of amyloid pathology in APP/PS1 mice. 
Cell type specific inhibition of NFκB signalling should be used in future studies to prevent 
confounds of simultaneous neuronal and microglial NFκB inhibition as happens in Nfkb1 
knockout mice. In this direction, one can employ lentiviral system to express dominant 
negative IKK-2 (Inhibitor of nuclear factor kappa-B kinase-β), in order to effectively block 
canonical NFκB pathway in defined spatial and temporal patterns.  
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6.2.3 IMPACT OF Nfkb1 GENE KNOCKOUT ON MICROGLIA AND 
INFLAMMATORY PATHOLOGIES 
Microglia are activated by fibrillar Aβ deposits of APP/PS1 mice (Morgan et al., 
2005)(Morgan, 2009). This increase in microglial reactivity can be demonstrated by elevation 
of microglial CD45 expression. We employed CD45 immunohistochemistry and examined 
brain sections from Nfkb1 wild-type and Nfkb1-/- mice under APP/PS1 background at 8- and 
12–month age points. At the age of 8 months, we saw no changes in CD45 immunoreactivity 
due to Nfkb1 gene deletion.  However, at 12 months of age we noticed a significant 56% drop 
in CD45 immunoreactivity in APP/PS1 mice deficient in Nfkb1 gene compared with Nfkb1 
wild-type carriers. NFκB p65 DNA-binding activity was also significantly enhanced in Nfkb1 
wild-type but not in Nfkb1-/- APP/PS1 mice (data not shown), indicating that NFκB 
upregulation was prevented in the absence of functional Nfkb1 subunit. In addition, there was 
a significant elevation of Tnf and Il1b gene expressions in Nfkb1-/- mice. This is consistent with 
a previous report, where CD45 deletion in APP mice as well resulted in elevation of Tnf and 
Il1b cytokine gene expression (Zhu et al., 2011). This particular study and data from current 
study suggest that substantial suppression of CD45 (> 50% to total ablation) is associated with 
a pro-inflammatory microglial phenotype. In stark contrast, in our hIVIG study, a meagre 
36% suppression of CD45 immunoreactivity was associated with robust decrease in Tnf gene 
expression and enhanced neurogenesis, indicating an anti-inflammatory microglial 
phenotype. However, Iba-1 and CD68 quantifications revealed no significant Nfkb1 genotype 
effects. Our data indicate that Nfkb1 gene deficiency in APP/PS1 mice enhanced Aβ induced 
neuroinflammation, indicating that Nfkb1 plays an important role in inhibiting M1 pro-
inflammatory phenotypes of microglia (Porta et al., 2009). In our LPS experiment, acute 
injections of LPS resulted in a significant decrease in Iba-1 positive microglia in Nfkb1-/- mice. 
This decrease was evident in contralateral saline injected side as well, indicating an overall 
reduction of basal Iba-1 expression in Nfkb1-/- mice. CD68 immunoreactivity, however, did not 
show Nfkb1 genotype specific changes due to LPS injection. Overall, both our age series 
experiment and LPS experiment indicate specific changes in microglial phenotypes 
accompanied by elevated Tnf and Il1b pro-inflammatory gene expression in Nfkb1-/- mice 
under APP/PS1 background. Importantly, this pro-inflammatory microglial phenotype did 
not worsen memory impairments in APP/PS1 mice. 
6.2.4 TARGETING NFΚB PATHWAY IN ALZHEIMER’S DISEASE -
PROSPECTS AND CAVEATS 
NFκB pathway plays a vital regulatory role in initiation, maintenance and resolution of 
inflammation within the AD brain. Even  modest immunomodulation may have profound 
effects on the progression of disease. In such a scenario, targeting various components of 
NFκB pathway seems explicit. Mouse models lacking specific components of NFκB pathway 
are excellent tools for validating the targets in NFκB pathway in spite of certain limitations. 
Knockout mice have “inhibition” of the particular gene function starting from early 
development, while when applied as a therapy the reduction is sudden. Knockout mice are 
likely to adapt and develop compensatory mechanisms. Deletion of various components of 
the NFκB pathway can be lethal during embryonic development or postnatal, so one may 
never know the true extent of gene knockout in adulthood. Furthermore, genetic deficiencies 
in mouse models need not necessarily be translated to humans, who frequently have certain 
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residual activity of targeted component of NFκB activation (McDonald et al., 2006). 
Moreover, while interpreting the phenotype of knockout mice, NFκB independent activities 
of respective proteins need to be taken into account. Presence of functional redundancy 
among NFκB proteins can sometimes partly compensate for their loss in knockout mice 
(Pasparakis et al., 2006). Existence of cross-talk between canonical and alternative pathways 
at the level of IKKs and transcription factors also confounds the interpretation of transgenic 
phenotypes. Lastly, loss of NFκB function may as well result in disruption of other key 
intracellular signalling pathway (Gerondakis et al., 2006). It is also possible that our Nfkb1-/- 
mice may inhibit NFκB signalling involving Nfkb1, however, functions of subunits, those 
independent from Nfkb1, might still remain. Also, Nfkb1 is involved in signalling not 
traditionally considered as NFκB signalling. Therefore, cell specific depletion of NFκB might 
be needed to inhibit only pro-inflammatory NFκB signalling in microglia and astrocytes 
sparing beneficial NFκB signalling in neurons necessary for survival. 
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7 Conclusions 
We ran altogether 6 experiments to see whether pharmacological and genetic 
immunomodulation in transgenic APP/PS1 mice can impact their amyloid and microglial 
pathologies. More specifically, we treated young and aged APP/PS1 mice with a single i.p 
injection of hIVIG for 1 day, 1 week, 3 weeks, 3 months and 8 months. Consistently, in all 
experiments hIVIG did not reduce or lower on brain Aβ burden. Instead, with chronic 
treatment soluble levels of brain Aβ levels were elevated without any concomitant change in 
Aβ plaque burden. We also found no evidence that suggests Aβ plaque disintegration, 
microglia mediated Aβ phagocytosis or peripheral sink mechanism as mode of action for 
hIVIG. As our sample had enough power to detect small changes in Aβ, we can conveniently 
conclude that treatment with hIVIG had very limited effect on the development and 
progression of Aβ plaque pathology in APP/PS1 mice. Chronic treatment with hIVIG also 
resulted in changes in specific sub-populations of microglia, suppressed Tnf gene expression, 
and fostered neurogenesis. Importantly, changes in microglia correlated with changes in Tnf 
and number of newborn neurons, indicating that hIVIG treatment effects are mutually linked 
and are not pro-inflammatory. Therefore, based on our data we can conclude that hIVIG may 
have many inter-related effects on ongoing neuroinflammation in APP/PS1 mice. 
Immunomodulatory and anti-inflammatory effects may mediate beneficial effects of hIVIG in 
human AD patients. 
In our NFκB study, our objective was to see whether immunomodulation induced by 
genetic manipulation of the NFκB signalling pathway affects progression of amyloid and glial 
pathologies in APP/PS1 mice. For this, we followed our novel Nfkb1 deficient mice under 
APP/PS1 background in three age points up to 12 months. Furthermore, in an independent 
experiment we ascertained whether an extra acute LPS stimulus may impact hippocampal Aβ 
burden. However, we noticed very limited and sometimes conflicting effects of NFκB Nfkb1 
on amyloid pathologies of APP/PS1 mice. Even an extra LPS stimulus did not bring about any 
significant changes to Aβ burden. Based on our data, we can conclude that NFκB Nfkb1 has 
very a limited role in modulating amyloid pathology of APP/PS1 mice. NFκB Nfkb1 defecient 
mice on APP/PS1 background showed profound changes in microglia and elevated Tnf and 
Il1b gene expression, indicating a pro-inflammatory microglial phenotype. Importantly, gene 
deletion of Nfkb1 did not worsen age dependent memory impairments seen in APP/PS1 mice. 
In conclusion, in both studies we found immunomodulatory effects on neuroinflammatory 
processes but very limited effects on amyloid pathology in APP/PS1 mice. 
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